Title: Mutant forms of EtxB and CtxB and their use as carriers

Applicant/Assignee: HUNTER IMMUNOLOGY LTD

Application No.: 10/743391   Filing Date: 22/Dec/2003

Abstract:The present invention describes the use of a mutant form of EtxB or CtxB to deliver an agent to a target cell wherein the mutant has GM-1 binding activity

but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB.

Priority: GB20010015382 Applic. Date: 2001-06-22; WO2002GB02829 Applic. Date: 2002-06-20

Inventor: HIRST TIMOTHY R [AU]

Title: Pharmaceutical dosage forms of biguanide-sulfonylurea combinations

Applicant/Assignee:

Application No.: 10/534908   Filing Date: 13/May/2005

Abstract:The present invention relates to orally administered pharmaceutical compositions that include a combination of antidiabetic agents wherein one agent is present in an extended release form and the other agent is present in an immediate release form. For example, in one embodiment the dosage form includes an extended release layer that includes a biguanide

and an immediate release layer that includes a sulfonylurea.

Priority: IN2002DE01154 Applic. Date: 2002-11-15; WO2003IB05206 Applic. Date: 2003-11-17

Inventor: TREHAN ANUPAM [IN]; MADAN SUMIT [IN]; ARORA VINOD K [IN]; MALIK RAJIV [IN]

Title: Pharmaceutical formulations for the safe administration of drugs used in the treatment of drug addiction and processes for obtaining the same

Applicant/Assignee: IBSA INSTITUT BIOCHIMIQUE S.A

Application No.: 11/170314   Filing Date: 28/Jun/2005

Abstract:The present invention provides safe pharmaceutical formulations for drugs used in the treatment of drug addiction, namely formulations which render the abusive administration of the drug contained in these formulations not feasible, together with processes for obtaining said formulations.

Priority: IT2004MI01317 Applic. Date: 2004-06-30

Inventor: ECHANAGORRIA ANGEL M [IT]; BRAMBILLA LUIGI [IT]; IACCHETTI GIOVANNI [IT]

Title: Methods and products related to treatment and prevention of hepatitis C virus infection

Applicant/Assignee: COLEY PHARMACEUTICAL GMBH

Application No.: 11/183253   Filing Date: 15/Jul/2005

Abstract:The invention provides methods for identifying and treating subjects having hepatitis C infections. In some instances, the subjects are those that are non-responsive to non-CpG therapy. Preferably, the subjects are treated with C class CpG immunostimulatory nucleic acids having a semi-soft backbone.

Priority: WO2003IB05520 Applic. Date: 2003-10-29; US20020421987P Applic. Date: 2002-10-29

Inventor: AHLUWALIA NAVNEET K [CA]; EFLER SUSAN M [CA]; DAVIS HEATHER L [CA]; VOLLMER JORG [DE]

Title: Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods

Applicant/Assignee: LEK PHARMACEUTICALS D.D

Application No.: 10/524993   Filing Date: 18/Feb/2005

Abstract:Pharmaceutically suitable crystalline and amorphous alkali and earth-alkali salts of 2-n-butyl-4-chloro-5-hidrox-ymethyl-1-[[2'-(1H-tetrazole-5-yl)[1.1'-biphenyl]-4-yl]-1 Himidazole have been prepared and new manufacturing, purification and isolation procedure for said salts in high purity have been described. Stable pharmaceutical compositions containing new crystalline potassium salts of 2-n-butyl-5-chloro-5hidroxymethyl-1-[[2'-(1H-tetrazole-5-yl)[1.1'-biphenyl]-44-yl]-1H-imidazole have been prepared.

Priority: SI20030000026 Applic. Date: 2003-01-30; SI20030000025 Applic. Date: 2003-01-30; SI20030000145 Applic. Date: 2003-06-12; SI20030000157 Applic. Date: 2003-06-26; SI20030000270 Applic. Date: 2003-11-05; WO2004SI00001 Applic. Date: 2004-01-29

Inventor: ANTONCIC LJUBOMIR [SI]; COPAR ANTON [SI]; SVETE PETER [SI]; HUSU-KOVACEVIC BREDA [SI]; HAM ZORAN [SI]; MAROLT BORIS [SI]

Title: Electrospun amorphous pharmaceutical compositions

Applicant/Assignee:

Application No.: 10/523835   Filing Date: 07/Feb/2005

Abstract:The present invention is directed to use of electrospinning, i.e. the process of making polymer nanofibers from either a solution or melt under electrical forces, to prepare stable, solid dispersions of amorphous drugs in polymer nanofibers.

Priority: US20020401726P Applic. Date: 2002-08-07; WO2003US24641 Applic. Date: 2003-08-07

Inventor: IGNATIOUS FRANCIS [US]; SUN LINGHONG [US]

Title: Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one

Applicant/Assignee: SOLVAY PHARMACEUTICALS B.V

Application No.: 11/178309   Filing Date: 12/Jul/2005

Abstract:The present invention relates to an extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one or a pharmaceutically acceptable salt thereof or a hydrate of said pharmaceutically acceptable salt thereof. The invention further relates to the preparation of these extended release formulations and their use in the prevention or treatment of disorders, especially pain and CNS disorders such as depression, anxiety and movement disorders.

Priority: US20040588036P Applic. Date: 2004-07-15

Inventor: BRUINS NICO [NL]; FRIJLINK HENDERIK W [NL]; DE VRIES MICHIEL H [NL]

Title: Novel floating dosage form

Applicant/Assignee:

Application No.: 10/518909   Filing Date: 01/Sep/2005

Abstract:Present invention relates to a novel pharmaceutical composition containing an active ingredient(s) which is retained in the stomach or upper part of gastrointestinal tract for controlled delivery of medicament for improved local treatment, and/or better absorption from upper parts of gastrointestinal tract for effective therapeutic results. Present invention also provides a method for preparation of the said dosage form preferably in the form of a bilayer tablet, in which one layer constitutes for spatial control and the other being for temporal control.

Priority: IN2002MU00565 Applic. Date: 2002-06-26; WO2003IN00229 Applic. Date: 2003-06-25

Inventor: LOHRAY BRAJ B [IN]; TIWARI SANDIP B [IN]; PAI RAVEENDRA M [IN]; MURTHY KRISHNA T [IN]; MEHTA PAVAK R [IN]

Title: Delayed release carnitine

Applicant/Assignee:

Application No.: 11/223086   Filing Date: 09/Sep/2005

Abstract:A sustained release, orally administered pharmaceutical composition comprising carnitine and an acceptable pharmaceutical excipient is described for the treatment of carnitine deficiency and other carnitine responsive conditions. The sustained release formulation avoids the characteristic problems of gastrointestinal invitation, dumping in the urine and bacterial degradation attendant previously known oral formulations of carnitine.

Priority: US2003-384085 Applic. Date: 2003-03-07; US1993-109159 Applic. Date: 1993-08-19; US1993-078985 Applic. Date: 1993-06-16

Inventor: SHUG AUSTIN L [US]; GULBRANDSEN CARL E [US]

Title: Bisphosphonates inorganic carriers

Applicant/Assignee:

Application No.: 11/157003   Filing Date: 20/Jun/2005

Abstract:Intercalated hydrotalcite-bisphosphonate compositions have improved bioavailability, less irritation in the GI tract and a more constant controlled delivery rate of the active component. These hybrid organic drug-inorganic carrier are useful to build-up skeleton bone and to incorporate into a dentifrice to strengthen the hydroxyapatite mineral on teeth. Added advantages in using hydrotalcite are that it is an excellent anti acid ingredient and certain anionic forms of analgesics vitamins, and pro-vitamins can be intercalated into the clay providing synergy to the bisphosphonate therapy. Other bioactive molecules in their anionic form can also be included, e.g., certain hormones, and nutritional supplements to name a few classes.

Priority: US20040589221P Applic. Date: 2004-07-19

Inventor: STOCKEL RICHARD F [US]

Title: Methods of treating acute pain using diclofenac

Applicant/Assignee:

Application No.: 11/180996   Filing Date: 13/Jul/2005

Abstract:New pharmaceutical compositions for oral use containing diclofenac preferably together with alkali metal bicarbonates in amounts of from about 20 to about 80 by weight with respect to diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other, side effects

in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.

Priority: IT1996MI00992 Applic. Date: 1996-05-17; US2000-524747 Applic. Date: 2000-03-14; US1998-192493 Applic. Date: 1998-11-17; WO1997EP02709 Applic. Date: 1997-05-15

Inventor: REINER GIORGIO [IT]; REINER ALBERTO [IT]

Title: Use of betel leaf extract to induce IFN-gamma production from human peripheral blood T cells and as a Th1 type immunomodulator

Applicant/Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH ORGANISATION

Application No.: 11/222815   Filing Date: 12/Sep/2005

Abstract:This invention relates to use of betel leaf extract to induce IFNgamma from human peripheral blood mononuclear cells and as a Th1 type immuno modulator, wherein the said method comprises the steps of, preparing water extract of betel leaf, preparation of human peripheral blood mononuclear cells, incubation of hPBMC with betel leaf extract for a period of 18-48 hours, extraction of RNA for cytokine specific RT-PCR or for flow cytometry for the detection of intracellular cytokine protein, subjecting RNA for RT-PCR to obtain PCR products using IFNgamma specific known primers, and enhancement of IFNgamma as reflected by IFNgamma specific band.

Priority: US2002-319618 Applic. Date: 2002-12-16; US2000-746017 Applic. Date: 2000-12-26

Inventor: BANDYOPADHYAY SANTU [IN]; PAL BIKASH [IN]; BHATTACHARYA SAMIR [IN]; RAY MITALI [IN]; ROY KESHAB C [IN]

Title: Pharmaceutical products for treating neoplastic disease and inflammation

Applicant/Assignee: KGK SYNERGIZE INC

Application No.: 11/135694   Filing Date: 24/May/2005

Abstract:Disclosed in certain embodiments is a pharmaceutical formulation and a functional food comprising a pharmaceutical ingredient comprising an active agent combination comprising flavonoids and tocotrienols in a ratio of about 75:25 to about 95:5 and at least one pharmaceutically acceptable excipient and methods to treat neoplastic diseases and inflammation.

Priority: US20040574487P Applic. Date: 2004-05-26

Inventor: GUTHRIE NAJLA [CA]

Title: Targeted hydrophilic polymer, binders with interferon and medical composite comprising above binders

Applicant/Assignee: BEIJING JIANKAI TECHNOLOGY CO., LTD

Application No.: 10/514492   Filing Date: 01/Aug/2005

Abstract:The present invention relates to an active targeted water-solubility macromolecule polymer, conjugate With interferon and pharmaceutical composition comprising the conjugate. The targeted agent includes, for example, glucose, galatose and the like, as well as their derivates. The conjugate of the present invention is well in water-solubility and havc long physiological cycle half-life period, and have specific recognition to pathology organize, improved and increased medication effect of interferon to Hepatitis B, Hepatitis C etc. infectivity sickness and cancer, infect complication etc.

Priority: WO2002CN00331 Applic. Date: 2002-05-14; WO2002CN00919 Applic. Date: 2002-12-27

Inventor: JI SHISHAN [CN]; ZHU DEQUAN [CN]

Title: Nebulized pharmaceutical compositions for the treatment of bronchial disorders

Applicant/Assignee:

Application No.: 11/182279   Filing Date: 14/Jul/2005

Abstract:The present invention provides methods and pharmaceutical compositions for the treatment of bronchial disorders by inhalation therapy. In various embodiments, the active ingredient of the pharmaceutical compositions is one or more of a sulfated pentasaccharide and a peptidomemtic of a tripeptide. In various embodiments, the active ingredient of the pharmaceutical compositions is one or more of argatroban and fondaparinux.

Priority: US20040588154P Applic. Date: 2004-07-14

Inventor: O'CONNOR MICHAEL F [US]; NAURECKAS EDWARD T [US]; NOTH IMRE [US]

Title: Sustained release formulation of tramadol

Applicant/Assignee:

Application No.: 10/508615   Filing Date: 11/Aug/2005

Abstract:This invention relates to sustained release oral dosage forms comprising tramadol or a salt thereof dispersed in a matrix, wherein said matrix comprises xanthan gum.

Priority: EP20020076130 Applic. Date: 2002-03-22; WO2003EP03050 Applic. Date: 2003-03-21

Inventor: EIVASKHANI REZA [DE]; BRAUN CHRISTIAN [DE]; MERKLE STEFAN [DE]

Title: Extended release venlafaxine besylate tablets

Applicant/Assignee: SYNTHON IP INC

Application No.: 10/895984   Filing Date: 22/Jul/2004

Abstract:Venlafaxine besylate is formulated into an extended release tablet in high loading rates by use of a coating that contains ammonio methacrylate copolymer(s).

Priority:

Inventor: CUCALA ESCOI JOAN [ES]; GALLEGO LUENGO MONTSERRAT [ES]; MARGALLO LANA INOCENCIA [ES]

Title: PTH-like peptides

Applicant/Assignee: ABIOGEN PHARMA S.P.A

Application No.: 11/185906   Filing Date: 19/Jul/2005

Abstract:The present invention relates to peptides that are parathyroid hormone (PTH) analogs, useful for the treatment of hypoparathyroidism and diseases characterized by bone mass reduction, such as osteoporosis, and for stimulating bone repair or favoring the engraftment of a bone implant

to the pharmaceutical compositions comprising these PTH-like peptides and use thereof.

Priority: IT2004MI01440 Applic. Date: 2004-07-19

Inventor: CAPORALE ANDREA [IT]; FIORI NEREO [IT]; SCHIEVANO ELISABETTA [IT]; MAMMI STEFANO [IT]; PEGGION EVARISTO [IT]; CHOREV MICHAEL [US]; WITTELSBERGER ANGELA [US]

Title: Compositions containing policosanol and biotin and their pharmaceutical uses

Applicant/Assignee:

Application No.: 10/898889   Filing Date: 26/Jul/2004

Abstract:A composition is provided which contains policosanol and biotin and which may be used for treating, preventing and or reducing metabolic syndrome, hypercholesterolemia and hypoglycemia related diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, obesity, insulin resistance, dyslipidemia, raised blood pressure, fatigue, premenstrual syndrome, anxiety, depression and/or neurodegenerative disorders, and/or raising HDL cholesterol in humans and animals. The method comprises administering policosanol and biotin which together effectively lower blood glucose levels and lower the LDL/HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to biotin.

Priority:

Inventor: BERLIN ROGER [US]

Title: Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses

Applicant/Assignee:

Application No.: 10/898897   Filing Date: 26/Jul/2004

Abstract:A composition is provided which contains policosanol and omega-3 fatty acids and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), sudden cardiac death, ventricular fibrillation, tachycardia, hypertension, inflammation, thrombosis, deep-vein thrombosis, stroke, macular degeneration, autoimmune and/or immunoregulatory diseases, cardiovascular diseases, anxiety, depression and/or neurodegenerative disorders, and/or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and omega-3 fatty acids which together effectively lower the LDL/HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to omega-3 fatty acids.

Priority:

Inventor: BERLIN ROGER [US]

Title: Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

Applicant/Assignee:

Application No.: 11/176830   Filing Date: 06/Jul/2005

Abstract:Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines.

Priority: US2003-658834 Applic. Date: 2003-09-08; US20030457135P Applic. Date: 2003-03-21; US20020409898P Applic. Date: 2002-09-09

Inventor: GANTIER RENE [FR]; GUYON THIERRY [FR]; VEGA MANUEL [FR]; DRITTANTI LILA [FR]

Title: Disintegrant assisted controlled release technology

Applicant/Assignee:

Application No.: 10/900415   Filing Date: 28/Jul/2004

Abstract:A disintegrant assisted controlled release device is disclosed. The device is a combination of a swelling disintegrant or super-disintegrant and water insoluble polymer or water soluble polymer, or both, and one or more water soluble or water insoluble active pharmaceutical ingredient(s). The said device is stabilized by a humectant or trehalose.

Priority:

Inventor: ODIDI ISA [CA]; ODIDI AMINA [CA]

Title: Compositions containing policosanol and chromium and/or chromium salts and their pharmaceutical uses

Applicant/Assignee:

Application No.: 10/900049   Filing Date: 27/Jul/2004

Abstract:A composition is provided which contains policosanol and chromium and/or chromium salts and which may be used for treating, preventing and or reducing metabolic syndrome, hypercholesterolemia and hypoglycemia related diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, obesity, insulin resistance, dyslipidemia, raised blood pressure, fatigue, premenstrual syndrome, anxiety, depression and/or neurodegenerative disorders, and/or raising HDL cholesterol and/or lean body mass in humans and animals. The method comprises administering policosanol and chromium and/or chromium salts which together effectively lower blood glucose levels and lower the LDL/HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to chromium and/or chromium salts.

Priority:

Inventor: BERLIN ROGER [US]

Title: Cancer cell growth inhibition by black bean (Phaseolus vulgaris L) extracts

Applicant/Assignee: INSTITUTO TECNOLOGICO Y DE ESTUDIOS SUPERIORES DEMONTERREY INSTITUTO TECHNOLOGICO Y DE ESTUDIOS SUPERIORES DE MONTERREY

Application No.: 11/125782   Filing Date: 10/May/2005

Abstract:A group of phytochemical compounds extracted from whole germinated or not germinated black beans (Phaseolus vulgaris L) and/or their dry milled fractions such as seed coats or hulls and cotyledons is described. These phytochemicals are classified as phenolics, such as polyphenols, flavonoids, coumarins, and tannins, triterpenes such as saponins, phytosterols and other antioxidant compounds that proved to be effective to decrease cancer proliferation of hormone dependent mammary (MCF-7), hormone independent hepatic (HepG2) and colon (Caco2) cancer cells. They also effectively protect against chemical damage induced with DMBA and furthermore prevented cancer induced by this chemical in Wistar rats and also reduced tumor size when consumed after tumor detection.

Methanol, acetone, ethanol, water and mixtures of these solvents were used to obtain the extracts from raw, cooked, and germinated black beans of different varieties, both from the whole grain and the hulls. The black bean malting process produced extracts rich in aglycone forms of the previous mentioned compounds that were more biologically active against MCF-7 cancer cell proliferation. Both raw extracts, C-18 HPLC refined extracts and fractionated extracts may be used in the treatment, prophylaxis, amelioration or defense against a variety of hormone dependent and independent cancers.

The extracts and compounds have additional utilities, e.g., lower cholesterol or lower oxidation of LDL and/or inhibit cholesterol synthesis (or the enzyme therefor) and/or reduce liver fibrosis and/or reduce symptoms of menopause and/or stimulate calcium absorption and/or have estrogenic activity such as feminizing estrogenic activity and/or are antioxidants, for instance, as an active ingredient in a nutritional supplement and/or as a food, cosmetic or pharmaceutical antioxidants or colorants.

Priority: US20040570029P Applic. Date: 2004-05-10

Inventor: GUTIERREZ-URIBE JANET A [MX]; SERNA-SALDIVAR SERGIO R O [MX]; MORENO-CUEVAS JORGE E [MX]; HERNANDEZ-BRENES CARMEN [MX]; GUAJARDO-TOUCHE ELSA M [MX]

Title: Use of methyl pyruvate for the purpose of increasing muscle energy production.

Applicant/Assignee:

Application No.: 10/710710   Filing Date: 29/Jul/2004

Abstract:The present invention relates to the use of methyl pyruvic acid (a methyl ester of pyruvic acid) and/or methyl pyruvate (methyl pyruvate is the ionized form of methyl pyruvic acid) for the purpose of increasing muscle energy production. When used as a dietary supplement, energizer or pharmaceutical, this anion can be formulated as a salt. The methyl pyruvate compounds which can be used in the present method include: (1) a salt using a monovalent cation (such as sodium or potassium methyl pyruvate) or (2) a divalent cation (such as calcium or magnesium methyl pyruvate) and analogs of these compounds which can act as substrates or substrate analogs for methyl pyruvate Use of methyl pyruvate and/or methyl pyruvic acid can be effective when administered orally or infused on either a chronic and/or acute basis. In the following text, the terms "methyl pyruvate, methyl pyruvate compounds, methyl pyruvic acid" are used interchangeably.

Priority:

Inventor: ANTOSH STANLEY C [US]; MEDURI ANTHONY J [US]

Title: Use of methyl pyruvate for the purpose of reducing weight gain in mammals.

Applicant/Assignee:

Application No.: 10/710830   Filing Date: 05/Aug/2004

Abstract:The present invention relates to the use of methyl pyruvic acid (a methyl ester of pyruvic acid) and/or methyl pyruvate (methyl pyruvate is the ionized form of methyl pyruvic acid) for the purpose of reducing weight (fat) gain in mammals by orally administering therapeutically effective amounts of methyl pyruvate. The method also has the effect of increasing body protein concentration, improving insulin resistance, lower fasting insulin levels, preventing fat deposition and increasing cellular energy production. When used as a dietary supplement, energizer or pharmaceutical, this anion can be formulated as a salt. The methyl pyruvate compounds which can be used in the present method include: (1) a salt using a monovalent cation (such as sodium or potassium methyl pyruvate) or (2) a divalent cation (such as calcium or magnesium methyl pyruvate) and analogs of these compounds which can act as substrates or substrate analogs for methyl pyruvate Use of methyl pyruvate and/or methyl pyruvic acid can be effective when administered orally or infused on either a chronic and/or acute basis. In the following text, the terms "methyl pyruvate, methyl pyruvate compounds, methyl pyruvic acid"are used interchangeably.

Priority: US2004-710710 Applic. Date: 2004-07-29

Inventor: ANTOSH STANLEY C [US]; MEDURI ANTHONY J [US]

Title: Compositions containing policosanol and B vitamins and their pharmaceutical uses

Applicant/Assignee:

Application No.: 10/900040   Filing Date: 27/Jul/2004

Abstract:A composition is provided which contains policosanol and B vitamins and which may be used for treating and or reducing hypercholesterolemia and hyperhomocysteinemia diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, Lp(a), triglycerides, homocysteine, coronary heart disease (heart attacks and strokes), carotid artery disease, inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, anxiety, depression, neurodegenerative disorders (such as but not limited to Alzheimers), and/or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and B vitamins which together effectively lower the risk of heart disease. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to B vitamins.

Priority:

Inventor: BERLIN ROGER [US]

Title: Crystallization of polyol compositions, crystalline polyol composition product and use thereof

Applicant/Assignee: DANISCO SWEETENERS OY

Application No.: 10/517692   Filing Date: 05/Jul/2005

Abstract:The present invention relates to a microcrystallized polyol comprising at least two polyols, wherein said polyols are selected from the group consisting of maltitol, xylitol and lactitol and wherein said composition contains at least 25% by weight of each of at least two of said polyols microcrystallized together into a solid microcrystalline product. The present invention also relates to a process for the microcrystallization of polyols into a polyol composition. The microcrystallized polyol composition can be used in confectionery, foodstuffs, oral hygiene products and pharmaceuticals and in dietetic products.

Priority: FI20020001312 Applic. Date: 2002-07-03; WO2003FI00533 Applic. Date: 2003-07-02

Inventor: EROMA OLLI-PEKKA [FI]; NYGREN JOHANNA [FI]; HEIKKILA HEIKKI [FI]; SORENSEN PER BO [DK]; SARKKI MARJA-LEENA [FI]; FAIRS IAN [GB]; GROS HAKAN [FI]

Title: Inhalable medicaments containing a new anticholinergic, corticosteroids, and betamimetics

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/182382   Filing Date: 15/Jul/2005

Abstract:A pharmaceutical formulation comprising: (a) at least one anticholinergic of formula 1 wherein X<-> is an anion with a single negative charge

(b) at least one corticosteroid (2)

and (c) at least one betamimetic (3), and the enantiomers, mixtures of the enantiomers, racemates, solvates, hydrates, or physiologically acceptable acid addition salts thereof, processes for preparing them and their use in the treatment of respiratory diseases.

Priority: DE200410038886 Applic. Date: 2004-08-10; DE200410053023 Applic. Date: 2004-11-03

Inventor: PIEPER MICHAEL P [DE]; PAIRET MICHEL [DE]

Title: Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria

Applicant/Assignee:

Application No.: 10/523114   Filing Date: 02/Aug/2005

Abstract:The present invention relates to immunogenic compositions and vaccines for the prevention or treatment of Gram negative bacterial infection. Immunogenic compositions of the invention comprise transferrin binding protein and Hsf, and the combination of these two antigens have been shown to act synergistically to produce antibodies with high activity in a serum bactericidal assay. This combination of antigens is useful for use in vaccines against Neisseria meningitidis, Neisseria gonorrhoeae, Moraxella catarrhalis and Haemophilus influenzae.

Priority: GB20020018037 Applic. Date: 2002-08-02; GB20020018036 Applic. Date: 2002-08-02; GB20020018035 Applic. Date: 2002-08-02; GB20020018051 Applic. Date: 2002-08-02; GB20020020197 Applic. Date: 2002-08-30; GB20020020199 Applic. Date: 2002-08-30; GB20020025524 Applic. Date: 2002-11-01; GB20020025531 Applic. Date: 2002-11-01; GB20020030164 Applic. Date: 2002-12-24; GB20020030168 Applic. Date: 2002-12-24; GB20020030170 Applic. Date: 2002-12-24; GB20030005028 Applic. Date: 2003-03-05; WO2003EP08567 Applic. Date: 2003-07-31

Inventor: BERTHET FRANCOIS-XAVIER J [BE]; BIEMANS RALPH [BE]; DENOEL PHILIPPE [BE]; FERON CHRISTIANE [BE]; GORAJ CARINE [BE]; POOLMAN JAN [BE]; WEYNANTS VINCENT [BE]

Title: Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein

Applicant/Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD

Application No.: 10/506665   Filing Date: 07/Sep/2004

Abstract:The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an AssPP epitope spanning the ss-secretase cleavage site of AssPP and a method for inducing an immune response against the ss-secretase cleavage site of AssPP using this immunizing composition. The present invention is also directed to antibodies against the ss-secretase cleavage site of AssPP and their use in a method for inhibiting the formation of amyloid ss.

Priority: US20020361344P Applic. Date: 2002-03-05; WO2003US06388 Applic. Date: 2003-03-04

Inventor: SOLOMON BEKA [IL]

Title: Pharmaceutical composition for extended release of phenytoin sodium

Applicant/Assignee:

Application No.: 11/199169   Filing Date: 09/Aug/2005

Abstract:The present invention provides an oral extended release solid pharmaceutical composition of phenytoin sodium or its pharmaceutically acceptable derivative thereof and the process of manufacturing the same the said extended release oral solid pharmaceutical composition comprising of at least one suitable pharmaceutically acceptable excipient alongwith phenytoin sodium. The said extended release oral solid pharmaceutical composition is manufactured by blending phenytoin sodium with at least one suitable pharmaceutically acceptable excipient and granulating the blend optionally using at least one suitable binder dissolved in an organic solvent or mixture of solvents.

Priority: US20040600114P Applic. Date: 2004-08-09

Inventor: PATEL SANJAY [US]; MUKHERJI GOUR [IN]; PATIL JAYADEV [IN]; MATE SIDHARTH [IN]

Title: Methods and compositions for the diagnosis and treatment of cancer

Applicant/Assignee:

Application No.: 11/200527   Filing Date: 09/Aug/2005

Abstract:Methods for the treatment of squamous cell carcinoma using a p53-expressing viral vector are disclosed. In particular embodiments, the vector is a replication-deficient adenovirus. In addition, there are provided methods for examining the development and treatment of microscopic residual disease in the context of post-surgical environments and in body cavities.

Priority: US1996-758033 Applic. Date: 1996-11-27; US19950007810P Applic. Date: 1995-11-30

Inventor: CLAYMAN GARY L [US]

Title: Pharmaceutical products and composition comprising specific anticholinergic agents, beta-2 agonists and corticosteroids

Applicant/Assignee: CIPLA LTD

Application No.: 10/525736   Filing Date: 06/Jun/2005

Abstract:This invention relates to pharmaceutical products and compositions for use in the treatment of asthma and related disorders, and especially but not exclusively for the treatment of chronic obstructive pulmonary disease (COPD). More particularly, the invention provides pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids.

Priority: GB20020020095 Applic. Date: 2002-08-29; GB20020027342 Applic. Date: 2002-11-22; WO2003GB03751 Applic. Date: 2003-08-29

Inventor: LULLA AMAR [IN]; MALHOTRA GEENA [IN]

Title: Enteric coated oral pharmaceutical to erode kidney stones

Applicant/Assignee: MED FIVE, INC

Application No.: 11/066621   Filing Date: 25/Feb/2005

Abstract:A treatment protocol by which a renal stone patient is administered a chelating agent, generally once a day and preferably by mouth, during a treatment phase and is later administered the same chelating agent once a week, during a "maintenance" phase. The chelating agent is most preferably ethylene diamine tetraacetic acid (EDTA) and may be provided in a dosage form having an enteric coating and at least one external cathode and at least one external anode to create a galvanic current upon contact of the dosage form with the patient's intestinal contents.

Priority: US20040547909P Applic. Date: 2004-02-26

Inventor: KEITH ALEC D [US]; CRISP WILLIAM E [US]

Title: Conjugates of GM-CSF moiety and a polymer

Applicant/Assignee:

Application No.: 11/181692   Filing Date: 14/Jul/2005

Abstract:Conjugates of a GM-CSF moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions comprising conjugates to a patient.

Priority: US20040588601P Applic. Date: 2004-07-16

Inventor: BOSSARD MARY J [US]; ZHANG PING [US]

Title: Pulmonary delivery of enzymatic medical countermeasures

Applicant/Assignee:

Application No.: 11/195041   Filing Date: 02/Aug/2005

Abstract:The present invention provides for non-invasive treatment of nerve agent poisoning by administering nerve agent neutralizing enzymes to the pulmonary epithelium of a subject, by inhalation, where they accumulate within the lungs. Localization of such enzymes in the pulmonary epithelium results in neutralization of the nerve agents at the lungs. As a result, nerve agents move by diffusion out of the blood through the pulmonary capillaries, duc to the organophosphorus nerve agents rapid diffusion across the cell membranes of the body via diffusion, down their concentration gradients. The present invention presents a practical method of administering nerve agent neutralizing enzymes, without requiring passage into the blood plasma, and without requiring blood plasma activity of the enzyme.

Priority: US20040603186P Applic. Date: 2004-08-20

Inventor: TURNER JEFFREY D [CA]

Title: Taste masked dosage forms and processes for their preparation

Applicant/Assignee:

Application No.: 10/526844   Filing Date: 27/Jul/2005

Abstract:The invention relates to taste masked dosage forms utilizing low amounts of taste masking polymer, and simple and economical processes for the preparation of the taste masked dosage forms. The taste-masked dosage form includes one or more drugs and one or more cationic polymers synthesized from dimethylaminoethyl methacrylate and neutral methacrylic acid esters. The wt/wt ratio of the drug to polymer is less than about one to two.

Priority: IN2002DE00903 Applic. Date: 2002-09-04; WO2003IB03779 Applic. Date: 2003-09-04

Inventor: MURPANI DEEPAK [IN]; ARORA VINOD K [IN]; MALIK RAJIV [AU]

Title: Pharmaceutical compositions of cell lysate and processes for the production and use thereof

Applicant/Assignee: INNOGENETICS N.V CELLTRAN LIMITED

Application No.: 10/537301   Filing Date: 02/Jun/2005

Abstract:The present invention relates to a pharmaceutical composition comprising a non-viable cell lysate and at least one antiflocculant and/or antisedimentation agent(s). The pharmaceutical composition of the present invention comprising the cell lysate is in the form of a solution or a suspension or a lyophilisate, in particular, the homogenized cell lysate compositions are in the form of solutions or suspensions or lyophilisates. The present invention further discloses processes for the production and the use of the pharmaceutical composition.

Priority: EP20020447238 Applic. Date: 2002-12-03; US20020433912P Applic. Date: 2002-12-17; WO2003EP50891 Applic. Date: 2003-11-25

Inventor: VERVAET CHRIS [BE]; REMON JEAN-PAUL [BE]; DELAEY BERNARD [BE]; DE WAELE PETER [BE]

Title: Pharmaceutical composition for inhibition of tumor growth or metastasis

Applicant/Assignee: HEPAGUARD BIOTECHNOLOGY (INT'L) CO., LTD

Application No.: 11/156522   Filing Date: 21/Jun/2005

Abstract:A pharmaceutical composition for inhibition of tumor growth or metastasis which comprises an effective amount of Phyllanthus urinaria L. extracts, or the combination of the foregoing Phyllanthus urinaria L. extracts and pharmaceutical acceptable carries, adjuvants or excipients.

Priority: TW20040124644 Applic. Date: 2004-08-17

Inventor: LIN JUI Y [TW]; MACH WENDY B [TW]; CHEN PO-HSUN [TW]

Title: Method for preventing and/or treating the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered an effective amount of bioflavonoids extract derived from fructus crataegus (lipid metabolism and fructus crataegus)

Applicant/Assignee:

Application No.: 11/226862   Filing Date: 13/Sep/2005

Abstract:A method for treating and/or preventing the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered thereto an effective amount of bioflavonoids extract derived from fructus crataegus such as

rutin, quercetin, kaempferol and vitexin or a mixture thereof.

Priority: US2003-337434 Applic. Date: 2003-01-06

Inventor: LIAO BENEDICT S [US]; LIAO JUDY F [US]; LIAO ALEX [US]; LIAO AUSTIN [US]; LIAO BURTON A [US]; LIAO-TUNG SU-HSIN [US]; LIAO-NIENG SUSAN [US]; NIENG CATHY [US]; LIAO-CHEN SU-LIEN [US]; LIAO SCHUE-YUAN [US]

Title: Composition containing tinospora cordifolia and process for obtaining same

Applicant/Assignee:

Application No.: 11/219117   Filing Date: 02/Sep/2005

Abstract:The present invention relates to a composition for use in a nutritional product, dietary supplement, food or pharmaceutical composition wherein such composition includes the plant Tinospora cordifolia or Tinospora cordifolia extract and is used to treat allergies, including but not limited to seasonal, perennial, or sporadic allergic rhinitis. The present invention further relates to an extraction process for obtaining such composition.

Priority: US20040606749P Applic. Date: 2004-09-02

Inventor: HINGORANI LAL [IN]; THAWANI VIJAY [IN]

Title: Purified Arabinogalactan-Protein (AGP) composition useful in the treatment psoriasis and other disorders

Applicant/Assignee: LUPIN LABORATORIES LIMITED LUPIN LIMITED

Application No.: 10/931814   Filing Date: 01/Sep/2004

Abstract:A purified Arabinogalactan-Protein (AGP) composition isolated through a selective method from the leaves and/or stems of Argemone mexicana plant is described. Also described is a purified Arabinogalactan-Protein (AGP) composition isolated from the leaves and/or stems of Argemone mexicana plant, which has one or more of the following effects: immunosuppression, lymphoproliferation inhibition, cytokine modulation such as IL-2 inhibition, IFN-gamma inhibition, or IL-10 induction

keratinocyte proliferation inhibition, keratolytic activity and inhibitory activity in Mouse Ear Swelling test (MEST).

Priority:

Inventor: ARORA SUDERSHAN K [IN]; SRIVASTAVA VANDITA [IN]; WALUNJ SAMEER S [IN]

Title: N-acyl modified polysaccharides and pharmaceutical compositions comprising same

Applicant/Assignee:

Application No.: 11/214332   Filing Date: 28/Aug/2005

Abstract:This invention relates to novel N-acyl modified polysaccharides and pharmaceutical compositions comprising the modified polysaccharides. Further the invention relates to processes for using such compounds to inhibit lipases, to lower cholesterol, to lower the absorption of dietary fat, or as a dietary fiber supplement. In a preferred aspect of the invention the modified polysaccharides are capable of absorbing substantial amounts of oils or fats while dissipating in an aqueous solution. The invention also relates to a non-absorbable and essentially non-digestible polysaccharide fiber composition.

Priority: US20040605935P Applic. Date: 2004-08-30; US20040605931P Applic. Date: 2004-08-30

Inventor: GENTRY MULLINS JOHN J [US]

Title: Method for producing an immediately decomposing oral form of administration which releases active ingredients

Applicant/Assignee: ROEHM GMBH & CO. KG

Application No.: 10/542283   Filing Date: 15/Jul/2005

Abstract:The invention relates to a method for producing an oral form of administration which decomposes immediately and releases active ingredients in the mouth. According to said method, (a) an anionic pharmaceutical active ingredient is intensively mixed with (b) a copolymer consisting of radically polymerized C1-C4 esters of the acrylic acid or methacrylic acid and other (meth)acrylate monomers containing functional tertiary amino groups, and (c) between 5 and 50 wt. %, in relation to (b), of a C12-C22 carboxylic acid in the melted mass

the mixture is solidified and ground to form a powder containing active ingredients having an average particle size of 200 mum or less

and the powder is encapsulated in a water-soluble matrix consisting of pharmaceutically standard adjuvants, on the condition that no more than 3 wt. %, in relation to the copolymer, of emulsifiers with an HLB value of at least 14 must be contained therein. The invention also relates to the powder containing active ingredients and the uses of the same.

Priority: DE20031004403 Applic. Date: 2003-01-28; WO2003EP13059 Applic. Date: 2003-11-21

Inventor: PETEREIT HANS-ULRICH [DE]; MEIER CHRISTIAN [DE]; GRYCZKE ADREAS [DE]

Title: Pharmaceutical formulations of potassium ATP channel openers and uses thereof

Applicant/Assignee: ESSENTIALIS, INC

Application No.: 11/212130   Filing Date: 25/Aug/2005

Abstract:Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering KATP channel openers with other drugs to treat diseases of humans and animals.

Priority: US20040604085P Applic. Date: 2004-08-25; US20050654571P Applic. Date: 2005-02-22; US20050668912P Applic. Date: 2005-04-06; US20040624219P Applic. Date: 2004-11-03

Inventor: COWEN NEIL M [US]; KASHKIN KENNETH B [US]

Title: Stabilised solid drug dispersions in an organic carrier and a process for preparing the same

Applicant/Assignee: EURAND S.P.A

Application No.: 10/540139   Filing Date: 21/Jun/2005

Abstract:New solid drug dispersions are described in which the drug is present in amorphous form and massively dispersed (in bulk) inside the particles of an organic carrier selected from cross-linked polymers and/or a complexing agents. These dispersions are obtainable by mixing together the drug and the carrier and applying an oscillating electromagnetic field to the mixture, to a frequency belonging to the microwave region

the microwaves are applied according to a specific heating cycle wherein the drug-carrier mixture is heated at a temperature higher than the melting point of the drug for at least 5 minutes. With respect to the known techniques, the present invention allows to increase in the amount of drug incorporated into the carrier in amorphous form, and to increase the physical stability of the amorphous phase. This is particularly useful in the preparation of pharmaceutical compositions based on drugs which are crystalline in nature, such as are notoriously sparingly soluble in water: thanks to the increased amounts and stability of the drug in amorphous form, the resulting formulations have a more rapid and intense effect, and are endowed with greater bioavailability.

Priority: IT2002MI02748 Applic. Date: 2002-12-23; WO2003EP14740 Applic. Date: 2003-12-22

Inventor: COLOMBO ITALO [IT]; GERVASONI DARIO [IT]

Title: GRAS composition for enhanced mucosal delivery of parathyroid hormone

Applicant/Assignee: NASTECH PHARMACEUTICAL COMPANY INC

Application No.: 11/246450   Filing Date: 06/Oct/2005

Abstract:What is described is an aqueous pharmaceutical composition for intranasal delivery of PTH, comprising a PTH molecule, and one or more excipients selected from the group consisting of a chelating agent, an alcohol, and a surface active agent, wherein the PTH molecule selected from the group consisting of SEQ NO: 1, SEQ NO: 2, and SEQ NO: 3.

Priority: US2005-126996 Applic. Date: 2005-05-10; US20040570113P Applic. Date: 2004-05-10

Inventor: COSTANTINO HENRY R [US]; LI CHING-YUAN [US]

Title: Use of methyl pyruvate or methyl pyruvic acid for the treatment of diseases of the nervous system and for protecting a human central nervous system against neuronal degeneration caused by defective intracellular energy production.

Applicant/Assignee:

Application No.: 10/711255   Filing Date: 04/Sep/2004

Abstract:The present invention relates to the use of methyl pyruvic acid (a methyl ester of pyruvic acid) and/or methyl pyruvate (methyl pyruvate is the ionized form of methyl pyruvic acid) for the purpose of treating diseases of the nervous system and/or to prevent against neuronal degeneration due to defective intracellular energy production. Methyl pyruvate compounds can be used as therapeutically effective agents against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, Parkinson's disease, stroke, Huntington's disease, amyotropic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination, demyelination disorders, or cellular disorders which interfere with the energy metabolism of neurons and mitochondrial diseases. Use of methyl pyruvate and/or methyl pyruvic acid can be effective when administered orally or infused on either a chronic and/or acute basis. Treatment can be effective even when administered after the onset of an ischemic event that triggers neurodegeneration. In the following text, the terms "methyl pyruvate, methyl pyruvate compounds, methyl pyruvic acid" are used interchangeably.

Priority:

Inventor: ANTOSH STANLEY C [US]; MEDURI ANTHONY J [US]

Title: Wet granulation process

Applicant/Assignee: PARI GMBH

Application No.: 10/517910   Filing Date: 08/Dec/2004

Abstract:The invention is in the field of pharmaceutical dosage forms, and more particularly in the field of pharmaceutical granules and processes for making granules. The invention provides a process for preparing pharmaceutical granules which contain an active ingredient in the form of a salt, said process comprising the steps of (a) providing a powder containing the active ingredient as a free base or acid, and (b) agglomerating the powder by adding a granulation liquid to form granules

wherein step (b) is conducted in the presence of a neutralization agent capable of neutralizing the active ingredient, and for a sufficient amount of time to allow the active ingredient to become at least partially converted into a salt. The invention also provides pharmaceutical granules obtainable by said process and pharmaceutical compositions comprising said granules. The invention further provides the use of pharmaceutical granules for the pulmonary delivery of an active ingredient.

Priority: EP20020025006 Applic. Date: 2002-11-08; WO2003EP11949 Applic. Date: 2003-10-28

Inventor: LINTZ FRANK-CHRISTOPHE [DE]; KELLER MANFRED [DE]

Title: Orally disintegrating tablets of atomoxetine

Applicant/Assignee:

Application No.: 11/223819   Filing Date: 09/Sep/2005

Abstract:A coated multi-particulate pharmaceutical dosage form such as an orally disintegrating tablet (ODT) presentation for delivering atomoxetine or a pharmaceutically acceptable salt thereof, a selective norepinephrine reuptake inhibitor indicated for the treatment of ADHD, into the body to maintain a therapeutically effective amount of atomoxetine in the plasm. The dosage form may comprise one or more populations of coated atomoxetine-containing particles (beads, pellets, granules etc.) providing a pre-designed rapid release profile after a predesigned lag-time of about 0 to 6 hours following oral administration.

Priority: US20040609312P Applic. Date: 2004-09-13

Inventor: VENKATESH GOPI M [US]; HARMON TROY M [US]; TAYLOR JOHN [US]

Title: Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene

Applicant/Assignee: PFIZER INC

Application No.: 11/270766   Filing Date: 08/Nov/2005

Abstract:A fast disintegrating dosage form of varenicline comprising an effective amount of varenicline or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the dosage form disintegrates in a patient's oral cavity in less than three minutes. Also provided are a method for reducing nicotine addiction, aiding in the cessation of, or lessening of tobacco use in a subject by administering to the subject an effective amount of the fast disintegrating dosage form of varenicline or pharmaceutically acceptable salts thereof

a method of treating a disorder or condition by administering an effective amount of the fast disintegrating dosage form of varenicline

and, various methods of manufacturing or forming an immediate dosage form of varenicline.

Priority: US2002-300608 Applic. Date: 2002-11-20; US20010334652P Applic. Date: 2001-11-30; US20050642083P Applic. Date: 2005-01-07

Inventor: ZIEGLER CARL B [US]; JOHNSON BARBARA A [US]

Title: Novel composition

Applicant/Assignee: LABORATOIRE GLAXOSMITHKLINE

Application No.: 11/203573   Filing Date: 09/Aug/2005

Abstract:A pharmaceutical composition comprising N-[(1-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide (SB 207266) or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable carriers, wherein at least some of the SB 207266 or salt thereof is in granulated form. Preferably, a filler and/or binder are also present.

Priority: GB20000019524 Applic. Date: 2000-08-08; GB20010018919 Applic. Date: 2001-08-02; GB20010019022 Applic. Date: 2001-08-03; US2002-055817 Applic. Date: 2002-01-23; WO2001GB03590 Applic. Date: 2001-08-08

Inventor: BUXTON PHILIP C [GB]; THOMSON SEONA [GB]; VAN-SCHIE DIRK M J [GB]

Title: D-methionine formulation with improved biopharmaceutical properties

Applicant/Assignee: MOLECULAR THERAPEUTICS, INC

Application No.: 11/225107   Filing Date: 14/Sep/2005

Abstract:The present invention provides pharmaceutical suspensions of D-methionine in which the aqueous solubility of D-methionine is exceeded, thereby allowing oral administration of higher doses. The present invention also provides processes for preparing these suspensions. The present invention further provides methods for preventing, treating, or ameliorating oral mucositis, hearing loss due to chemotherapy, antibiotics and noise, neuronal damage due to various CNS disorders and injuries, and anthracycline toxicity.

Priority: US20040609255P Applic. Date: 2004-09-14

Inventor: SUNKARA PRASAD [US]

Title: Pharmaceutical dosage forms with impeded extractability of a sympathomimetic

Applicant/Assignee: BASF AKTIENGESELLSCHAFT

Application No.: 11/225176   Filing Date: 14/Sep/2005

Abstract:A solid oral pharmaceutical dosage form of a sympathomimetic with impeded extractability of the sympathomimetic, comprising I) a sympathomimetic (component I) II) an excipient mixture (component II) composed of a) 5 to 50% by weight of hydroxyalkylcelluloses or alkylcelluloses or mixtures thereof b) 5 to 70% by weight of xant

Priority: DE200410045037 Applic. Date: 2004-09-15

Inventor: KOLTER KARL [DE]; WICHTNER MARCUS [DE]; MEYER KATHRIN [DE]; EINIG HEINZ [DE]

Title: Formulation comprising itraconazole

Applicant/Assignee: NEKTAR THERAPEUTICS UK LIMITED

Application No.: 11/228541   Filing Date: 16/Sep/2005

Abstract:Formulations of azole antifungals such as itraconazole and particularly formulations, co-formulations and compositions of itraconazole with one or more oligomeric and/or polymeric excipients are disclosed. Methods for preparation of the formulations, co-formulations and compositions include co-precipitating the two materials from a common solvent or solvent mixture using a compressed (typically supercritical or near-critical) fluid anti-solvent as in the GAS (Gas Anti-Solvent) precipitation method. The formulations, co-formulations, compositions, methods of making and methods of delivering, are useful as pharmaceutical compositions and in medical treatment by virtue of their at least parity, preferably improved or enhanced solubility or dissolution characteristics, resulting in at least parity, preferably improved or enhanced bioavailability and/or pharmacokinetics.

Priority: US20040611102P Applic. Date: 2004-09-17

Inventor: GERMAN CAROLINE [GB]; SLOAN RAYMOND [GB]

Title: Pharmaceutical composition for inhibiting influenza virus infection and reproduction

Applicant/Assignee: FAR EAST MICROALGAE IND. CO., LTD

Application No.: 11/128189   Filing Date: 13/May/2005

Abstract:The present invention relates to a pharmaceutical composition for inhibiting influenza virus infection and reproduction, comprising a effective amount of C-phycocyanin (C-PC), allophycocyanin (APC), spirulina growth factor (SGF) or the mixture thereof. The present invention also provides a method for extracting said pharmaceutical composition, comprising the steps of: (a) adding hypotonic buffer solution to organic blue-green algae powder and mixing thoroughly

(b) incubating the mixture below room temperature overnight

(c) separating and purifying the mixture by a centrifuge

(d) collecting the suspending supernatant and detecting it by a spectrometer to determine ingredients and content

and (e) spray drying the supernatant

characterized in which low-temperature extraction is employed to maintain the bioactivity and nutrients of the pharmaceutical composition.

Priority: TW20040128553 Applic. Date: 2004-09-21

Inventor: CHIUEH CHUANG C [TW]; SHIH SHIN R [TW]

Title: Pharmaceutical composition comprising esterol derivatives for use in cancer therapy

Applicant/Assignee:

Application No.: 10/521040   Filing Date: 16/Aug/2005

Abstract:The present invention relates to a method of treating or preventing estrogen-sensitive tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula

Priority: EP20020077812 Applic. Date: 2002-07-12; EP20030075435 Applic. Date: 2003-02-14; WO2003NL00513 Applic. Date: 2003-07-11

Inventor: COELINGH BENNINK HERMAN JAN T [NL]; BUNSCHOTEN EVERT J [NL]

Title: Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof

Applicant/Assignee: PLIVA-LACHEMA A.S. A CZECH REPUBLIC CORPORATION

Application No.: 10/549296   Filing Date: 15/Sep/2005

Abstract:The invention relates to a pharmaceutical composition containing the platinum complex of formula (I) as an active substance where A, A', B, B', X and X' have specific meanings, in a mixture with at least one pharmaceutically acceptable excipient, characterized in that it is formed of a granulate with particles smaller than 0.5 mm in size prepared by wet granulation of a mixture of platinum complex of tetravalent platinum of formula (I) wetted by water, at least one neutral saccharide and at least one native and/or modified polysaccharide, being optionally contained in a capsule or a sack or being optionally pressed into the form of a tablet, while the surface of the granulate, the capsule or the tablet is optionally coated with a layer of at least one pharmaceutically acceptable substance enabling enterosolvent dissolution of the active substance in bowels only and/or at least one pharmaceutically acceptable substance enabling the controlled release of the active substance. The invention relates also the method of manufacturing of said pharmaceutical composition.

Priority: CZ20030000915 Applic. Date: 2003-03-31; CZ20040000235 Applic. Date: 2004-02-12; WO2004CZ00017 Applic. Date: 2004-03-30

Inventor: FRANC ALES [CZ]; SOVA PETER [CZ]

Title: Compounds to treat hiv infection and aids

Applicant/Assignee:

Application No.: 10/497898   Filing Date: 28/Mar/2005

Abstract:The present invention relates to compounds of formula I: useful HIV infection, AIDS, and other similar diseases. These compounds include inhibitors of the retroviral integrase enzyme that are useful in the treatment of HIV infection, AIDS, and other similar diseases characterized by integration of a retroviral genome into a host chromosome. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce incorporation of a donor DNA into a receiving DNA.

Priority: US20010339137P Applic. Date: 2001-12-07; WO2002US39254 Applic. Date: 2002-12-06

Inventor: BURKE TERRENCE R [US]; ZHANG XUECHUN [US]; PAIS GODWIN C [US]; SVAROVSKAIA EVGUENIA [US]; PATHAK VINAY K [US]; MARCHAND CHRISTOPHE [US]; POMMIER YVES [US]

Title: Solid dosage form comprising a fibrate and a statin

Applicant/Assignee:

Application No.: 10/513778   Filing Date: 14/Jul/2005

Abstract:The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of a fibrate, notably fenofibrate, and a statin (also known as a HMG CoA reductase inhibitors), which compositions are manufactured without any need of addition of water or an aqueous medium and wherein at least 80% of the active substances (i.e. the fibrate and the statin) are present in the composition in dissolved form in order to ensure suitable bioavailability of both active ingredients upon oral administration

Priority: DK20030001503 Applic. Date: 2003-10-10; DK20040000464 Applic. Date: 2004-03-23; WO2004DK00668 Applic. Date: 2004-10-01

Inventor: HOLM PER [DK]; NORLING TOMAS [DK]

Title: Coated polyunsaturated fatty acid-containing particles and coated liquid pharmaceutical-containing particles

Applicant/Assignee:

Application No.: 10/523225   Filing Date: 31/Jan/2005

Abstract:A process for coating a polyunsaturated fatty acid (PUFA)-containing carrier particle or a PUFA matrix particle, or a liquid pharmaceutical-containing carrier particle or a liquid pharmaceutical matrix particle. Also disclosed are such particles made by the process of the invention and foods, pharmaceuticals, beverages, nutritional supplements, infant formula, pet food and animal feed with incorporate such particles.

Priority: US20020403598P Applic. Date: 2002-08-14; WO2003US25873 Applic. Date: 2003-08-14

Inventor: DALZIEL SEAN M [US]; FRIEDMANN THOMAS E [US]; SCHURR GEORGE A [US]

Title: Cancer specific gene MH15

Applicant/Assignee: MEDIGEN BIOTECHNOLOGY CORPORATION

Application No.: 11/074129   Filing Date: 07/Mar/2005

Abstract:MH15 (Hn1L) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MH15 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MH15 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MH15 expression or activity, thereby treating cancer, in vivo.

Priority: US20040551084P Applic. Date: 2004-03-08

Inventor: CHANG STANLEY [TW]; CHANG HSUN-LANG [TW]; KUO WEI-YING [TW]; CHEN KUO-YEN [TW]; LI NING-YI [TW]; HSU CHIH-PING [TW]; HO PEI-HSUN [TW]

Title: Methods and compositions for the treatment of diseases characterized by pathological calcification

Applicant/Assignee: NANOBAC PHARMACEUTICALS, INC

Application No.: 11/102798   Filing Date: 11/Apr/2005

Abstract:Methods and compositions are provided which contains preparations of calcium chelators, bisphosphonates, antibiotics, antimicrobial agents, cytostatic agents, calcium ATPase and pyrophosphatase pump inhibitors, calcium phosphate-crystal dissolving agents, agents effective against calcium phosphate-crystal nucleation and crystal growth, and/or a combination of supportive agents and which may be used for treating and or reducing pathological calcifications, the growth of Nanobacterium and calcification-induced diseases including, but not limited to, Arteriosclerosis, Atherosclerosis, Coronary Heart Disease, Chronic Heart Failure, Valve Calcifications, Arterial Aneurysms, Calcific Aortic Stenosis, Transient Cerebral Ischemia, Stroke, Peripheral Vascular Disease, Vascular Thrombosis, Dental Plaque, Gum Disease (dental pulp stones), Salivary Gland Stones, Chronic Infection Syndromes such as Chronic Fatigue Syndrome, Kidney and Bladder Stones, Gall Stones, Pancreas and Bowel Diseases (such as Pancreatic Duct Stones, Crohn's Disease, Colitis Ulcerosa), Liver Diseases (such as Liver Cirrhosis, Liver Cysts), Testicular Microliths, Chronic Calculous Prostatitis, Prostate Calcification, Calcification in Hemodialysis Patients, Malacoplakia, Autoimmune Diseases. Erythematosus, Scleroderma, Dermatomyositis, Antiphospholipid Syndrome, Arteritis Nodosa, Thrombocytopenia, Hemolytic Anemia, Myelitis, Livedo Reticularis, Chorea, Migraine, Juvenile Dermatomyositis, Grave's Disease, Hypothyreoidism, Type 1 Diabetes Mellitus, Addison's Disease, Hypopituitarism, Placental and Fetal Disorders, Polycystic Kidney Disease, Glomerulopathies, Eye Diseases (such as Corneal Calcifications, Cataracts, Macular Degeneration and Retinal Vasculature-derived Processes and other Retinal Degenerations, Retinal Nerve Degeneration, Retinitis, and Iritis), Ear Diseases (such as Otosclerosis, Degeneration of Otoliths and Symptoms from the Vestibular Organ and Inner Ear (Vertigo and Tinnitus)), Thyroglossal Cysts, Thyroid Cysts, Ovarian Cysts, Cancer (such as Meningiomas, Breast Cancer, Prostate Cancer, Thyroid Cancer, Serous Ovarian Adenocarcinoma), Skin Diseases (such as Calcinosis Cutis, Calciphylaxis, Psoriasis, Eczema, Lichen Ruber Planus), Rheumatoid Arthritis, Calcific Tenditis, Osteoarthritis, Fibromyalgia, Bone Spurs, Diffuse Interstitial Skeletal Hyperostosis, Intracranial Calcifications (such as Degenerative Disease Processes and Dementia), Erythrocyte-Related Diseases involving Anemia, Intraerythrocytic Nanobacterial Infection and Splenic Calcifications, Chronic Obstructive Pulmonary Disease, Broncholiths, Bronchial Stones, Neuropathy, Calcification and Encrustations of Implants, Mixed Calcified Biofilms, and Myelodegenerative Disorders (such as Multiple Sclerosis, Lou Gehrig's and Alzheimer's Disease) in humans and animals. The method comprises administering the various classes of compositions of the present invention, which together effectively inhibit or treat the development of calcifications in vivo.

Priority: US2004-891483 Applic. Date: 2004-07-15

Inventor: KAJANDER E O [US]; AHO K M [FI]; CIFTCIOGLU N [US]; MILLICAN B [US]

Title: Medicaments for inhalation comprising steroids and an anticholinergic

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/168619   Filing Date: 27/Jun/2005

Abstract:The present invention relates to novel pharmaceutical compositions based on steroids and salts of an anticholinergic, processes for preparing them and their use in the treatment of respiratory complaints.

Priority: EP20040015200 Applic. Date: 2004-06-29

Inventor: PIEPER MICHAEL P [DE]; PAIRET MICHEL [DE]

Title: Adherent and erodible film to treat a moist surface of a body tissue

Applicant/Assignee: ACCESS PHARMACEUTICALS, INC

Application No.: 11/192524   Filing Date: 29/Jul/2005

Abstract:A thin, flexible, bilayer or multi-layer film which when applied to a moist surface of a body tissue adheres and delivers an active agent, pharmaceutical compound, nutraceutical, flavor or other substance to the underlying surface and/or body cavity and erodes at a predetermined rate. In one application, the amount of time that the active agent remains in contact with the teeth surfaces is controlled by the composition and thickness of the backing layer of the composite film. This erosion or residence time can be regulated from one half hour to several hours, depending upon the desired therapeutic or cosmetic application.

Priority: US2001-931319 Applic. Date: 2001-08-16; US2003-444512 Applic. Date: 2003-05-23

Inventor: MORO DANIEL G [US]; NOWOTNIK DAVID P [US]; CALLAHAN ERNEST H JR [US]

Title: Conveniently implantable sustained release drug compositions

Applicant/Assignee:

Application No.: 11/236426   Filing Date: 27/Sep/2005

Abstract:This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.

Priority: US20040614484P Applic. Date: 2004-10-01; US20050709665P Applic. Date: 2005-08-19

Inventor: WONG VERNON G [US]; WOOD LOUIS L [US]

Title: Dry polymer and lipid composition

Applicant/Assignee: CAMURUS AB

Application No.: 10/548588   Filing Date: 12/Sep/2005

Abstract:The present invention provides an orally administrable composition comprising a dry mixture of polymer, lipid and bioactive agent, being capable on contact with water or GI tract liquid of forming particles comprising said lipid and said bioactive agent and optionally also water. It is preferable that such particles have a liquid crystalline phase structure. The invention also provides a method for the formation of compositions comprising polymer, lipid and bioactive agent.

Priority: GB20030005941 Applic. Date: 2003-03-14; WO2004GB01099 Applic. Date: 2004-03-12

Inventor: LJUSBERG-WAHREN HELENA [SE]; JOABSSON FREDRIK [SE]; THURESSON KRISTER [SE]

Title: Mixed esters of hyaluronic acid with retinoic and butyric acids

Applicant/Assignee:

Application No.: 10/540939   Filing Date: 23/Jun/2005

Abstract:The present invention relates to mixed esters of hyaluronic acid, wherein the hydroxyl groups are partially esterified with retinoic and butyric acids. These mixed esters are characterized by specific degrees of esterification and by a high ratio between the degree of substitution with butyric acid and retinoic acid. They exhibit a high anti-proliferative activity associated with activation of cell differentiation, with consequent clinical relevance in the treatment of hyper-proliferative pathologies and in particular of solid and systemic tumors.

Priority: IT2002MI02745 Applic. Date: 2002-12-23; WO2003EP14732 Applic. Date: 2003-12-22

Inventor: PERBELLINI ALBERTO [IT]; CORADINI DANILA [IT]

Title: Solid pharmaceutical formulations comprising Diacereine and Meloxicam

Applicant/Assignee: LEOPOLDO ESPINOSA ABDALA

Application No.: 11/186031   Filing Date: 30/Sep/2005

Abstract:This invention relates to formulations in solid pharmaceutical forms containing diacereine and meloxicam. The present invention provides novel formulations comprising: (a) Diacereine, (b) Meloxicam, (c) one or more anti-adherent agents, (d) one or more disintegrating agents, (e) one or more binder agents, (f) one or more lubricants, (g) one or more diluents, (h) one or more solvents, and (i) any other additive which assists in formulation. The present invention also provides a method for treatment of osteoarthritis, rheumatoid arthritis, gout arthritis, multiple sclerosis, amyotrophic lateral sclerosis and related diseases, in addition of inflammatory processes originated from various etiologies, by administering suitable doses.

Priority: MX2004PA09698 Applic. Date: 2004-10-04

Inventor: ARMENTA MARIA ELENA G [MX]; MURILLO JOSEFINA S [MX]; OCHOA VICTOR GUILLERMO A [MX]; MENDOZA CONSUELO F [MX]

Title: Gel-based delivery of recombinant adeno-associated virus vectors

Applicant/Assignee:

Application No.: 11/055497   Filing Date: 10/Feb/2005

Abstract:Disclosed are water-soluble gel-based compositions for the delivery of recombinant adeno-associated virus (rAAV) vectors that express nucleic acid segments encoding therapeutic constructs including peptides, polypeptides, ribozymes, and catalytic RNA molecules, to selected cells and tissues of vertebrate animals. Also disclosed are gel-based rAAV compositions are useful in the treatment of mammalian, and in particular, human diseases, including for example, cardiac disease or dysfunction, and musculoskeletal disorders and congenital myopathies, including, for example, muscular dystrophy, acid maltase deficiency (Pompe's disease), and the like. In illustrative embodiments, the invention provides rAAV vectors comprised within a biocompatible gel composition for enhanced viral delivery/transfection to mammalian tissues, and in particular to vertebrate muscle tissues such as a human heart or diaphragm tissue.

Priority: US20040543508P Applic. Date: 2004-02-10

Inventor: MAH CATHRYN S [US]; FRAITES THOMAS J JR [US]; BYRNE BARRY J [US]

Title: Taste-masked pharmaceutical compositions

Applicant/Assignee:

Application No.: 11/248596   Filing Date: 12/Oct/2005

Abstract:There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity in about 60 seconds forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active) applied with a taste-masking membrane comprising a combination of water-insoluble and gastrosoluble polymers release not less than about 60% of the dose is in the stomach in about 30 minutes, thus maximizing the probability of achieving bioequivalence to the reference IR product having rapid onset of action (short Tmax). A process for preparing such compositions for oral administration using conventional fluid-bed equipment and rotary tablet press is also disclosed.

Priority: US20040617737P Applic. Date: 2004-10-12

Inventor: VENKATESH GOPI M [US]

Title: Bilayer tablet of telmisartan and simvastatin

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/236911   Filing Date: 28/Sep/2005

Abstract:A bilayer tablet comprises a first layer formulated for instant release of the angiotensin II receptor antagonist telmisartan from a dissolving tablet matrix and a second layer formulated for instant release of the HMG-CoA reductase inhibitor simvastatin from a disintegrating or eroding tablet matrix.

Priority: EP20040024239 Applic. Date: 2004-10-12

Inventor: KOHLRAUSCH ANJA [DE]

Title: Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent

Applicant/Assignee: EMISPHERE TECHNOLOGIES, INC

Application No.: 11/204778   Filing Date: 15/Aug/2005

Abstract:This invention relates to microparticles and/or nanoparticles containing a delivery agent and/or an active agent. This invention also relates to pharmaceutical formulations and solid dosage forms, including controlled release solid dosage forms of active agent and a delivery agent.

Priority: US20040601258P Applic. Date: 2004-08-13; US20040612810P Applic. Date: 2004-09-23

Inventor: DHOOT NIKHIL [US]; LEVCHIK HALINA [US]; MAJURU SHINGAI [US]; KLEIN GEORGE [US]; HARRIS JAMILA [US]; LIU PUCHUN [US]; DINH STEVEN [US]; LIAO JUN [US]; LEE JONGBIN [US]; ARBIT EHUD [US]; WANG NAI F [US]

Title: Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions

Applicant/Assignee: UNIGEN PHARMACEUTICALS, INC

Application No.: 11/254433   Filing Date: 19/Oct/2005

Abstract:The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds-Free-B-Ring flavonoids and flavans-for use in the prevention and treatment of diseases and conditions associated with mouth, gums and teeth. This composition of matter simultaneously inhibits cyclooxygenase (COX) and lipoxygenase (LOX) enzymatic activity and reduces cytokine production at the mRNA level in normal, aged and damaged periodontal cells and tissues. This invention further provides a method for the prevention and treatment of diseases and conditions of the mouth, gums and teeth. The method for preventing and treating diseases and conditions of the mouth, teeth and gums is comprised of administering to a host in need thereof a therapeutically effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants, preferably in the Scutellaria, Oroxylum, Acacia or Uncaria genus of plants and pharmaceutically and/or cosmetically acceptable carriers. Finally the present invention provides a method for the prevention and treatment of diseases and conditions of the mouth, teeth or gums, including but not limited to periodontal diseases, such as gingivitis, periodontitis, pulpitis, periodontal conditions caused by the physical implantation of oral dentures, trauma, injuries, bruxism, neoplastic and other degenerative processes

material alba, pellicles, dental plagues, calculus, and stains. Use of the composition described herein also affords the benefit of maintaining optimum saliva production and pH, minimizing bacterial growth, reducing the formation of pellicles and plague, inhibiting tooth decalcification and tooth caries (decay), promoting remineralization, which yields healthy gums, whitening teeth, maintaining healthy oral hygiene and reducing oral malodour (halitosis).

Priority: US2003-427746 Applic. Date: 2003-04-30; US2003-462030 Applic. Date: 2003-06-13; US2004-785704 Applic. Date: 2004-02-24; US2004-932571 Applic. Date: 2004-09-01; US20040620163P Applic. Date: 2004-10-19; US20020377168P Applic. Date: 2002-04-30; US20030450922P Applic. Date: 2003-02-26; US20030499742P Applic. Date: 2003-09-02

Inventor: JIA QI [US]; ZHAO YUAN [US]

Title: Agglomerates by crystallisation

Applicant/Assignee:

Application No.: 11/290185   Filing Date: 30/Nov/2005

Abstract:The present invention describes novel agglomerates in crystalline form of beta-lactum compounds, Furthermore, a process for the preparation of said agglomerates, wherein a solution or suspension of at least one beta-lactum compound in a solvent is mixed with one or more anti-solvents has been described.

Priority: EP19990201034 Applic. Date: 1999-04-01; US2002-937834 Applic. Date: 2002-02-13; WO2000EP02917 Applic. Date: 2000-04-03

Inventor: BOOIJ JOHANNES [NL]; LEFFERTS GEERTRUIDA A [NL]

Title: Methods and compositions including methscopolamine nitrate

Applicant/Assignee:

Application No.: 10/964252   Filing Date: 13/Oct/2004

Abstract:Therapeutic pharmaceutical compositions are provided that include an anticholinergic agent and a sedative agent. Particularly preferred anticholinergic agents include anticholinergic agents which do not substantially cross the blood-brain barrier. Methscopolamine nitrate is the preferred anticholinergic agent. The sedative agent may be a benzodiazepine or a barbiturate. Particularly, the sedative agent may be chlordiazepoxide hydrochloride, diazepam, or phenobarbital. Various methods using the compositions to alleviate gastrointestinal disorders or symptoms thereof are also provided.

Priority:

Inventor: PRESTON DAVID M [US]

Title: Methods and compositions including methscopolamine bromide

Applicant/Assignee: VICTORY PHARMA INCORPORATED

Application No.: 11/001748   Filing Date: 02/Dec/2004

Abstract:Therapeutic pharmaceutical compositions are provided that include an anticholinergic agent and a sedative agent. Particularly preferred anticholinergic agents include anticholinergic agents which do not substantially cross the blood-brain barrier. Methscopolamine bromide is the preferred anticholinergic agent. The sedative agent may be chlordiazepoxide hydrochloride or diazepam. Various methods using the compositions to alleviate gastrointestinal disorders or symptoms thereof are also provided.

Priority: US2004-964252 Applic. Date: 2004-10-13

Inventor: PRESTON DAVID M [US]

Title: Novel therapy for lysosomal enzyme deficiencies

Applicant/Assignee: UNIVERSITY OF MASSACHUSETTS

Application No.: 11/230017   Filing Date: 19/Sep/2005

Abstract:The present invention provides a therapeutic delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload trapping molecule and a payload molecule, wherein the payload molecule and the payload trapping molecule are soluble in the same solvent system wherein the payload molecule supplements the function of the deficient lysosomal enzyme. The invention further provides methods of making and methods of using the therapeutic delivery system.

Priority: US2004-869693 Applic. Date: 2004-06-16; US20040610872P Applic. Date: 2004-09-17

Inventor: GINNS EDWARD I [US]; OSTROFF GARY R [US]

Title: Stabilization of the profile of release of active substances from a formulation

Applicant/Assignee:

Application No.: 10/521295   Filing Date: 17/May/2005

Abstract:The invention discloses a method of a physical pre-treatment of an active substance, which modifies technologically important physical properties of the active substance so as to enable the manufacture of a formulation having a more stable release profile of the active substance over the whole shelf life of the medicine than the profile would be with the same composition, but without pre-treatment.

Priority: SI20020000179 Applic. Date: 2002-07-17; WO2003SI00025 Applic. Date: 2003-07-15

Inventor: RESMAN ALEKSANDER [SI]; FERCEJ-TEMELJOTOV DARJA [SI]; HUMAR VLASTA [SI]; OPRESNIK MARKO [SI]

Title: Large dose ribavirin formulations

Applicant/Assignee: THREE RIVERS PHARMACEUTICALS, LLC

Application No.: 11/201311   Filing Date: 11/Aug/2005

Abstract:The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg to 600 mg tablets. These dosage forms are bioequivalent to multiple doses of tablets containing small amounts of ribavirin.

Priority: US20040619013P Applic. Date: 2004-10-18

Inventor: KERRISH DONALD J [US]; DHANANTWARI RAVINDRA [US]

Title: Taste masking pharmaceutical composition containing levocetirizine

Applicant/Assignee: GLENMARK PHARMACEUTICALS LIMITED

Application No.: 11/193542   Filing Date: 29/Jul/2005

Abstract:A solid oral dosage composition is provided comprising a prophilactically or therapeutically effective amount of an active pharmaceutical ingredient comprising levocetirizine or a pharmaceutically acceptable salt thereof, the solid oral dosage composition having a coating thereon capable of providing taste masking of the levocetirizine or pharmaceutically acceptable salt thereof.

Priority: US20040592041P Applic. Date: 2004-07-29

Inventor: CHAUDHARI GHANSHYAM N [IN]; KHACHANE VASANT S [IN]; DESHMUKH VAIBHAV P [IN]; BHAMRE NITIN B [IN]

Title: Combination therapy for treating viral infections

Applicant/Assignee: ACHILLION PHARMACEUTICALS

Application No.: 11/252938   Filing Date: 18/Oct/2005

Abstract:A method of treating viral infections, particularly Hepatitis B (HBV) and Human Immunodeficiency Virus (HIV) infections, by administering Elvucitabine and a second active agent to a patient suffering viral infection is provided herein. The second active agent is, for example, an immunomodulatory compound, an anti-viral agent, or a combination comprising one or more of the foregoing active agents. For example the anti-viral agent may be a tyrosine kinase inhibitor, a CCR5 inhibitor, a non-nucleoside reverse transcriptase inhibitor, a protease inhibitor, an integrase inhibitor. Further provided herein are combination dosage forms comprising Elvucitabine and a second active agent. The combination dosage may be administered once per day. The Elvucitabine may be administered less frequently than the second active agent. Packaged pharmaceutical compositions comprising Elvucitabine, a second active agent, and instructions for using the composition for treating a viral infection by administering Elvucitabine and the second active agent are also provided.

Priority: US20040620023P Applic. Date: 2004-10-19

Inventor: POTTAGE JOHN [US]

Title: Methods and devices for sustained in-vivo release of an active agent

Applicant/Assignee:

Application No.: 11/238144   Filing Date: 27/Sep/2005

Abstract:The present invention includes methods and devices for providing sustained in-vivo release of an active agent to a subject. In some aspects, such release may be achieved by reacting an active agent in-vivo with a depot forming agent in order to form a sustained release active agent depot inside the subject. The depot can then release the active agent over a sustained period of time.

Priority: US20040623150P Applic. Date: 2004-10-27; US2005-238104 Applic. Date: 2005-09-27

Inventor: HIGUCHI JOHN [US]; LI S K [US]; HIGUCHI WILLIAM I [US]; HASTINGS MATTHEW S [US]

Title: ND

Applicant/Assignee: ND

Application No.: ND   Filing Date: ND

Abstract:ND

Priority: ND

Inventor: ND

Title: Tablets from a poorly compressible substance

Applicant/Assignee:

Application No.: 10/972095   Filing Date: 22/Oct/2004

Abstract:A solid composition suitable for forming into a tablet includes a pharmaceutically active substance in an amount sufficient to provide a therapeutic effect when administered

from about 0.2 to about 15 weight %, based on the total weight of the composition, of a water-soluble preparation of a fat-soluble vitamin

and from about 10 to 80 weight %, based on the total weight of the composition, of an excipient. Another aspect of the present invention is method for making the solid composition.

Priority:

Inventor: YUAN JINGHUA [US]; CLIPSE NANCY M [US]; WU STEPHEN H [US]

Title: Vp2-modified raav vector compositions and uses therefor

Applicant/Assignee:

Application No.: 10/513348   Filing Date: 17/Oct/2005

Abstract:Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in the cells and tissues of selected mammals, including, for example, human tissues and host cells.

Priority: WO2004US05205 Applic. Date: 2004-02-19

Inventor: WARRINGTON KENNETH H [US]; OPIE SHAUN R [US]; MUZYCZKA NICHOLAS [US]

Title: Medicament for prevention and treatment of bone fracture and osteoporosis

Applicant/Assignee: SAGITTARIUS LIFE SCIENCE CORP

Application No.: 10/976599   Filing Date: 28/Oct/2004

Abstract:The present invention provides a pharmaceutical composition which can be used to prevent and treat bone fracture and osteoporosis. The composition is composed of Semen lactucae sativae 0.1-1, Lignum aquilariae resinatum 2-20, Fructus oryzae 1-5, Resina boswelliae carterii 0.1-1, Rhizoma atractylodis macrocephalae 0.1-1 and Semen cuscutae 0.1-1. The whole or the specific parts of the plants can be used to prepare the inventive pharmaceutical composition

preferred plants are Aquilariae lignum containing resin and Boswellia carterii containing resin. This pharmaceutical composition can be formulated into lozenge, tablet, film coated tablets, capsule, soft capsule, granule, powder, pill, solution, emulsion, injection solution, injection, ointment, cream, spray or inhalant.

Priority: WO2002CN00534 Applic. Date: 2002-08-02; CN20021019186 Applic. Date: 2002-05-14

Inventor: LIU SUYING [TW]; TSAL YIMING [TW]

Title: Dye-free pharmaceutical suspensions and related methods

Applicant/Assignee:

Application No.: 10/977655   Filing Date: 29/Oct/2004

Abstract:A dye-free pharmaceutical suspension having a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent having an average particle size of between about 10 and about 100 microns, an effective amount of non-reducing sweetener

an effective amount of water

and an effective amount of a suspending system

wherein the dye-free pharmaceutical suspension has a pH of from about 5 to about 6 and is substantially free of a reducing sugar and related methods.

Priority:

Inventor: BUEHLER GAIL K [US]

Title: Dye-free pharmaceutical suspensions and related methods

Applicant/Assignee:

Application No.: 10/977670   Filing Date: 29/Oct/2004

Abstract:A dye-free pharmaceutical suspension having a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent, an effective amount of non-reducing sweetener

an effective amount of water

and an effective amount of a suspending system

and an effective amount of an opacifier, wherein the dye-free pharmaceutical suspension has a pH of from about 5 to about 6 and is substantially free of a reducing sugar and related methods.

Priority:

Inventor: BUEHLER GAIL K [US]

Title: Dye-free pharmaceutical suspensions and related methods

Applicant/Assignee:

Application No.: 10/978035   Filing Date: 29/Oct/2004

Abstract:A dye-free pharmaceutical suspension having a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent, an effective amount of non-reducing sweetener

an effective amount of water

and an effective amount of a suspending system

wherein the dye-free pharmaceutical suspension has a pH of from about 5 to about 6 and is substantially free of a reducing sugar and related methods.

Priority:

Inventor: BUEHLER GAIL K [US]

Title: Formulations for tyrosine kinase inhibitors

Applicant/Assignee:

Application No.: 10/544213   Filing Date: 02/Aug/2005

Abstract:The present invention is related to a powder, powder blend or granulation formulation of 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-1H-quinolin-2-one, a tyrosine kinase inhibitor, which is adapted for reconstitution with a diluent. This invention is also related to a prepared aqueous suspension, or dispersion, formulation, particularly to a stable oral pharmaceutical formulation, comprising granules of 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-1H-quinolin-2-one mixed with a diluent. Additionally, the present invention is related to the method of preparing these formulations.

Priority: US20030458094P Applic. Date: 2003-03-27; WO2004US08828 Applic. Date: 2004-03-23

Inventor: KARKI SHYAM B [US]; DESHPANDE SAMEER R [US]; THOMPSON KAREN C [US]; PAYNE ANNE H [US]; GANDEK THOMAS P [US]

Title: Controlled release galantamine composition

Applicant/Assignee:

Application No.: 11/304128   Filing Date: 15/Dec/2005

Abstract:The present invention is concerned with controlled release compositions for oral administration comprising galantamine

and with processes of preparing such controlled release compositions.

Priority: EP19980204447 Applic. Date: 1998-12-24; US2001-868991 Applic. Date: 2001-07-26; WO1999EP10257 Applic. Date: 1999-12-20

Inventor: MCGEE JOHN P [BE]; GILIS PAUL M V [BE]; DE WEER MARC MAURICE G [BE]; DE CONDE VALENTIN FLORENT V [BE]; DE BRUIJN HERMAN JOHANNES C [BE]; VAN DYCKE FREDERIC ANNE R [BE]

Title: Methods for making pharmaceutical formulations comprising deagglomerated microparticles

Applicant/Assignee:

Application No.: 11/305461   Filing Date: 16/Dec/2005

Abstract:Methods are provided for making a dry powder blend pharmaceutical formulation comprising (i) forming microparticles which comprise a pharmaceutical agent

(ii) providing at least one excipient in the form of particles having a volume average diameter that is greater than the volume average diameter of the microparticles

(iii) blending the microparticles with the excipient to form a powder blend

and (iv) jet milling the powder blend to deagglomerate at least a portion of any of the microparticles which have agglomerated, while substantially maintaining the size and morphology of the individual microparticles. Jet milling advantageously can eliminate the need for more complicated wet deagglomeration processes, can lower residual moisture and solvent levels in the microparticles (which leads to better stability and handling properties for dry powder formulations), and can improve wettability, suspendability, and content uniformity of dry powder blend formulations.

Priority: US2002-324558 Applic. Date: 2002-12-19

Inventor: CHICKERING DONALD E III [US]; REESE SHAINA [US]; NARASIMHAN SRIDHAR [US]; STRAUB JULIE A [US]; BERNSTEIN HOWARD [US]; ALTREUTER DAVID [US]; HUANG ERIC K [US]

Title: Methods for making pharmaceutical formulations comprising deagglomerated microparticles

Applicant/Assignee:

Application No.: 11/305620   Filing Date: 16/Dec/2005

Abstract:Methods are provided for making a dry powder blend pharmaceutical formulation comprising (i) forming microparticles which comprise a pharmaceutical agent

(ii) providing at least one excipient in the form of particles having a volume average diameter that is greater than the volume average diameter of the microparticles

(iii) blending the microparticles with the excipient to form a powder blend

and (iv) jet milling the powder blend to deagglomerate at least a portion of any of the microparticles which have agglomerated, while substantially maintaining the size and morphology of the individual microparticles. Jet milling advantageously can eliminate the need for more complicated wet deagglomeration processes, can lower residual moisture and solvent levels in the microparticles (which leads to better stability and handling properties for dry powder formulations), and can improve wettability, suspendability, and content uniformity of dry powder blend formulations.

Priority: US2002-324558 Applic. Date: 2002-12-19

Inventor: CHICKERING DONALD E III [US]; REESE SHAINA [US]; NARASIMHAN SRIDHAR [US]; STRAUB JULIE A [US]; BERNSTEIN HOWARD [US]; ALTREUTER DAVID [US]; HUANG ERIC K [US]

Title: Coated particles and pharmaceutical dosage forms

Applicant/Assignee:

Application No.: 10/544920   Filing Date: 04/Nov/2005

Abstract:The present invention relates to coated particles and pharmaceutical dosage forms comprising the active substances sensitive to environmental influences. The coating of the present invention provides stability and protection of the active substance to environmental influences and in particular from oxidation and/or environmental humidity by coating.

Priority: SI20030000041 Applic. Date: 2003-02-12; WO2004SI00009 Applic. Date: 2004-02-11

Inventor: HUMAR VLASTA [SI]; BURJAK MATEJA [SI]; GRAHEK ROK [SI]; SALOBIR MATEJA [SI]; KERC JANEZ [SI]; KOCEVAR KLEMEN [SI]

Title: Modified release formulations of at least one form of tramadol

Applicant/Assignee:

Application No.: 10/517809   Filing Date: 11/Oct/2005

Abstract:The present invention provides for a modified release pharmaceutical composition comprising at least one form of tramadol selected from the group consisting of tramadol, enantiomers thereof, pharmaceutically acceptable salts thereof and combinations thereof, the composition exhibiting an in vitro dissolution profile (measured using the USP Basket Method at 75 rpm in 900 ml 0.1 N HCl at 37 DEG C.) such that after 2 hours, from about 0% up to about 30% (by weight) of the at least one form of tramadol is released, after 4 hours, from about 5% to about 22% (by weight) of the at least one form of tramadol is released, after 6 hours, from about 15% to about 38% (by weight) of the at least one form of tramadol is released, after 8 hours, more than about 40% (by weight) of the at least one form of tramadol is released.

Priority: US20020357851P Applic. Date: 2002-02-21; WO2003US04866 Applic. Date: 2003-02-21

Inventor: SETH PAWAN [US]; MAES PAUL [US]

Title: Formulations of finasteride

Applicant/Assignee:

Application No.: 10/535826   Filing Date: 21/Nov/2005

Abstract:This invention relates to pharmaceutical formulations of finasteride that include Gelucire(R).

Priority: IS20020006633 Applic. Date: 2002-11-22; WO2003IS00034 Applic. Date: 2003-11-21

Inventor: JOHANNSSON FJALAR [IS]

Title: Methods and formulations for making pharmaceutical compositions containing bupropion

Applicant/Assignee: BIOKEY, INC

Application No.: 11/265918   Filing Date: 03/Nov/2005

Abstract:Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating antidepressant or smoking cessation. In one aspect, the invention provides a pharmaceutical formulation comprising a core, including bupropion and its salt derivatives, and a coating. The coating may include from about 5% to about 99% by weight of the coating of a pharmaceutically acceptable pH-independent polymer. The coating may further include from about 0.001% to about 30% by weight of the coating of a surfactant. In another aspect, the invention provides methods for preparing and administering a pharmaceutical composition in oral dosage form, such as a tablet.

Priority: US20040626317P Applic. Date: 2004-11-08

Inventor: CHOW SAN-LAUNG [US]; WONG DAVID [US]; GARCIA DAMIAN [US]

Title: Methods and formulations for making controlled release oral dosage form

Applicant/Assignee: BIOKEY, INC

Application No.: 11/295851   Filing Date: 06/Dec/2005

Abstract:Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating antidepressant or smoking cessation. In one aspect, the invention provides a pharmaceutical formulation comprising a core, including bupropion and its salt derivatives, and a coating. The coating may include one or more surfactants and aqueous dispersions of one or more insoluble pharmaceutical acceptable polymers. The core may also include aqueous dispersions of one or more insoluble pharmaceutical acceptable polymers. In another aspect, the invention provides methods for preparing and administering a pharmaceutical composition in oral dosage form, such as a tablet.

Priority: US20040626317P Applic. Date: 2004-11-08; US2005-265918 Applic. Date: 2005-11-03

Inventor: CHOW SAN-LAUNG [US]; WONG DAVID [US]; GARCIA DAMIAN [US]

Title: High-dosage extended-release formulation of gepirone

Applicant/Assignee: FABRE-KRAMER PHARMACEUTICALS, INC

Application No.: 10/981663   Filing Date: 05/Nov/2004

Abstract:The present invention relates to high-dosage extended-release formulation of gepirone and methods of treating major depression by administering the same to a subject in need thereof. More specifically, the present invention relates to a high-dosage extended-release tablet form of gepirone. The present invention also relates to a method of treating depression in mammals by administering to a subject in need thereof an effective amount the high-dosage extended-release formulation of gepirone in accordance with the present invention.

Priority:

Inventor: KRAMER STEPHEN J [US]; FABRE LOUIS F [US]

Title: Composition containing an extract of fructus psoraleae for inhibiting anxiety and depression, improving memory and treating dementia

Applicant/Assignee:

Application No.: 11/271317   Filing Date: 10/Nov/2005

Abstract:Disclosed is a composition comprising of an extract of Fructus Psoraleae for inhibiting anxiety and depression and improving memory. The composition can be used in medicaments and health care foods for preventing and treating anxiety and depression of modern people suffering from brain impairment caused by environmental factors, such as various stresses, drinking, smoking and so on, improving memory, and preventing and treating dementia.

Priority: KR20040091252 Applic. Date: 2004-11-10

Inventor: KIM SUNG-JIN [KR]

Title: Pharmaceutical compositions for the treatment of urinary incontinence

Applicant/Assignee:

Application No.: 10/524131   Filing Date: 13/Sep/2005

Abstract:Pharmaceutical compositions for the treatment of urinary incontinence with a cholinergic and musulotropic substance, combined or not combined with a little resorbed estrogen agent, by local route, wherein the cholinergic and musculotropic substance is oxybutynin, or one of its salts, and the little resorbed estrogen agent is chosen from estriol, 16-epiestriol or estradiol in free, esterified and/or etherified form suited for vaginal or rectal administration and a method of treating urinary incontinence.

Priority: FR20020010058 Applic. Date: 2002-08-07; WO2003FR02471 Applic. Date: 2003-08-06

Inventor: ROUGAIGNON CAROLINE [MC]; LANQUETIN MICHEL [FR]

Title: Monoterpene compositions and uses thereof

Applicant/Assignee:

Application No.: 10/498566   Filing Date: 17/Nov/2005

Abstract:The present invention relates to pharmaceutical compositions and methods for the mucosal and oral administration of monoterpenes and derivatives thereof. The compositions of this invention further comprise one or more surfactants and cosolvents and are in the form of self-emulsifying compositions. The compositions of the invention may further comprise water-insoluble therapeutic agents, vaccines and diagnostics. Such agents include but are not limited to taxanes, steroids, topoisomerase inhibitors such as etoposide and other water-insoluble or lipophilic drugs.

Priority: US20010339778P Applic. Date: 2001-12-11; US20020378900P Applic. Date: 2002-05-07; WO2002US39545 Applic. Date: 2002-12-11

Inventor: CONSTANTINIDES PANAYIOTIS P [US]; PATIL REENA T [US]; BOLOTIN ELIJAH M [US]; LIANG LIKAN [US]

Title: Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil

Applicant/Assignee: J.P.M.E.D. LTD

Application No.: 10/535961   Filing Date: 20/May/2005

Abstract:The invention provides a composition of matter for treating infected skin and mucousal membranes, said composition comprising at least one anti-microbial drug

and at least one essential oil, in combination with a substantially, alcohol-free carrier system, said carrier being selected from a liquid carrier or a semi-solid carrier, said carrier system being selected from isotonic system and a moderately hypertonic system.

Priority: IL20020152993 Applic. Date: 2002-11-21; IL20030158901 Applic. Date: 2003-11-17; WO2003IL00980 Applic. Date: 2003-11-19

Inventor: FRIEDMAN DORON I [IL]

Title: Sustained release heterodisperse hydrogel systems for insoluble drugs

Applicant/Assignee: PENWEST PHARMACEUTICALS CO

Application No.: 11/333027   Filing Date: 17/Jan/2006

Abstract:A sustained release pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, an optional cationic cross-linking agent, and a medicament having moderate to poor solubility is disclosed. In certain embodiments, the sustained release excipient is granulated with a solution or suspension of a hydrophobic polymer in an amount effective to slow the hydration of the gelling agent when the formulation is exposed to an environmental fluid. In another embodiment, the tablet is coated with a hydrophobic polymer.

Priority: US2004-798225 Applic. Date: 2004-03-11; US2000-654691 Applic. Date: 2000-09-05; US1998-207298 Applic. Date: 1998-12-08; US1997-843573 Applic. Date: 1997-04-18; US1996-651901 Applic. Date: 1996-05-21; US1995-447236 Applic. Date: 1995-05-22; US1993-118924 Applic. Date: 1993-09-09

Inventor: BAICHWAL ANAND R [US]

Title: Taste-masked pharmaceutical compositions prepared by coacervation

Applicant/Assignee: EURAND PHARMACEUTICALS LIMITED

Application No.: 11/213266   Filing Date: 26/Aug/2005

Abstract:There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredients, rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates rapidly with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing one or more actives) with a taste-masking membrane applied by a modified solvent coacervation process comprising a water-insoluble polymer and at least one gastrosoluble inorganic or organic pore-former, exhibit a pleasant taste when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach.

Priority: US20040627525P Applic. Date: 2004-11-12

Inventor: LAI JIN-WANG [US]; QIAN KEN K [US]; VENKATESH GOPI M [US]

Title: Taste-masked pharmaceutical compositions with gastrosoluble pore-formers

Applicant/Assignee:

Application No.: 11/256653   Filing Date: 21/Oct/2005

Abstract:There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active), coated with a taste-masking membrane comprising a water-insoluble polymer and one or more gastrosoluble inorganic or organic pore-formers (practically insoluble in water and saliva, but soluble in an acidic buffer), exhibit acceptable taste-masking when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach.

Priority: US20040621144P Applic. Date: 2004-10-21

Inventor: LAI JIN-WANG [US]; VENKATESH GOPI M [US]; QIAN KEN K [US]

Title: Sustained release formulations of sotalol

Applicant/Assignee:

Application No.: 11/134089   Filing Date: 20/May/2005

Abstract:Sustained release compositions of sotalol, or a pharmaceutically acceptable salt thereof, are provided. In certain examples, sotalol, or a pharmaceutically acceptable salt thereof, may be administered in an effective amount to provide a therapeutic effect to a patient, such as, for example, a patient suffering from a cardiac disorder. In some examples, sotalol combined with a sustained release system may be administered to provide a sustained release of sotalol for a desired period, e.g., at least about 24 hours.

Priority: US20040573367P Applic. Date: 2004-05-20

Inventor: SINGH BRAMAH N [US]

Title: Compositions comprising fenofibrate and simvastatin

Applicant/Assignee:

Application No.: 10/988828   Filing Date: 15/Nov/2004

Abstract:The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor simvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCsimvastatin) of between about 800 and about 29,300. The solid compositions are manufactured without any need of addition of water or aqueous medium and comprise at least 80% of the active substances fenofibrate and simvastatin in dissolved form, or, optionally, atorvastatin in micronized form, in order to ensure suitable bioavailability.

Priority: DK20030001503 Applic. Date: 2003-10-10; DK20040000464 Applic. Date: 2004-03-23; WO2004DK00668 Applic. Date: 2004-10-01

Inventor: HOLM PER [DK]; NORLING TOMAS [DK]

Title: Use of inositol-tripyrophosphate in treating tumors and diseases

Applicant/Assignee:

Application No.: 11/175979   Filing Date: 06/Jul/2005

Abstract:Inositol-tripyrophosphate is an allosteric effector of hemoglobin due to its ability to cross the plasma membrane of red blood cells and deliver oxygen to solid tumors, by lowering the oxygen affinity of the hemoglobin of red blood cells. The present invention is directed to the use of inositol-tripyrophosphate to reduce hemoglobin's affinity for oxygen in circulating red blood cells. The present invention is further directed to the use of inositol-tripyrophosphate to inhibit angiogenesis and enhance radiation sensitivity of hypoxic tumors. The present invention is further directed to the use of inositol-tripyrophosphate to enhance PO2 in hypoxic tumors.

Priority: US20040585804P Applic. Date: 2004-07-06

Inventor: NICOLAU CLAUDE [US]; GREFERATH RUTH [DE]; FYLAKTAKIDOU KONSTANTINA C [GR]; LEHN JEAN-MARIE [FR]

Title: Inhalable pharmaceutical compositions containing an anticholinergic, salmeterol, and a steroid

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/273782   Filing Date: 15/Nov/2005

Abstract:A pharmaceutical composition comprising an anticholinergic of formula 1 wherein X<-> is an anion

salmeterol xinafoate, or a hydrate, solvate, enantiomer, or mixtures of enantiomers thereof

and a steroid selected from ciclesonide, budesonide, and mometasone furoate, or a solvate or hydrate thereof.

Priority: DE200410056579 Applic. Date: 2004-11-23

Inventor: PIEPER MICHAEL P [DE]

Title: Inhalable pharmaceutical compositions containing an anticholinergic, formoterol, and a steroid

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/274648   Filing Date: 15/Nov/2005

Abstract:A pharmaceutical composition containing an anticholinergic of formula 1 wherein X<-> is an anion

a formoterol salt selected from formoterol fumarate and formoterol hemifumarate, or a hydrate, solvate, enantiomer, or mixtures of enantiomers thereof

and a steroid selected from ciclesonide, budesonide, and mometasone furoate, or a solvate or hydrate thereof.

Priority: DE200410056578 Applic. Date: 2004-11-23

Inventor: PIEPER MICHAEL P [DE]

Title: Compositions comprising azelastine and methods of use thereof

Applicant/Assignee: MEDPOINTE HEALTHCARE INC

Application No.: 11/284109   Filing Date: 22/Nov/2005

Abstract:The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of allergic rhinitis, non-allergic vasomotor rhinitis, allergic conjunctivitis, as well as other disorders. The compositions and methods of the present invention provide significant value in terms of patient acceptability, convenience, and compliance.

Priority: US20040630274P Applic. Date: 2004-11-24

Inventor: DANG PHUONG G [US]; LAWRENCE BRIAN D [US]; BALWANI GUL [US]; D ADDIO ALEXANDER D [US]

Title: Solid dosage form comprising a fibrate

Applicant/Assignee: LIFECYCLE PHARMA A/S

Application No.: 10/513807   Filing Date: 08/Nov/2004

Abstract:The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.

Priority: DK20030001503 Applic. Date: 2003-10-10; DK20040000464 Applic. Date: 2004-03-23; DK20040001006 Applic. Date: 2004-06-25; WO2004DK00667 Applic. Date: 2004-10-01

Inventor: HOLM PER [DK]; NORLING TOMAS [DK]

Title: Bilayer tablet of telmisartan and amlodipine

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/265722   Filing Date: 02/Nov/2005

Abstract:A bilayer tablet comprises a first layer formulated for instant release of the angiotensin II receptor antagonist telmisartan from a dissolving tablet matrix and a second layer formulated for instant release of the calcium channel blocker amlodipine from a disintegrating or eroding tablet matrix.

Priority: EP20040026234 Applic. Date: 2004-11-05

Inventor: EISENREICH WOLFRAM [DE]

Title: Dosage forms of risedronate

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: 11/286875   Filing Date: 23/Nov/2005

Abstract:Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between risedronate and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food.

Further, the present invention effects delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.

Priority: US2005-106816 Applic. Date: 2005-04-15; US20040573881P Applic. Date: 2004-05-24

Inventor: DANSEREAU RICHARD J [US]; BURGIO DAVID E JR [US]

Title: Extended release formulation of pramipexole dihydrochloride

Applicant/Assignee:

Application No.: 11/260066   Filing Date: 27/Oct/2005

Abstract:An extended release composition of Pramipexole or a pharmaceutical acceptable salt thereof, wherein the active agent is coated on a non pareil inert core, the drug loaded core is further coated with a polymeric layer which enables the release of the active agent over an extended period and optionally the extended release pellets being further blended with suitable excipients and compressed into a multi unit tablet and processes for the preparation of the said composition.

Priority: IN2004MU01153 Applic. Date: 2004-10-27

Inventor: KSHIRSAGAR RAJESH [IN]; JOSHI MAYANK [IN]; KUMAR AMRESH [IN]

Title: Oxcarbazepine dosage forms

Applicant/Assignee: GLENMARK PHARMACEUTICALS LIMITED

Application No.: 11/264836   Filing Date: 01/Nov/2005

Abstract:Dosage forms of oxcarbazepine or a pharmaceutically acceptable salt thereof and a pH modifying agent for use in oral administration are provided.

Priority: US20040623926P Applic. Date: 2004-11-01

Inventor: KRISHNAN ANANDI [IN]; KANNAN MUTHAIYYAN E [IN]; PATIL ATUL V [IN]

Title: Use of methyl pyruvate to increase cellular energy production downstream of glycolysis for the PARP-1 ablation of HIV without necrotic cell death caused by continuous, chronic PARP-1 activation through the concomitant depletion of ATP and NAD.

Applicant/Assignee:

Application No.: 10/904648   Filing Date: 20/Nov/2004

Abstract:The present invention relates to the use of methyl pyruvic acid (a methyl ester of pyruvic acid) and/or methyl pyruvate (methyl pyruvate is the ionized form of methyl pyruvic acid) for the purpose of increasing cellular energy production thereby providing energy for the continuous activation of PARP-1 and up-regulation of PPAR. It is well known that chronic activation of PARP causes ATP and NAD depletion with concomitant cell death. PARP is known to prevent HIV replication by competitive receptor inhibition. Use of methyl pyruvate and/or methyl pyruvic acid can be effective when administered orally or infused on either a chronic and/or acute basis. In the following text, the terms "methyl pyruvate, methyl pyruvate compounds, methyl pyruvic acid" are used interchangeably.

Priority:

Inventor: ANTOSH STANLEY C [US]; MEDURI ANTHONY J [US]

Title: Fast-melting tablets having taste-masking and sustained release properties

Applicant/Assignee:

Application No.: 11/267568   Filing Date: 04/Nov/2005

Abstract:Fast-melting tablets contain particles of an active ingredient and ion-exchange resin complex to mask unpleasant taste associated with the active ingredient. The resin complex particles can be coated or uncoated to impart sustained release properties to the active ingredient. A fast-melting tablet also comprises a dry binder and bulk diluent to form highly plastic granules that are subsequently compressed into tablets.

Priority: US2004-841979 Applic. Date: 2004-05-07; US20040624959P Applic. Date: 2004-11-04; US20030468449P Applic. Date: 2003-05-07

Inventor: JEONG SEONGHOON [US]; KIMURA SUSUMU [JP]; FU YOURONG [US]; PARK KINAM [US]

Title: Gastric acid secretion inhibiting composition

Applicant/Assignee: OREXO AB

Application No.: 10/531598   Filing Date: 25/Nov/2005

Abstract:An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.

Priority: SE20020003065 Applic. Date: 2002-10-16; WO2003SE01598 Applic. Date: 2003-10-15

Inventor: PETTERSSON ANDERS [SE]; NYSTROM CHRISTER [SE]; HAKANSSON YVONNE [SE]

Title: Compositions and methods for treating neuroendocrine tumors

Applicant/Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION

Application No.: 11/296404   Filing Date: 08/Dec/2005

Abstract:Methods and pharmaceutical compostions for treating or suppressing symptoms of neuroendocrine (NE) tumors comprising inhibiting the activities of GSK-3beta of the cancer cells. Also disclosed are pharmaceutical compositions for the methods. Preferably, the pharmaceutical composition comprises Li+, SB216763, SB415286, indirubins, Paullones, Hymenialdisine, Azakenpaullone, Thienyl and phenyl alpha-halomethyl ketones, CHR 99021, AR-A014418, Bis-7-azaindolylmaleimides, CHR 98023, CHR-98014, and ZM336372, or a pharmaceutically acceptable salt or derivative thereof.

Priority: US20040634082P Applic. Date: 2004-12-08

Inventor: KUNNIMALAIYAAN MUTHUSAMY [US]; CHEN HERBERT [US]

Title: Methods of producing coated products including active agent and products regarding same

Applicant/Assignee:

Application No.: 11/273941   Filing Date: 15/Nov/2005

Abstract:Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the products. The products include a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a consumable center. By chewing the product, the medicament or agent is released from the product within the buccal cavity.

Priority: US2002-044113 Applic. Date: 2002-01-09; US2000-631326 Applic. Date: 2000-08-03; US2000-510878 Applic. Date: 2000-02-23; US1999-286818 Applic. Date: 1999-04-06

Inventor: REAM RONALD L [US]; MATULEWICZ LEONARD [US]; WOKAS WILLIAM J [US]

Title: Tableted products including active agent

Applicant/Assignee:

Application No.: 11/273942   Filing Date: 15/Nov/2005

Abstract:Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the products. The products include a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a consumable center. By chewing the products, the medicament or agent is released from the product within the buccal cavity.

Priority: US2002-044113 Applic. Date: 2002-01-09; US2000-631326 Applic. Date: 2000-08-03; US2000-510878 Applic. Date: 2000-02-23; US1999-286818 Applic. Date: 1999-04-06

Inventor: REAM RONALD L [US]; MATULEWICZ LEONARD [US]; WOKAS WILLIAM J [US]

Title: Method of manufacturing sustained release microbeads containing venlafaxine HCL

Applicant/Assignee:

Application No.: 11/149527   Filing Date: 10/Jun/2005

Abstract:A sustained release Venlafaxine composition that includes a plurality of non-agglomerated, uniformly-shaped and sized microbeads of inert core particles having a first coating layer. The first coating layer includes an active agent of Venlafaxine or a pharmaceutical acceptable salt thereof, a binder, and an anti-tack agent. The active agent is present in the first coating layer in a concentration of at least about 5% to about 70% by weight of the composition, the binder is present in an amount of at least 35% by weight of the active agent, or in a further layer located upon or below the first coating layer, or as an alternating layer between plural first layers, wherein the binder is present in an amount of less than about 2.5% by weight of the composition, and the anti-tack agent is present in the first coating layer in a concentration of about 2.5% to about 20% by weight based on the weight of the active agent. The composition is also substantially free of organic acid.

Priority: IN2002MU01054 Applic. Date: 2002-11-28; US2005-138913 Applic. Date: 2005-05-27; WO2003IB05194 Applic. Date: 2003-11-17

Inventor: ANTARKAR AMIT K [IN]; VARDAM POONAM P [IN]; SHAH MAYA J [IN]; LALA RAJENDRA G [IN]

Title: Pharmaceutical application of 15- or 16-substituted testosterone analogues

Applicant/Assignee:

Application No.: 10/526730   Filing Date: 16/Sep/2005

Abstract:The invention relates to pharmaceutical dosage units for oral, transmucosal or transdermal administration containing 15- or 16-substituted testosterone analogues, as well as to therapeutic methods that employ these testosterone analogues. More particularly, the invention is concerned with such pharmaceutical dosage units containing at least 10 mug of an androgenic steroid selected from the group consisting of 15-hydroxytestosterones, 16-hydroxytestosterones, precursors thereof and mixtures of these hydroxytestosterones and/or their precursors

and a pharmaceutically acceptable excipient. The term "15-hydroxytestosterones" encompasses both 15beta-hydroxytestosterone (15alpha, 17beta-dihydroxy-4-androsten-3-one) and 15beta-hydroxytestosterone (15beta, 17beta-dihydroxy-4-androsten-3-one). Similarly, the term "16-hydroxytestosterones" encompasses both 16alpha-hydroxytestosterone hydroxytestosterone (16alpha, 17beta-dihydroxy-4-androsten-3-one) and 16alpha-hydroxytestosterone (16beta, 17beta-dihydroxy-4-androsten-3-one). The androgenic steroids according to the invention are advantageously employed in e.g. a method of treating or preventing androgen deficiency or a method of hormonal contraception.

Priority: EP20020078643 Applic. Date: 2002-09-05; WO2003NL00621 Applic. Date: 2003-09-05

Inventor: BUNSCHOTEN EVERT J [NL]; COELINGH BENNINK HERMAN JAN T [NL]; VAN DER LINDEN RENE F [NL]

Title: Methods of using temozolomide formulation intrathecally in the treatment of cancers

Applicant/Assignee: SCHERING CORPORATION

Application No.: 11/290779   Filing Date: 30/Nov/2005

Abstract:Methods are disclosed for treating cancer in a patient in need of such treating comprising intrathecally administering temozolomide in a pharmaceutical formulation in a therapeutically effective amount.

Priority: US20040632675P Applic. Date: 2004-12-02

Inventor: CUTLER DAVID L [US]

Title: Tablet comprising efletirizine and pseudoephedrine

Applicant/Assignee: UCB FARCHIM S.A

Application No.: 10/537553   Filing Date: 12/Nov/2003

Abstract:The present invention concerns a tablet comprising two distinct segments. More particularly the invention relates to combinations of two pharmaceutical substances and methods of treatment of allergic disorders.

Priority: EP20020080127 Applic. Date: 2002-12-06; WO2003EP12627 Applic. Date: 2003-11-12

Inventor: BERWAER MONIQUE [BE]; GUICHAUX ANTHONY [BE]; CUYPERS SERGE [BE]; DELEERS MICHEL [BE]; FANARA DOMENICO [IT]

Title: Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid

Applicant/Assignee: TARO PHARMACEUTICALS INDUSTRIES LTD

Application No.: 11/201024   Filing Date: 10/Aug/2005

Abstract:The present invention relates to a composition and a method of delivering a barbituric acid derivative to the central nervous system of a mammal in need of treatment for neurological conditions. In particular, the present invention relates to a method of administering an oral dosage form of a sodium salt of 5,5-diphenyl barbituric acid to enhance the bioavailability of 5,5-diphenyl barbituric acid and brain delivery of same.

Priority: US2003-735514 Applic. Date: 2003-12-11; US2003-354146 Applic. Date: 2003-01-30; US2004-865428 Applic. Date: 2004-06-10; US2003-333957 Applic. Date: 2003-01-27; WO2001US23420 Applic. Date: 2001-07-26; US20040600327P Applic. Date: 2004-08-10; US20020432470P Applic. Date: 2002-12-11; US20020352273P Applic. Date: 2002-01-30; US20000221672P Applic. Date: 2000-07-26

Inventor: GUTMAN DANIELLA [IL]; MOROS DANIEL [US]; YACOBI AVRAHAM [US]; RUTMAN HOWARD [US]

Title: Use for deferiprone

Applicant/Assignee: APOTEX INC

Application No.: 11/331101   Filing Date: 13/Jan/2006

Abstract:A method of treating iron induced cardiac disease in a patient with iron overload, such as in thalassemia or the like comprising administering to the patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat induced cardiac disease normally associated with iron overload.

Priority: WO2001CA00956 Applic. Date: 2001-06-28; US2003-311814 Applic. Date: 2003-04-04; CA20002313270 Applic. Date: 2000-06-30

Inventor: SPINO MICHAEL [CA]; PIGA ANTONIO [IT]

Title: Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions

Applicant/Assignee: OSTEOLOGIX A/S

Application No.: 11/269289   Filing Date: 07/Nov/2005

Abstract:Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.

Priority: DK20030001820 Applic. Date: 2003-12-09; DK20030000932 Applic. Date: 2003-06-20; DK20030000691 Applic. Date: 2003-05-07; WO2004DK00328 Applic. Date: 2004-05-06; WO2005DK00140 Applic. Date: 2005-02-28; WO2005DK00404 Applic. Date: 2005-06-17; WO2005DK00401 Applic. Date: 2005-06-17; US20030528442P Applic. Date: 2003-12-09

Inventor: HANSEN CHRISTIAN [DK]; NILSSON HENRIK [DK]; CHRISTGAU STEPHAN [DK]; ANDERSEN JENS E [DK]

Title: Agentfor reducing side effects of diclofenac

Applicant/Assignee:

Application No.: 10/524857   Filing Date: 21/Sep/2005

Abstract:The present invention relates to reduction of side effects of diclofenac or a salt thereof An agent for reducing side effects of diclofenac or a salt thereof which comprises ornoprostil. It is expected that a combination agent of diclofenac or a non-toxic salt thereof and ornoprostil is comparable to even superior to marketed diclofenac tablets or Arthrotec tables in effects and fast-acting property while showing little side effects (particularly digestive disorders, gastric ulcer, diarrhea/vomiting and renal disorder) and exerting excellent antipyretic, analgesic and antiinlfammatory effects. Also, by formulating the combination agent into a preparation of separation type pharmaceutical preparation, the stability of ornoprostil can be improved.

Priority: JP20020241271 Applic. Date: 2002-08-22; WO2003JP10562 Applic. Date: 2003-08-21

Inventor: SAKAI YOSHIKI [JP]; KATSUBE NOBUO [JP]; NISHIURA AKIO [JP]; YAMAMOTO MASANOBU [JP]; SUGISHITA KEN-ICHI [JP]

Title: Phosphorylated polymers and conjugates thereof

Applicant/Assignee:

Application No.: 11/342209   Filing Date: 27/Jan/2006

Abstract:The present invention is directed to absorbable polyesters comprising one or more monophosphate functionality

a conjugate comprising the foregoing polyester and a peptide and/or a bioactive agent

microparticles comprising an absorbable polyester

a conjugate comprising the microparticles and a peptide and/or a bioactive agent

an acylated or alkylated polysaccharide having one or more monophosphate functionality

a conjugate comprising the acylated or alkylated polysaccharide and a peptide and/or a bioactive agent

and pharmaceutical compositions thereof.

Priority: US2001-762431 Applic. Date: 2001-05-22; WO1999US18146 Applic. Date: 1999-08-10

Inventor: SHALABY SHALABY W [US]; CORBETT JOEL T [US]

Title: Rapamycin and il-10 for the treatment of immune diseases

Applicant/Assignee:

Application No.: 10/536316   Filing Date: 27/Nov/2003

Abstract:The invention discloses a combined preparation containing IL-10 and rapamucin able to induce immunosuppression and antigen-specific immune tolerance, and the use thereof in the treatment of diseases involving an excessive, dysfunctional or uncontrolled immune response mediated by T cells.

Priority: US20020429561P Applic. Date: 2002-11-29; WO2003EP13351 Applic. Date: 2003-11-27

Inventor: RONCAROLO MARIA G [IT]; BATTAGLIA MANUELA [IT]

Title: Taste-masked prednisolone oral formulations

Applicant/Assignee:

Application No.: 11/010472   Filing Date: 13/Dec/2004

Abstract:An improved taste-masked pharmaceutical prednisolone composition contains prednisolone sodium phosphate taste-masked with an effective taste-masking amount of rum ether.

Priority:

Inventor: WHITEHEAD KEITH [US]

Title: Pharmaceutical excipients comprising inorganic particles in association with an organic polymeric material and forming a solid reticulated matrix, compositions, manufacturing and use thereof

Applicant/Assignee:

Application No.: 10/531073   Filing Date: 16/Dec/2005

Abstract:A pharmaceutical excipient comprising a solid, reticulated matrix, wherein the matrix comprises an aggregation of inorganic particles in association with an organic polymeric material, defines a plurality of pores with a mean width in the range of about 0.01-500 m, and has a specific surface area of at least about 1 m2/g is described, as are products comprising such excipients, methods of making them and use thereof.

Priority: US20020418055P Applic. Date: 2002-10-11; WO2003GB04463 Applic. Date: 2003-10-10

Inventor: TOBYN MICHAEL [GB]; STANIFORTH JOHN N [GB]; CLINCH CHERYL [GB]; HEARN MATTHEW P [GB]; WALSH DOMINIC [GB]; HALL SIMON R [GB]

Title: Antiviral compositions

Applicant/Assignee:

Application No.: 11/347071   Filing Date: 03/Feb/2006

Abstract:The present invention is concerned with pharmaceutical compositions of antiviral compounds which can be administered to a mammal, in particular a human, suffering from a viral infection. These compositions comprise particles obtainable by melt-extruding a mixture comprising one or more antiviral compounds and one or more appropriate water-soluble polymers and subsequently milling said melt-extruded mixture.

Priority: EP19990203128 Applic. Date: 1999-09-24; US2002-088805 Applic. Date: 2002-03-21; WO2000EP08522 Applic. Date: 2000-08-31

Inventor: VERRECK GEERT [BE]; BAERT LIEVEN [BE]

Title: Rapidly absorbed liquid compositions

Applicant/Assignee:

Application No.: 11/342186   Filing Date: 27/Jan/2006

Abstract:The present invention provides a method which provides for a faster absorption of pharmaceutically acceptable amines. The method provides a pharmaceutically acceptable amine in combination with a non-steroidal anti-inflammatory drug in a liquid form. A preferred embodiment employs pseudoephedrine and ibuprofen.

Priority: US2003-608170 Applic. Date: 2003-06-26; US2002-323433 Applic. Date: 2002-12-19; US2001-777086 Applic. Date: 2001-02-05; US1999-329900 Applic. Date: 1999-06-10

Inventor: GELOTTE CATHY K [US]; HILLS JOANNA F [US]; PENDLEY CHARLES E II [US]; SHAH MANOJ N [US]

Title: Formulations of bisphosphonate drugs with improved bioavailability

Applicant/Assignee: BANNER PHARMACAPS INC

Application No.: 11/014252   Filing Date: 16/Dec/2004

Abstract:This invention relates to formulations of bisphosphonates such as alendronate. The formulations taught herein enhance bioavailability of bisphosphonates and reduce esophageal and gastric ulcerations associated with them. Also taught herein are methods of preparing the formulations and their clinical use in the treatment of osteoporosis and other bone diseases.

Priority:

Inventor: KIM TAE K [US]; FATMI AQEEL A [US]

Title: Pharmaceutical composition based on agonist of benzodiazepine

Applicant/Assignee:

Application No.: 10/559290   Filing Date: 02/Dec/2005

Abstract:The present invention describes the use of pharmaceutical compounds in pharmaceutical compositions for sublingual administration, including as active ingredient thereof, an agonist of the central receptor of benzodiazepinics chosen among diazepam, lorazepam, bromazepam, triazolam, alprazolam, flunitrazepam, nitrazepam and midazolam maleate, in a mixture with a pharmaceutical excipient consisting of, at least, 70% of the weight of the final formulation containing 40-45% by weight of lactose, 15-27% by weight of sorbitol and 12-16% by weight of cellulose.

Priority: BR20030002017 Applic. Date: 2003-06-02; WO2004BR00076 Applic. Date: 2004-05-26

Inventor: VANDONI GUIDO [IT]; OLIANI CARLO [BR]; COELHO ADRIANO [BR]; ZANIBONI HENY [BR]

Title: Stabilized ramipril compositions and methods of making

Applicant/Assignee:

Application No.: 11/269388   Filing Date: 07/Nov/2005

Abstract:The present invention relates to ramipril compositions with improved stability. More particularly, the present invention is directed to pharmaceutical compositions comprising ramipril that are stabilized against decomposition into degradation products, namely, ramipril-diketopiperazine and ramipril-diacid, during formulation and storage conditions. The present invention also relates to methods for making and methods of manufacturing stabilized ramipril compositions.

Priority: US20040625270P Applic. Date: 2004-11-05

Inventor: WILSON EDWARD S [US]; BEASLEY MARTIN W [US]

Title: Leukotriene and integrin inhibitor combination and treatment method

Applicant/Assignee:

Application No.: 11/314487   Filing Date: 19/Dec/2005

Abstract:The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a therapeutically active amount of montelukast, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable thereof, and one or more pharmaceutically acceptable excipients. These novel solid pharmaceutical dosage forms are useful in the treatment or control of asthma. The present invention also provides a method for treating asthma employing the solid pharmaceutical dosage forms and a method for preparing the pharmaceutical dosage forms.

Priority: US20040638214P Applic. Date: 2004-12-22

Inventor: SANDHU HARPREET K [US]; VALACER DAVID J [US]

Title: Composition comprising a mixture of active principles, and method of preparation

Applicant/Assignee: ETHYPHARM

Application No.: 10/544311   Filing Date: 21/Jan/2004

Abstract:Active principle-based coated particle, in which both the core and the coating contain active principle, includes a core which contains a first active principle while the coating contains a second active principle, which is different in nature.

Priority: FR20030001308 Applic. Date: 2003-02-05; US20030447198P Applic. Date: 2003-02-13; WO2004EP50035 Applic. Date: 2004-01-21

Inventor: CHENEVIER PHILIPPE [CA]; MARECHAL DOMINIQUE [CA]

Title: Formulations of human growth hormone comprising a non-naturally encoded amino acid

Applicant/Assignee: AMBRX, INC

Application No.: 11/316483   Filing Date: 21/Dec/2005

Abstract:Formulations of modified human growth hormone polypeptides are provided.

Priority: US20040638616P Applic. Date: 2004-12-22; US20050680617P Applic. Date: 2005-05-13; US20050728035P Applic. Date: 2005-10-17

Inventor: HAYS ANNA-MARIA [US]; BUECHLER YING [US]; LITZINGER DAVID C [US]

Title: Stabilized polymeric thiol reagents

Applicant/Assignee:

Application No.: 11/316051   Filing Date: 21/Dec/2005

Abstract:Disclosed are water soluble polymeric reagents comprising the structure POLY-[Y-S-W]x, where POLY is a water soluble polymer

Y is a hydrocarbon-based spacer group, x is 1 to 25, and S-W is a thiol, protected thiol, or thiol-reactive derivative. Preferably, the water soluble polymer is a PEG polymer. Also disclosed are conjugates of such polymeric reagents with pharmaceutically relevant molecules, and methods of their formation and use.

Priority: US20040639823P Applic. Date: 2004-12-21; US20050705968P Applic. Date: 2005-08-04

Inventor: KOZLOWSKI ANTONI [US]; MCMANUS SAMUEL [US]

Title: Cosmetic and pharmaceutical foam

Applicant/Assignee: FOAMIX LTD

Application No.: 10/532618   Filing Date: 22/Dec/2005

Abstract:The invention relates to an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a foam adjuvant agent, a surface-active agent and a water gelling agent. The cosmetic or pharmaceutical foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble pharmaceutical and cosmetic agents.

Priority: IL20020152486 Applic. Date: 2002-10-25; US20020429546P Applic. Date: 2002-11-29; WO2003IB05527 Applic. Date: 2003-10-24

Inventor: TAMARKIN DOV [IL]; FRIEDMAN DORON [IL]; EINI MEIR [IL]

Title: Anesthetic composition for topical administration

Applicant/Assignee:

Application No.: 10/562392   Filing Date: 01/Jun/2004

Abstract:It comprises a mixture of lidocaine, prilocaine and tetracaine, or their pharmaceutically acceptable salts. The preferred composition comprises the following components in the indicated approximate w/w percentages: 1.5% of lidocaine base

1.5% of prilocaine base

4% of tetracaine base

10% of methylpynrolidone

2% of dimethyl sulfoxide

0.08% of topical hyaluronidase

1.5% of guar gum

1% of Tween-20

0.5% of Tween-80, and the necessary amount of water to 100%. It exhibits a a high concentration on skin, a deep anesthetic effect and a significantly more rapid onset of the anesthetic effect than comparable transdermal anesthetics.

Priority: ES20030001548 Applic. Date: 2003-06-19; WO2004EP50967 Applic. Date: 2004-06-01

Inventor: FITA FERNANDO B [ES]

Title: Over-coated product including consumable center and medicament

Applicant/Assignee:

Application No.: 11/269980   Filing Date: 09/Nov/2005

Abstract:Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes one or more coatings having a medicament or agent. The coatings can further comprise one or more fat-based confectioneries to provide a coated product that has an improved aesthetic and taste appeal to a consumer. The medicament or agent is present within a coating that surrounds a consumable center. By chewing the coated product, the medicament or agent is released from the product within the buccal cavity.

Priority: US2002-044113 Applic. Date: 2002-01-09; US2000-631326 Applic. Date: 2000-08-03; US2000-510878 Applic. Date: 2000-02-23; US1999-286818 Applic. Date: 1999-04-06

Inventor: REAM RONALD L [US]; MATULEWICZ LEONARD [US]; WOKAS WILLIAM J [US]; REAM BRIAN [US]

Title: Pharmaceutical compositions containing abiguanide-glitazone combination

Applicant/Assignee:

Application No.: 10/534909   Filing Date: 16/Nov/2005

Abstract:The present invention relates to an orally administered pharmaceutical composition that is a combination of two or more antidiabetic agents in which one of the antidiabetic agents is present in an extended release form and the other antidiabetic agent is present in an immediate release form.

Priority: IN2002DE01155 Applic. Date: 2002-11-15; WO2003IB05140 Applic. Date: 2003-11-13

Inventor: TREHAN ANUPAM [IN]; MADAN SUMIT [IN]; ARORA VINOD K [IN]; MALIK RAJIV [AT]

Title: Sublingual administration of non-steroidal anti-inflammatory pharmacological substances

Applicant/Assignee:

Application No.: 10/560337   Filing Date: 09/Dec/2005

Abstract:The present invention relates to a sublingual administration method of non-steroidal ant-inflammatory, referred as FANS, which allows to considerably reduce the therapeutic dose, with the additional advantage of increasing the quickness of the effects and improving the tolerability.

Priority: IT2003RM00288 Applic. Date: 2003-06-10; WO2004IB01755 Applic. Date: 2004-05-28

Inventor: CIOLI VALERIO [IT]

Title: Method and composition for stable and controlled delivery of (-)-hydroxycitric acid

Applicant/Assignee:

Application No.: 11/287905   Filing Date: 28/Nov/2005

Abstract:The present invention provides stable encapsulated (-)-hydroxycitric acid ("HCA")-containing compositions and methods of making the same. A method is provided by which the hygroscopic salts of HCA in their relatively pure and active forms, including especially the potassium salt, but also including the sodium salt, are rendered non-hygroscopic and stable (that is, not prone to lactonization, not readily subject to attachment to ligands which inhibit absorption or lead to excretion, and so forth) such that these HCA salts might be included in dry delivery formats, liquid delivery and in controlled-release vehicles. The nonhygroscopic salts of HCA and its derivatives likewise may be protected against acid degradation, lactonization and undesirable ligand binding when exposed to acidic environments or other challenging conditions. The method taught herein can be employed to reduce the polar/ionic qualities of HCA salts and derivatives when presented to the intestinal lumen to provide advantages in absorption.

Priority: WO2004US17187 Applic. Date: 2004-05-28; US2003-447992 Applic. Date: 2003-05-29

Inventor: CLOUATRE DALLAS L [US]; DUNN JAMES M [US]; DUNN CAROLINE [US]

Title: Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof

Applicant/Assignee: J. B. CHEMICALS & PHARMACEUTICALS LTD

Application No.: 11/314890   Filing Date: 21/Dec/2005

Abstract:Bilayer tablet comprising an immediate release first layer comprising an effective amount of oxcarbazepine and at least one pharmaceutically acceptable excipients and a controlled release second layer comprising an effective amount of oxcarbazepine and pharmaceutically acceptable excipients wherein the total amount of oxcarbazepine impurities is less than or equal to about 2% by weight. A process for preparation of controlled release bilayer tablets is capable of delivering oxcarbazepine from one layer immediately followed by a controlled delivery of oxcarbazepine from a matrix forming layer, and a process for preparation of oxcarbazepine bilayer tablets. Bilayer tablets of oxcarbazepine, which maintain a therapeutically effective blood concentration of oxcarbazepine with once a day administration.

Priority: IN2004MU01425 Applic. Date: 2004-12-29

Inventor: MEHTA BHARAT P [IN]; SHAH RAJEN [IN]; JOSHI MILIND D [IN]

Title: Injectable non-aqueous suspension

Applicant/Assignee:

Application No.: 11/305938   Filing Date: 19/Dec/2005

Abstract:The present invention relates generally to compositions and methods for administering a biologically active agent, and more specifically to injectable non-aqueous suspensions.

Priority: US20040638448P Applic. Date: 2004-12-23

Inventor: CHEN GUOHUA [US]; HOUSTON PAUL R [US]; LUK ANDREW S [US]

Title: Virus preparations and methods

Applicant/Assignee: AURX, INC

Application No.: 11/021275   Filing Date: 23/Dec/2004

Abstract:Methods are disclosed for the preparation of herpesvirus, such as herpes simplex virus type 2 for vaccine use. Such viruses can be grown on serum free or serum containing media and can be prepared from the virus containing culture supernatant or virus containing cells. The virus is prepared for subsequent pharmaceutical formulation by methods which may include treatment with solid phase affinity reagents containing sulfate- or sulfonate-comprising binding groups. Such sulfated polysaccharide groups as heparin or dextran sulfate may be used, and eluted with salt solutions. The process can be combined with other culture, harvesting and formulation steps.

Priority:

Inventor: CALTON GARY J [US]; FISHELEVICH RITA [US]

Title: Promotion of peroxisomal catalase function in cells

Applicant/Assignee: WAYNE STATE UNIVERSITY

Application No.: 10/533124   Filing Date: 27/Dec/2005

Abstract:The molecular mechanisms of peroxisome biogenesis have begun to emerge: in contrast, relatively little is known about how the organelle functions as cells age. The present inventors characterized age-related changes in peroxisomes of human cells and showed that aging compromises peroxisomal targeting signal 1 (PTS1) protein import, with the critical antioxidant enzyme, catalase, especially affected. The number and appearance of peroxisomes are altered in these cells, and the organelles accumulate the PTS1-import receptor. Pex5p, on their membranes. Concomitantly, cells produce increasing amounts of the toxic metabolite, H2O2, and this increased load of reactive oxygen species (ROS) may further reduce peroxisomal protein import and exacerbate the effects of aging.

Disclosed are novel compositions and methods for restoring catalase in peroxisomes by use of targeted catalase modified at its C-terminus and/or N-terminus, optionally in combination with polypeptides which promote cellular uptake of proteins, to prevent or overcome the changes that follows aging or that are associated with a number of diseases or disorders.

Priority: US20020422100P Applic. Date: 2002-10-30; WO2003US34512 Applic. Date: 2003-10-30

Inventor: TERLECKY STANLEY R [US]; WALTON PAUL A [CA]

Title: Vaccine

Applicant/Assignee:

Application No.: 10/533841   Filing Date: 23/Nov/2005

Abstract:The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative fused to an additional HIV protein selected from a non-structural protein or capsid protein or fragment or immunogenic derivative thereof. Preferably the HIV envelope molecule is gp120 and preferred fusions include one or more of HIV Nef, Gag, RT or Tat. Preferably the HIV envelope molecule is non-glycosylated in mammalian cells.

Priority: GB20020025786 Applic. Date: 2002-11-05; WO2003EP12429 Applic. Date: 2003-11-03

Inventor: ERTL PETER F [GB]

Title: Injectable non-aqueous suspension

Applicant/Assignee:

Application No.: 11/305947   Filing Date: 19/Dec/2005

Abstract:The present invention relates generally to compositions and methods for administering a biologically active agent, and more specifically to injectable non-aqueous suspensions.

Priority: US20040638486P Applic. Date: 2004-12-23

Inventor: CHEN GUOHUA [US]; HOUSTON PAUL R [US]; LUK ANDREW S [US]

Title: Synergistic combination comprising roflumilast and formoterol

Applicant/Assignee: ATLANTA PHARMA AG

Application No.: 10/535816   Filing Date: 26/Nov/2003

Abstract:The invention relates to the combined administration of roflumilast and formoterol for the treatment of respiratory tract disorders.

Priority: EP20020026505 Applic. Date: 2002-11-27; WO2003EP13275 Applic. Date: 2003-11-26

Inventor: KOLASSA NORBERT [AT]; WEIMAR CHRISTIAN [DE]; BUNDSCHUH DANIELA [CH]; BEUME ROLF [DE]; MARX DEGENHARD [DE]

Title: Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases

Applicant/Assignee: ALTANA PHARMA AG

Application No.: 10/550192   Filing Date: 21/Sep/2005

Abstract:The invention relates to the administration of roflumilast and an anticholinergic agent selected from the group of an ipratropium, oxitropium or tiotropium salt for the treatment of respiratory diseases.

Priority: EP20030007104 Applic. Date: 2003-03-28; WO2004EP50376 Applic. Date: 2004-03-26

Inventor: BUNDSCHUH DANIELA [CH]; WOLLIN STEFAN-LUTZ [DE]; WEIMAR CHRISTIAN [DE]

Title: Pharmaceutical compositions for nasal delivery

Applicant/Assignee:

Application No.: 10/547030   Filing Date: 01/Mar/2004

Abstract:According to the invention there is provided a powdered pharmaceutical formulation suitable for nasal delivery which is a freeze-dried blend of active material and excipient(s) containing: 0.5-50% by wt of active material 50-99.5% by wt of excipient(s), and in which at least 0.1% by wt of the blend is an amorphous state, which can be directly obtained by freeze drying without the need for milling and without containing the pronounced low particles defined as finings. Such powders retain free-flowing properties on storage, are physically and chemically stable and are readily soluble.

Priority: GB20030004636 Applic. Date: 2003-02-28; WO2004GB00846 Applic. Date: 2004-03-01

Inventor: MERKUS FRANCISCUS W H [BE]; LAMBERT PETER A [GB]; ADAMS GERALD [GB]

Title: Taste masking system for alprazolam

Applicant/Assignee: CIMA LABS INC

Application No.: 11/325038   Filing Date: 04/Jan/2006

Abstract:The present invention relates to taste masking system, taste masked formulations, dosage forms made from those formulations and methods of making those formulations that involve dissolving or dispersing a pH dependant polymer and alprazolam in a solvent, granulating using that material or forming layers over a solid support therewith. This can be followed with the use of an overcoating layer.

Priority: US20050641807P Applic. Date: 2005-01-06; US20050642619P Applic. Date: 2005-01-10

Inventor: HABIB WALID [US]; MOE DEREK [US]

Title: Taste masking system for non-plasticizing drugs

Applicant/Assignee: CIMA LABS INC

Application No.: 11/325673   Filing Date: 04/Jan/2006

Abstract:The present invention relates to taste masking system, taste masked formulations, dosage forms made from those formulations and methods of making those formulations that involve dissolving or dispersing a pH dependant polymer and a non-plasticizing active pharmaceutical ingredient in a solvent, granulating using that material or forming layers over a solid support therewith. This can be followed with the use of a taste masking overcoating layer.

Priority: US20050641807P Applic. Date: 2005-01-06; US20050642619P Applic. Date: 2005-01-10

Inventor: HABIB WALID [US]; MOE DEREK [US]

Title: Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it

Applicant/Assignee: PIERRE FABRE MEDICAMENT

Application No.: 11/025348   Filing Date: 30/Dec/2004

Abstract:This invention relates to solid and stable dispersions of a hydrosoluble derivative of vinca alkaloids in at least one polyethyleneglycol with a molecular mass between 800 and 30 000.

Priority:

Inventor: BOUGARET JOEL [FR]; LEVERD ELIE [FR]; IBARRA MARIE-DOMINIQUE [FR]

Title: Granulate comprising an oily substance, corresponding production method and tablet

Applicant/Assignee: HEXAL AG

Application No.: 10/541894   Filing Date: 02/Dec/2005

Abstract:The invention relates to a process for the preparation of granules comprising an oily substance. It relates also to granules for a pharmaceutical formulation and to a tablet as a product of further processing.

Priority: DE20031000325 Applic. Date: 2003-01-09; WO2003EP14097 Applic. Date: 2003-12-11

Inventor: KLOKKERS KARIN [DE]; OTTO INA E [DE]; MEYER HEIDEMARIE E E [DE]

Title: Tamsulosin core with a coating of polyvinylpyrrolidone and polyfinylacetate

Applicant/Assignee:

Application No.: 10/562737   Filing Date: 30/Jun/2004

Abstract:The present invention is directed to a sustained/release pharmaceutical composition containing Tamsulosin and having a reduced food effect.

Priority: DE20031029812 Applic. Date: 2003-07-01; DE20031033497 Applic. Date: 2003-07-22; WO2004EP07131 Applic. Date: 2004-06-30

Inventor: SEGULA MOJCA [SI]; PISEK ROBERT [SI]; VRECER FRANC [SI]; BREZNIK MARJANCA [SI]; CERNOSA LIDIA [SI]; BANKO IVANKA [SI]

Title: Amphiphilic macrocyclic derivatives and their analogues

Applicant/Assignee: UNIVERSITY COLLEGE DUBLIN

Application No.: 11/295724   Filing Date: 07/Dec/2005

Abstract:Soluble amphiphilic macrocycle analogues having lipophilic groups attached to one side of the units making up the macrocycle and hydrophilic groups attached to the other side. These amphiphilic macrocyclic derivatives have the ability to self-assemble in aqueous solvent forming micelles or vesicles and can be used as hosts for the solubilisation and/or stabilisation of various compounds. Embodiments of the present invention utilise macrocyclic oligosaccharides and preferably cyclodextrin as the macrocyclic derivatives to be modified.

Priority: IE20000000326 Applic. Date: 2000-04-28; US2002-281070 Applic. Date: 2002-10-25; WO2001IE00057 Applic. Date: 2001-04-30

Inventor: DARCY RAPHAEL [IE]; PENKLER LAWRENCE J [ZA]; RAVOO BART J [IE]

Title: New pharmaceutical compositions based on anticholinergics and tace-inhibitors

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 10/544238   Filing Date: 07/Feb/2004

Abstract:The present invention relates to novel pharmaceutical compositions based on anticholinergics and TACE (TNF alpha converting enzyme) inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.

Priority: EP20030002986 Applic. Date: 2003-02-11; WO2004EP01144 Applic. Date: 2004-02-07

Inventor: MEADE CHRISTOPHER J M [DE]; PIEPER MICHAEL P [DE]; PAIRET MICHEL [DE]

Title: Capsaicinoid gel formulation and uses thereof

Applicant/Assignee: ALGORX PHARMACEUTICALS, INC

Application No.: 11/286059   Filing Date: 23/Nov/2005

Abstract:The present invention provides capsaicinoid gel formulations and methods for relieving pre- and post-surgical pain at a site in a human or animal by administering at a surgical site in a human or animal in need thereof a dose of capsaicinoid gel in an amount effective to attenuate post-surgical pain at the surgical site, the dose of capsaicin ranging from 100 mug to 10,000 mug.

Priority: US20040630577P Applic. Date: 2004-11-24

Inventor: BURCH RONALD M [US]; ANDERSON TIMOTHY A [US]; LAZAR JEFF [US]

Title: Formulations useful against hepatitis C virus infections

Applicant/Assignee: GPC BIOTECH AG

Application No.: 10/536950   Filing Date: 16/Nov/2005

Abstract:The present invention relates generally to chemical compounds and substances which are effective against Hepatitis C virus (HCV) infections. Moreover, the present invention relates to compositions comprising said compounds and/or substances, to methods for preventing HCV infections as well use of the compounds and/or substances for the preparation of compositions useful for the prophylaxis and/or treatment of HCV infections. Useful compounds and substances according to the invention are selenium, selenium salts, Vitamin D3 and retinoids, like all trans retinoic acid and salts thereof, C1-C alkyl amides of all trans retinoic acid and salts thereof, C1-C10 alkyl esters of all trans retinoic acid and salts thereof, 9-cis retinoic acid and salts thereof, C1-C10 alkyl amides of 9-cis retinoic acid and salts thereof, C1-C10 alkyl esters of 9-cis retinoic acid and salts thereof, (E)-4-[2(5,6,7,8-tetrahydro-5,5,8,8-tetra methyl-2-naphthalenyl-1-propenyl)benzoic acid (TTNPB), (4-[5,6,7,8-tetrahydro5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic acid (AM-580), N-(4-hydroxyphenyl)retinamide (4-HPR), and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN).

Priority: DE20021055861 Applic. Date: 2002-11-29; DE20031005138 Applic. Date: 2003-02-07; US20020430367P Applic. Date: 2002-12-03; US20030446246P Applic. Date: 2003-02-11; WO2003EP13514 Applic. Date: 2003-12-01

Inventor: HERGET THOMAS [DE]; KLEBL BERT [DE]

Title: Repeat sequence protein polymer active agent congjugates, methods and uses

Applicant/Assignee: GENENCOR INTERNATIONAL, INC

Application No.: 11/351712   Filing Date: 10/Feb/2006

Abstract:Biomolecular conjugates are provided which comprise the conjugation product of a repeat sequence protein polymer and at least one active agent. Additional aspects provide methods for their manufacture and various industrial and consumer applications.

Priority: US2004-845936 Applic. Date: 2004-05-14; US20030470464P Applic. Date: 2003-05-14

Inventor: COLLIER KATHERINE D [US]; CUEVAS WILLIAM A [US]; KUMAR MANOJ [US]

Title: Dosage forms with an enterically coated core tablet

Applicant/Assignee:

Application No.: 11/190766   Filing Date: 26/Jul/2005

Abstract:The present invention provides a pharmaceutical dosage form for oral administration to a patient comprising an enterically coated core tablet sheathed in an annular body of compressed powder or granular material. The present invention also provides a pharmaceutical dosage form for co-administration of two or more active pharmaceutical ingredients. The present invention also provides a method comprising administering the dosage form of the present invention to a patient with impaired gastric motility, such as a patient with Parkinson's disease.

Priority: US20040591482P Applic. Date: 2004-07-26; US20040591820P Applic. Date: 2004-07-27

Inventor: LERNER E I [IL]; ROSENBERGER VERED [IL]; AQUA OFER [IL]; FLASHNER-BARAK MOSHE [IL]

Title: Novel solid pharmaceutical composition comprising amisulpride

Applicant/Assignee: SANOFI-AVENTIS

Application No.: 11/327603   Filing Date: 06/Jan/2006

Abstract:The invention relates to a solid pharmaceutical composition for oral administration of amisulpride, which comprises at least one coated amisulpride particle and at least one pharmaceutically acceptable excipient suitable for an orodispersible administration of the composition.

Priority: FR20030008409 Applic. Date: 2003-07-09; WO2004FR01792 Applic. Date: 2004-07-08

Inventor: ANDRE FREDERIC [FR]; CRUZ HENRI D [FR]; DENNI MICHEL [FR]; LEWIS GARETH [FR]; MIGNONNEAU JEROME [FR]; RIBARDIERE AGNES [FR]

Title: Combinations comprising antimuscarinic agents and PDE4 inhibitors

Applicant/Assignee:

Application No.: 11/375308   Filing Date: 14/Mar/2006

Abstract:Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary diseases.

Priority: ES20040001312 Applic. Date: 2004-05-31; US2005-141169 Applic. Date: 2005-05-31

Inventor: ESCARDO JORDI G [ES]; CALVO JESUS L [ES]; RYDER HAMISH [ES]; DIAZ PIO O [ES]

Title: Novel amorphous form of erlotinib hydrochloride and its solid amorphous dispersion

Applicant/Assignee: MAI DE LTD

Application No.: 11/033523   Filing Date: 12/Jan/2005

Abstract:The present invention relates to novel amorphous form of [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl) (erlotinib hydrochloride), to solid amorphous dispersion of erlotinib hydrochloride and a carrier such as PVP or solid PEG, to processes for their preparations, to pharmaceutical compositions containing them and to method of treatment using the same. The amorphous form or solid amorphous dispersion of erlotinib hydrochloride obtained in this invention is useful in preparing pharmaceutical dosage forms.

Priority:

Inventor: HUANG LE [CN]

Title: Amorphous tacrolimus and preparation thereof

Applicant/Assignee:

Application No.: 11/326724   Filing Date: 05/Jan/2006

Abstract:The present invention provides amorphous tacrolimus in a free drug particulate form. Also provided are methods for preparing amorphous tacrolimus, and a tablet containing amorphous tacrolimus.

Priority: US20050641868P Applic. Date: 2005-01-05; US20050705681P Applic. Date: 2005-08-03

Inventor: KERI VILMOS [HU]; KOVACSNE-MEZEI ADRIENNE [HU]; CSORVASI ANDREA [HU]; MESZAROS SOS ERZSEBET [HU]

Title: Bendamustine pharmaceutical compositions

Applicant/Assignee: CEPHALON, INC

Application No.: 11/330868   Filing Date: 12/Jan/2006

Abstract:The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.

Priority: US20050644354P Applic. Date: 2005-01-14

Inventor: BRITTAIN JASON E [US]; FRANKLIN JOE C [US]

Title: Pharmaceutical compositions comprising amoxicillin and clavulanic acid

Applicant/Assignee:

Application No.: 10/536543   Filing Date: 28/Jun/2005

Abstract:The present invention relates to the formed particles comprising amoxicillin and clavulanic acid, the particles being obtained wet granulation. The invention also relates to the procedure for the preparation of these particles and to the pharmaceutical compositions comprising them.

Priority: SI20020000282 Applic. Date: 2002-11-26; SI20030000247 Applic. Date: 2003-09-24; WO2003SI00043 Applic. Date: 2003-11-25

Inventor: KERC JANEZ [SI]; SALOBIR MATEJA [SI]

Title: Stabilized individually coated ramipril particles, compositions and methods

Applicant/Assignee: KING PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC

Application No.: 11/269387   Filing Date: 07/Nov/2005

Abstract:The present invention relates to novel ramipril crystalline particles with improved stability and bioavailability. More particularly, the present invention is directed to individually coated, single ramipril crystalline particles for pharmaceutical and biopharmaceutical applications in oral therapies that are stabilized against decomposition into degradation products, namely, ramipril-DKP and ramipril-diacid, during formulation and storage conditions. The present invention also relates to stabilized ramipril pharmaceutical compositions, novel anhydrous pharmaceutical grade ramipril powders, methods for improving ramipril bioavailability, and methods of manufacture and stabilization of ramipril formulations. The novel, anhydrous pharmaceutical grade ramipril powders and ramipril compositions and dosage forms formed therewith are useful in the treatment of cardiovascular disorders and have the advantage that they provide greater stability against decomposition into ramipril-DKPs and ramipril-diacids under formulation and storage conditions. In addition, they maintain consistent label ramipril potency over extended shelf-life and provide reduced in vivo variability in the bioavailability of ramipril among subjects when administered orally.

Priority: US20040625270P Applic. Date: 2004-11-05

Inventor: WILSON EDWARD S [US]; SILLS KEVIN H [US]; JOLLY M K [US]; BEASLEY MARTIN W [US]; HAUSE DAVID P [US]

Title: Telmisartan and hydrochlorothiazide combination therapy

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/300947   Filing Date: 15/Dec/2005

Abstract:A pharmaceutical composition comprising about 80 mg of telmisartan or a salt thereof and about 25 mg of hydrochlorothiazide or about 160 mg of telmisartan or a salt thereof and about 50 mg of hydrochlorothiazide, and methods of treating hypertension in patients with such combination.

Priority: US20040637042P Applic. Date: 2004-12-17

Inventor: SCHUMACHER HELMUT E [DE]; RIEDEL AXEL [DE]; BOEHM PETER [DE]

Title: Controlled release and taste masking oral pharmaceutical composition

Applicant/Assignee: COSMO TECHNOLOGIES LIMITED

Application No.: 11/378378   Filing Date: 20/Mar/2006

Abstract:Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

Priority: IT1999MI01317 Applic. Date: 1999-06-14; IT2000MI00422 Applic. Date: 2000-03-03; US2001-009532 Applic. Date: 2001-12-12; WO2000EP05356 Applic. Date: 2000-06-09

Inventor: VILLA ROBERTO [IT]; PEDRANI MASSIMO [IT]; AJANI MAURO [IT]; FOSSATI LORENZO [IT]

Title: Controlled release pharmaceutical compositions of carbidopa and levodopa

Applicant/Assignee:

Application No.: 10/510468   Filing Date: 11/Apr/2003

Abstract:The present invention relates to controlled release pharmaceutical compositions of carbidopa and levodopa that include a combination of different molecular weight cellulose ethers and in particular, hydroxypropyl cellulose ether.

Priority: IN2002DE00447 Applic. Date: 2002-04-11; WO2003IB01361 Applic. Date: 2003-04-11

Inventor: GOGIA MONA [IN]; MATHUR RAJEEV S [IN]; SETHI SANJEEV [IN]

Title: Coating composition for taste masking coating and methods for their application and use

Applicant/Assignee:

Application No.: 10/538354   Filing Date: 11/Dec/2003

Abstract:The present invention relates to coating compositions for taste masking and methods for applying the coating compositions to dosage forms to mask the taste of a medicinal substance. The taste masking coating compositions generally include a copolymer of acrylate and methacrylate with a quaternary ammonium group in combination with sodium carboxymethylcellulose and a polyvinyl alcohol-polyethylene glycol copolymer.

Priority: IN2002DE01240 Applic. Date: 2002-12-11; WO2003IB05877 Applic. Date: 2003-12-11

Inventor: GANDHI RAJESH [IN]; ISSA CHAYAPATHY [IN]; MALIK RAJIV [AU]

Title: Stable pharmaceutical composition comprising an active substance in the form of solid solution

Applicant/Assignee:

Application No.: 11/317769   Filing Date: 23/Dec/2005

Abstract:The present invention relates to a novel pharmaceutical comprising an active substance in the form of solid solution. The stability of active substance in the pharmaceutical composition is significantly improved relative to the stability of non-formulated active substance.

Priority: SI20040000351 Applic. Date: 2004-12-24

Inventor: STANIC LJUBIN TIJANA [SI]; SIRCA JUDITA [SI]

Title: Compositions comprising anti-proliferative agents and use thereof

Applicant/Assignee:

Application No.: 11/289156   Filing Date: 28/Nov/2005

Abstract:The invention relates to anti-proliferative agents derived from plants, wherein the agents are capable of inducing a plant organ into a state of dormancy or maintaining the organ in the state of dormancy. The invention further discloses compositions comprising the anti-proliferative agents and the use of said compositions to inhibit undesired or deleterious cell proliferation in plant or mammal tissue.

Priority: US2003-465911 Applic. Date: 2003-06-20; US2001-915768 Applic. Date: 2001-07-27; US1999-367898 Applic. Date: 1999-11-29; WO1998IL00085 Applic. Date: 1998-02-23

Inventor: SOUDANT ETIENNE [FR]; OPPEN-BEZALEL LEA V [DE]; ZIV MEIRA [IL]; PERRY INON [IL]

Title: Room-temperature stable dronabinol formulations

Applicant/Assignee: INSYS THERAPEUTICS, INC

Application No.: 11/299183   Filing Date: 09/Dec/2005

Abstract:A room temperature stable cannabinoid formulation is disclosed. In preferred embodiments, the cannabinoid formulation is dronabinol in an oil-based carrier contained within a hard gelatin capsule.

Priority: US20040634474P Applic. Date: 2004-12-09

Inventor: KOTTAYIL S G [US]; ZHU ZHONGYUAN [US]; GOSKONDA VENKAT R [US]

Title: Polymer-von Willebrand factor-conjugates

Applicant/Assignee:

Application No.: 11/317582   Filing Date: 23/Dec/2005

Abstract:The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.

Priority: US20040639244P Applic. Date: 2004-12-27; US20050668378P Applic. Date: 2005-04-04; US20050671901P Applic. Date: 2005-04-15; US20050685086P Applic. Date: 2005-05-26

Inventor: SCHEIFLINGER FRIEDRICH [AT]; TURECEK PETER [AT]; SIEKMANN JUERGEN [AT]

Title: Antidepressant oral pharmaceutical compositions

Applicant/Assignee:

Application No.: 11/215911   Filing Date: 31/Aug/2005

Abstract:Novel enteric compositions suitable for oral administration comprising Duloxetine or its pharmaceutical derivatives thereof and methods for preparing such compositions are disclosed. Such compositions contain a core consisting of a Duloxetine or its pharmaceutical derivatives thereof, the said core comprised of a pharmaceutically inert nuclei and the Duloxetine or its pharmaceutical derivatives thereof compressed together, an intermediate and an enteric layer. Duloxetine or its pharmaceutical derivatives thereof may be any pharmaceutically acceptable prodrug, salt, solvate or derivative of Duloxetine. The novel compositions prepared according to the present invention have enhanced stability and bioavailability.

Priority:

Inventor: SESHA RAMESH [US]

Title: Anticoagulant composition

Applicant/Assignee: LTP LIPID TECHNOLOGIES PROVIDER AB

Application No.: 10/516858   Filing Date: 21/Jul/2005

Abstract:A solid heparin tablet composition has a melting point of 25 DEG C. or higher and is a continuous lipid component containing one or more polar lipids, one or more non-polar lipids, optionally one or several of water and mono- to trivalent alcohol in an amount of up to 15% by weight of the composition, and native heparin or fractionated heparin. Also described is a corresponding tablet, processes for production of the composition and the tablet, and a method of preventing or treating conditions amenable to preventive or therapeutic treatment by administration of the tablet.

Priority: SE20020001922 Applic. Date: 2002-06-20; WO2003SE00973 Applic. Date: 2003-06-12

Inventor: HERSLOF BENGT [SE]; TINGVALL PER [SE]

Title: Pharmaceutical compositions and uses comprising mucuna pruriens seed powder and extracts thereof in the treatment of neurological diseases

Applicant/Assignee: PHYTRIX AG

Application No.: 10/533135   Filing Date: 18/Nov/2005

Abstract:The present invention provides pharmaceutical compositions comprising Mucuna pruriens seeds or one or more Mucuna pruriens seed components, substances, fractions or mixtures or substances obtained therefrom. Furthermore, the invention relates to the use of Mucuna pruriens seed powder or one or more Mucuna pruriens components, substances, fractions or mixtures or substances obtained therefrom for the preparation of a pharmaceutical composition for preventing, alleviating or treating neurological diseases. Additionally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for neuroprotection or neurostimulation and to methods of preparing extracts of Mucuna pruriens which can be used for the preparation of a pharmaceutical composition for treating neurological diseases.

Finally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for the treatment of Parkinson's Disease to obtain a broader therapeutic window in L-Dopa therapy, to delay a need for combination therapy, to obtain an earlier onset and longer duration of L-Dopa efficacy, and to prevent or alleviate acute and chronic L-Dopa toxicity.

Priority: EP20020024475 Applic. Date: 2002-10-30; WO2003EP10975 Applic. Date: 2003-10-02

Inventor: VAN DER GIESSEN ROB [CH]; OLANOW C W [US]; LEES ANDREW [GB]; WAGNER HILDEBERT [DE]

Title: Process for preparing particles containing an antiviral

Applicant/Assignee:

Application No.: 10/564845   Filing Date: 19/Jul/2004

Abstract:A process for preparing a particle comprising a co-precipitate surrounding a neutral hydrophilic carrier, said process comprising spraying an organic solution on a neutral hydrophilic carrier, said solution comprising at least one triazine or pyrimidine active ingredient having HIV inhibiting properties, one surface active agent, and one hydrophilic polymer, wherein the spraying of whole of the solution occurs in at least two separate steps, each of these steps followed by a grinding step of the product obtained at the end of the preceding step.

Priority: FR20030008720 Applic. Date: 2003-07-17; EP20040103156 Applic. Date: 2004-07-02; WO2004EP51545 Applic. Date: 2004-07-19

Inventor: LAMOUREUX GAEL [FR]; COUSIN GERARD [FR]; THORNE DANIEL JOSEPH C [BE]

Title: Small molecules for the treatment of atherosclerosis

Applicant/Assignee: THE UNIVERSITY OF ALABAMA RESEARCH FOUNDATION

Application No.: 11/201004   Filing Date: 09/Aug/2005

Abstract:This invention provides novel small molecules that ameliorate one or more symptoms of atherosclerosis. The small molecules are highly stable and readily administered via an oral route. The small molecules are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a small molecule in a mammal. In addition, the small molecules inhibit osteoporosis. When administered with a statin, the small molecules enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.

Priority: US20040600925P Applic. Date: 2004-08-11

Inventor: FOGELMAN ALAN M [US]; ANANTHARAMAIAH GATTADAHALLI M [US]; NAVAB MOHAMAD [US]

Title: Treating morning migraines with propranolol

Applicant/Assignee:

Application No.: 11/239687   Filing Date: 30/Sep/2005

Abstract:This invention relates to a method for preventing and treating morning migraine headaches. Pursuant to this method, a therapeutic amount of beta-adrenergic-blocking agent is administered nightly to a person that suffers from migraine attacks such that the blocking agent is first released during morning hours when the person is most susceptible to morning migraine.

Priority: US20040614545P Applic. Date: 2004-10-01

Inventor: ROTENBERG KEITH S [US]; BOBOTAS GEORGE [US]

Title: Opiopathies

Applicant/Assignee:

Application No.: 11/395200   Filing Date: 03/Apr/2006

Abstract:The present invention provides novel methods for classifying, diagnosing and/or treating a group of human and veterinary ailments involving endogenous opioid concentrations. Also provided is a novel use for an existing class of compounds, the opioids, to treat opiopathic ailments, particularly paresis/paralysis, pseudo-atrophy and/or opiopathic pain, and in the manufacture of pharmaceutical and veterinary formulations therefor. The invention also relates to neuropathic, polyneuropathic, neurologic and neurogenic ailments typically characterized by paresis/paralysis. These ailments can involve an abnormal concentration of one or more endogenous opioids, or the blockade, underexpression or overexpression of one or more opioid receptors. In that regard, the invention encompasses therapeutic uses, methods and compositions employing opiates and/or their receptors. In particular, the invention relates to certain laboratory testing methods, clinical testing methods, research and development methods, business methods, methods of treatment, novel therapeutic uses, and human and veterinary pharmaceutical dosage forms, dosing regimens and formulations, especially those pertaining to opiopathy (particularly hypo-opiopathy).

Priority: US2003-367386 Applic. Date: 2003-02-14; US20020357389P Applic. Date: 2002-02-15

Inventor: BROOKS-KORN HOWARD [US]

Title: Pharmaceutical formulations

Applicant/Assignee:

Application No.: 10/565462   Filing Date: 21/Jul/2004

Abstract:The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form.

Priority: US20030489159P Applic. Date: 2003-07-21; WO2004US23542 Applic. Date: 2004-07-21

Inventor: MCALLISTER STEPHEN M [US]; RABY JR RONALD K [US]; BROWN ADRIAN [US]

Title: Solid pharmaceutical composition comprising ramipril

Applicant/Assignee:

Application No.: 10/542675   Filing Date: 11/Aug/2005

Abstract:The present invention relates to solid pharmaceutical compositions comprising ramipril with a suitably low water content, and processes for preparing said compositions.

Priority: GB20030001471 Applic. Date: 2003-01-22; DE20031054862 Applic. Date: 2003-11-24; NL20031024899 Applic. Date: 2003-11-27; WO2004EP00456 Applic. Date: 2004-01-21

Inventor: BHARATRAJAN RAMASWAMI [IN]; ZEISL ERICH [AU]; KOFLER NIKLAUS [AU]; PATIL MANISHA R [IN]; SAHASRABUDHE PARFULLA S [IN]

Title: Method for the manufacture of a pharmaceutical composition in the form of tablets containing a fibrate and tablets obtained according to the method

Applicant/Assignee:

Application No.: 10/546999   Filing Date: 26/Aug/2005

Abstract:A method for the manufacture of a pharmaceutical composition containing the active ingredient fenofibrate or one of its derivatives, optionally in combination with a second active ingredient, in the form of tablets, characterized in that it comprises a compression step of the active ingredient and excipients by means of a dry method of granulation

Priority: FR20030002520 Applic. Date: 2003-02-28; WO2004FR50090 Applic. Date: 2004-02-27

Inventor: BESSE JEROME [FR]

Title: Sustained release pharmaceutical formulations

Applicant/Assignee:

Application No.: 11/326965   Filing Date: 05/Jan/2006

Abstract:Disclosed are novel ranolazine sustained release pharmaceutical formulations.

Priority: US20050642168P Applic. Date: 2005-01-06

Inventor: SASTRY SRIKONDA [US]; NYSHADHAM JANAKI [US]

Title: Bambuterol and integrin inhibitor combination and treatment method

Applicant/Assignee:

Application No.: 11/348386   Filing Date: 06/Feb/2006

Abstract:The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a therapeutically active amount of bambuterol, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable thereof, and one or more pharmaceutically acceptable excipients. These novel solid pharmaceutical dosage forms are useful in the treatment or control of asthma. The present invention also provides a method for treating asthma employing the solid pharmaceutical dosage forms and a method for preparing the pharmaceutical dosage forms.

Priority: US20050650664P Applic. Date: 2005-02-07

Inventor: RAMES ALEXIS [FR]; SANDHU HARPREET K [US]; VALACER DAVID J [US]

Title: Dual controlled release osmotic device

Applicant/Assignee:

Application No.: 11/321736   Filing Date: 29/Dec/2005

Abstract:A pharmaceutical composition and dosage form for the treatment of incontinence with oxybutynin and a second drug is provided. The second drug can be darifenacin or tolterodine. Depending upon the route of administration, the dosage form used, and the second drug used, the dosage form may independently include therapeutic or sub-therapeutic amounts of the oxybutynin and the second drug. Particular embodiments include a dosage form that provides a controlled release of oxybutynin and the second drug to maintain therapeutically effective levels oxybutynin and/or the second in a mammal for an extended period of time. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. A method of treating urinary (stress or urge) incontinence with the pharmaceutical composition and dosage form is provided. Together, oxybutynin and the second drug provide an overall improved therapeutic benefit over either agent alone when administered at approximately the same dose.

Priority: US2001-992488 Applic. Date: 2001-11-06

Inventor: VERGEZ JUAN A [AR]; RICCI MARCELO A [AR]

Title: Conjugates of an EPO moiety and a polymer

Applicant/Assignee: NEKTAR THERAPEUTICS

Application No.: 11/357936   Filing Date: 16/Feb/2006

Abstract:Conjugates of an EPO moiety and one or more non-peptidic water-soluble polymers are provided. Typically, the non-peptidic water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising such conjugates, methods of making conjugates, and methods of administering compositions comprising such conjugates to a patient.

Priority: US20050653451P Applic. Date: 2005-02-16

Inventor: BOSSARD MARY J [US]; STEPHENSON GAYLE [US]

Title: Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same

Applicant/Assignee:

Application No.: 11/330917   Filing Date: 11/Jan/2006

Abstract:The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention further provides oral formulations of protease-resistant or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic. The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, the protease-resistant polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, the protease-resistant polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, a protease-resistant polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof.

Priority: US2005-200531 Applic. Date: 2005-08-08; US20040600202P Applic. Date: 2004-08-09; US20040600134P Applic. Date: 2004-08-09; US20040604280P Applic. Date: 2004-08-24; US20040604415P Applic. Date: 2004-08-24

Inventor: HONG JIN [US]; SEIWERT SCOTT D [US]; BLATT LAWRENCE M [US]

Title: Taste masked pharmaceutical compositions

Applicant/Assignee: ABRIKA PHARMACEUTICALS, INC

Application No.: 11/346700   Filing Date: 03/Feb/2006

Abstract:A pharmaceutical composition for oral administration containing a pharmaceutically active ingredient coated with an amount of a polymer combination of an enteric polymer and an ammonio methacrylate copolymer to effectively mask the taste of the medicament. In a preferred embodiment, the ratio of the enteric polymer to the ammonio methacrylate copolymer is about 40:60 to about 90:10, preferably about 60:40, by weight of polymer. The pharmaceutical coating composition is soluble in the acidic environment of the stomach, which generally has a pH value of about 1.0 to 3.0, but relatively insoluble at higher pH values of the mouth. The coatings provide for rapid release and absorption of the drug after it passes through the mouth, and is particularly desirable in the case of liquid dosage forms.

Priority: US20050649644P Applic. Date: 2005-02-03

Inventor: WU CHUANBIN [US]; INJETY HAROLD [US]; WENG TIM [US]

Title: Extended-release propranolol composition

Applicant/Assignee:

Application No.: 11/268060   Filing Date: 07/Nov/2005

Abstract:An extended-release pharmaceutical composition comprising a core and a coating, wherein said core comprises propranolol or a pharmaceutically acceptable salt thereof and at least one excipient, and said coating comprises at least one water-soluble polymer and at least one water-insoluble polymer, wherein said coating is heated at a temperature of about 30 DEG C. to about 70 DEG C. after being applied to said core.

Priority: US20040625866P Applic. Date: 2004-11-08

Inventor: GUO MINTONG [US]; PALANISWAMY SURESH [US]; PATEL ASHISH A [US]; GASSERT CHAD M [US]; DAVILA PABLO [US]

Title: Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds

Applicant/Assignee:

Application No.: 11/292300   Filing Date: 02/Dec/2005

Abstract:Certain compounds, such as at least one chemical entity choen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, may in certain embodiments be used to treat patients suffering from one or more diseases responsive to inhibition of tyrosine kinase activity. The diseases may, for instance, be responsive to inhibition of Btk activity and/or B-cell proliferation. Example diseases include cancer, an autoimmune and/or inflammatory disease, and an acute inflammatory reaction.

Priority: US2004-861791 Applic. Date: 2004-06-04; US20030475634P Applic. Date: 2003-06-04; US20030519311P Applic. Date: 2003-11-11; US20040633378P Applic. Date: 2004-12-06

Inventor: CURRIE KEVIN S [US]; DESIMONE ROBERT W [US]; MITCHELL SCOTT A [US]; PIPPIN DOUGLAS A I [US]; DARROW JAMES W [US]; QIAN XIAOBING [US]; VELLECA MARK [US]; QIAN DAPENG [US]

Title: Segmented polymers and their conjugates

Applicant/Assignee: NEKTAR THERAPEUTICS AL, CORPORATION NEKTAR THERAPEUTICS

Application No.: 11/402350   Filing Date: 11/Apr/2006

Abstract:Segmented water soluble polymers, containing a higher molecular weight segment linked to a lower molecular weight segment, are described. In one embodiment, the polymer segments are poly(ethylene glycol) segments. The segmented polymers are functionalized and are useful for conjugation to various moieties such as pharmacologically active substances. Also described are conjugates of such polymers and methods of their preparation.

Priority: US2003-734858 Applic. Date: 2003-12-11; US2001-024357 Applic. Date: 2001-12-18; US20000256801P Applic. Date: 2000-12-18

Inventor: KOZLOWSKI ANTONI [US]; SHEN XIAOMING [US]; BENTLEY MICHAEL D [US]; FANG ZHIHAO [US]; SANDER TONY L [US]

Title: Ligands to enhance cellular uptake of biomolecules

Applicant/Assignee: CELL WORKS THERAPEUTICS, INC., A DELAWARE CORPORATION

Application No.: 11/256476   Filing Date: 21/Oct/2005

Abstract:The present invention relates to the design and synthesis of homogeneous A-L-P constructs, which contain a hepatic ligand to direct an oligomer or "payload" to a hepatocyte intracellularly via a receptor-mediated, ligand-directed pathway.

Priority: US2001-888164 Applic. Date: 2001-06-22; US1999-282455 Applic. Date: 1999-03-31; US1996-755062 Applic. Date: 1996-11-22; US19950007480P Applic. Date: 1995-11-22

Inventor: TSO PAUL O [US]; DUFF ROBERT [US]; ZHOU YUANZHONG [US]; DEAMOND SCOTT [US]; ROBY CLINTON [US]

Title: Stable pharmaceutical formulations of zonisamide and methods for their manufacture

Applicant/Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD

Application No.: 11/336546   Filing Date: 20/Jan/2006

Abstract:One of the embodiments of the present invention is directed toward a process for preparing a stable zonisamide pharmaceutical composition, comprising subjecting zonisamide to wet granulation with a granulation liquid to form a granulated mixture as the stable zonisamide pharmaceutical composition, wherein the granulation liquid is selected from purified water, alcohol and mixtures thereof. The stable zonisamide pharmaceutical composition can be used to fill capsule shells to prepare stable zonisamide capsules. Another embodiment of the invention concerns a for preparing a stable zonisamide pharmaceutical capsule, comprising (i) forming an intimate mixture with zonisamide powder and an effective amount of at least one pharmaceutically acceptable excipient by compressing, co-milling, co-micronization and/or co-compaction of the components, or subjecting the components to a similarly intensive process

and (ii) filling capsule shells with the intimate mixture to obtain the stable zonisamide pharmaceutical capsule.

Priority: US20050645030P Applic. Date: 2005-01-21

Inventor: HRAKOVSKY JULIA [IL]; TENENGAUZER RUTH [IL]

Title: Methods of treating disease with random copolymers

Applicant/Assignee: PEPTIMMUNE, INC

Application No.: 11/283406   Filing Date: 17/Nov/2005

Abstract:The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers. The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the formulations or dosing regimens of random copolymer described herein.

Priority: WO2005US16340 Applic. Date: 2005-05-09; WO2005US16344 Applic. Date: 2005-05-09; US20040569292P Applic. Date: 2004-05-07; US20050663333P Applic. Date: 2005-03-18

Inventor: RASMUSSEN JAMES [US]; ZHANG JIANXIN [US]; BALDWIN SAM [US]; ZANELLI ERIC [US]; YU BEI [US]; BONNIN DUSTAN [US]; JOHNSON KEITH [US]

Title: Modified human growth hormone

Applicant/Assignee: AMBRX, INC

Application No.: 11/316534   Filing Date: 21/Dec/2005

Abstract:Modified growth hormone polypeptide and uses thereof are provided.

Priority: US20040638616P Applic. Date: 2004-12-22; US20050727996P Applic. Date: 2005-10-17

Inventor: CHO HO S [US]; DANIEL THOMAS O [US]; DIMARCHI RICHARD D [US]; HAYS ANNA-MARIA [US]; WILSON TROY E [US]; SIM BEE-CHENG [US]; LITZINGER DAVID C [US]

Title: Delivery of substances to cells

Applicant/Assignee: PHOGEN LIMITED

Application No.: 11/223449   Filing Date: 09/Sep/2005

Abstract:Aggregates comprising VP22 protein and oligonucleotides or polynucleotides can be used together with a disaggregating agent (simultaneously or sequentially) to treat target cells by delivery of molecules to the cells and/or to prevent cell proliferation and/or to kill cells.

Priority: GB20000022101 Applic. Date: 2000-09-08; US2001-949093 Applic. Date: 2001-09-07

Inventor: O'HARE PETER FRANCIS [GB]; BREWIS NEIL D [GB]; NORMAND NADIA M [FR]; SUNASSEE KAVITHA R [GB]

Title: Pharmaceutical compositions of ganciclovir

Applicant/Assignee:

Application No.: 10/532024   Filing Date: 22/Oct/2003

Abstract:The technical field of the invention relates to pharmaceutical compositions of 9-(1,3-dihydroxy-2-propoxymethyl) guanine (ganciclovir) that are stable and contain more than 1% water content. One pharmaceutical composition includes ganciclovir having more than about 1% water content, and one or more pharmaceutically acceptable excipients. The ganciclovir retains at least about 97% of its initial purity after one month, at least about 96% of its initial purity after two months, and at least about 95% of its initial purity after three months when stored at 40 DEG C. and 75% RH. In particular, the water content may be between about 2% and about 6%.

Priority: IN2002DE01058 Applic. Date: 2002-10-22; WO2003IB04664 Applic. Date: 2003-10-22

Inventor: MATHUR RAJEEV S [IN]; KUMAR PANANCHUKUNNATH M [IN]; ROY SUNILENDU B [IN]; MALIK RAJIV [AT]

Title: Preparation of amorphous form of indiplon

Applicant/Assignee: MAI DE LTD

Application No.: 11/347753   Filing Date: 06/Feb/2006

Abstract:The present invention is directed to amorphous form of indiplon, to processes for preparing said amorphous form, to pharmaceutical compositions containing the same, and to method of treatment using the same. Additionally, the present invention also relates to the preparation of solid amorphous dispersion of indiplon and a carrier which includes PVP and solid PEG etc.

Priority: CN20051033218 Applic. Date: 2005-02-18

Inventor: HUANG LE [CN]; HUANG HUI M H [US]

Title: Combinations comprising antimuscarinic agents and beta-adrenergic agonists

Applicant/Assignee:

Application No.: 11/409157   Filing Date: 21/Apr/2006

Abstract:Combinations comprising (a) a beta2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.

Priority: ES20040001312 Applic. Date: 2004-05-31; US2005-141428 Applic. Date: 2005-05-31

Inventor: GRAS ESCARDO JORDI [ES]; LLENAS CALVO JESUS [ES]; RYDER HAMISH [ES]; ORVIZ DIAZ PIO [ES]

Title: Formulations of ladostigil tartrate

Applicant/Assignee:

Application No.: 11/361379   Filing Date: 24/Feb/2006

Abstract:Disclosed are formulations of ladostigil tartrate, including pharmaceutical compositions, process for the manufacture, and use thereof.

Priority: US20050656477P Applic. Date: 2005-02-24

Inventor: LICHT DANIELLA [IL]; LOVINGER IOANA [IL]; CACIULARU FANNY [IL]; GILBERT ADRIAN [IL]

Title: Dry powder inhaler devices, multi-dose dry powder drug packages, control systems, and associated methods

Applicant/Assignee:

Application No.: 11/294681   Filing Date: 05/Dec/2005

Abstract:Dry powder inhalers with integrated active energy patient assist dispersal systems are configured with control systems which provide adjustable energy output responsive to the user's inspiratory capabilities and/or the flowability of the dry powder drug being administered. The multi-dose dry drug package includes a piezoelectric polymer substrate (such as PVDF) which flexes to deform and provide mechanical oscillation in a selected region of the package corresponding to the dry powder drug dose in the exit flow path and is thus actively dispersed into the exit flow path of the inhaler during the user's inspiratory activity. Control systems employ fuzzy logic models of the flowability of particular drug formulations (also being able to compensate or allow for the particular type of excipient used) and/or adjust for the real-time measured inspiratory efforts of the user. Manufacturing process control systems can adjust certain parameters in response to a fuzzy logic model of the flowability of the dry powder and other conditions associated with the dry powder drug being produced and/or dispensed.

Priority: US2003-204609 Applic. Date: 2003-01-29; WO2001US02262 Applic. Date: 2001-01-24; US20000188543P Applic. Date: 2000-03-10

Inventor: HICKEY ANTHONY J [US]; CROWDER TIMOTHY M [US]

Title: Extended release formulations of poorly soluble antibiotics

Applicant/Assignee:

Application No.: 11/267943   Filing Date: 04/Nov/2005

Abstract:An extended release pharmaceutical compressed composition and dosage form comprising poorly water soluble macrolide antibiotic, surfactant and non-lipophilic, non-polymeric excipient is disclosed. The composition releases the macrolide antibiotic over an extended period of time, generally at least over 12 hours, even in the absence of a release rate-retarding polymer, release rate-retarding coating or release rate-retarding lipophilic excipient. The composition is suitable for once daily or twice daily oral administration for the treatment of many different types of bacterial infections. One embodiment of the compressed composition includes a drug-containing granular composition and a binding composition, wherein the two are mixed together and then compressed into a tablet or pill. The surfactant is in admixture with or coated onto the macrolide antibiotic, and it can be included in the granular composition and/or the binding composition. The non-polymeric, non-lipophilic excipient is included in the granular composition and/or the binding composition.

Priority: US20040626277P Applic. Date: 2004-11-09

Inventor: BURNSIDE BETH A [US]; ROWLINGS COLIN [US]; WASSINK SANDRA E [US]; TREACY DONALD J JR [US]; KOLENG JOHN J [US]

Title: Tablets with improved drug substance dispersibility

Applicant/Assignee:

Application No.: 11/357303   Filing Date: 17/Feb/2006

Abstract:The present invention relates to a method for the preparation of pharmaceutical compositions in the form of tablets with improved drug substance dispersibility, which method comprises a) preparing a dispersion of at least one pharmaceutically active drug substance and at least one surfactant and/or binder in a liquid

b) preparing a carrier by dry blending at least one porous carrier and one or more excipient(s)

and c) spray granulating the dispersion prepared in step a) onto the carrier prepared in step b) to obtain a spray-granulated product.

Priority: EP20050101458 Applic. Date: 2005-02-25

Inventor: BERNIGAL NATHALIE [FR]; GARCIA ERIC [FR]; PAGE SUSANNE [DE]; TARDIO JOSEPH [FR]

Title: Controlled release venlafaxine formulations

Applicant/Assignee: PENWEST PHARMACEUTICALS CO.,

Application No.: 11/363760   Filing Date: 28/Feb/2006

Abstract:In certain embodiments, the present invention is directed to a controlled release oral solid dosage form comprising a matrix comprising a therapeutically effective amount of venlafaxine, an active metabolite of venlafaxine, or a pharmaceutically acceptable salt thereof, dispersed in a cross-linked gelling agent, the matrix providing a controlled release of venlafaxine, active metabolite of venlafaxine, or salt thereof to provide 24 hour therapeutic plasma levels after oral administration to human patients.

Priority: US20050657035P Applic. Date: 2005-02-28; US20050750594P Applic. Date: 2005-12-14

Inventor: KETSELA SARA [US]; DINICOLA DEAN [US]; BAICHWAL ANAND R [US]

Title: Pharmaceutical combinations of hydrocodone and naltrexone

Applicant/Assignee: EURO-CELTIQUE S.A

Application No.: 10/562494   Filing Date: 09/Sep/2004

Abstract:Disclosed is a pharmaceutical composition comprising from about 5 to about 20 mg of hydrocodone or a pharmaceutically acceptable salt thereof and from 0.055 to about 0.56 mg naltrexone or pharmaceutically acceptable salt thereof.

Priority: WO2004US29521 Applic. Date: 2004-09-09; US20030506222P Applic. Date: 2003-09-25

Inventor: OSHLACK BENJAMIN [US]; WRIGHT CURTIS [US]; BREDER CHRIS [US]

Title: Combination enzyme for cystic fibrosis

Applicant/Assignee:

Application No.: 11/232180   Filing Date: 21/Sep/2005

Abstract:A stable preparation of digestive/pancreatic enzymes which can be readily formed into a dosage formulation is provided as a treatment of pancreatic insufficiency in persons having cystic fibrosis. The dosage formulation can be administered either by an oral preparation including, but not limited to, a microcapsule, mini-capsule, time released capsule, sprinkle or other methodology. A further object of this invention is to provide a stabilized preparation of a combination medicant which resists degradation by light, heat, humidity or association with commonly used excipients.

Priority: US20040613666P Applic. Date: 2004-09-28

Inventor: FALLON JOAN M [US]

Title: Methods and compositions for treating herpes infections

Applicant/Assignee:

Application No.: 11/367772   Filing Date: 03/Mar/2006

Abstract:A method of treatment or prophylaxis of herpes infections and associated disease states by administration of compositions comprising immunoglobulins. Methods comprising intravenous and topical administration of immunoglobulins are provided.

Priority: WO2004US28559 Applic. Date: 2004-09-01; US2003-656781 Applic. Date: 2003-09-05

Inventor: BETZ ULRICH [DE]; RADTKE KLAUS-PETER [US]

Title: Pharmaceutical formulation and a method of making same

Applicant/Assignee:

Application No.: 10/542032   Filing Date: 12/Dec/2003

Abstract:The methods of the present invention and the formulations made from those methods, allow the stable integration of multiple actives within a single formulation. The solubilisation of an active in a suitable solvent and the subsequent adsorption onto a sorbing medium provide effective protection for the active from any adverse conditions within the liquid in which the active-loaded sorbing medium is dispersed. As a result the liquid can be formulated to suit the requirements of the actives that may include therein. As a result the actives may be stably integrated within the formulation.

Priority: NZ20020523128 Applic. Date: 2002-12-12; WO2003NZ00272 Applic. Date: 2003-12-12

Inventor: RAZZAK MAJID HAMEED A [NZ]

Title: Roflumilast and integrin inhibitor combination and treatement method

Applicant/Assignee:

Application No.: 11/365569   Filing Date: 01/Mar/2006

Abstract:The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a therapeutically active amount of roflumilast, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable thereof, and one or more pharmaceutically acceptable excipients. These novel solid pharmaceutical dosage forms are useful in the treatment or control of asthma. The present invention also provides a method for treating asthma employing the solid pharmaceutical dosage forms and a method for preparing the pharmaceutical dosage forms.

Priority: US20050658719P Applic. Date: 2005-03-04

Inventor: SANDHU HARPREET K [US]; VALACER DAVID J [US]

Title: Solid lercanidipine free base

Applicant/Assignee: RECORDATI IRELAND LIMITED

Application No.: 11/364861   Filing Date: 27/Feb/2006

Abstract:The invention provides substantially pure lercanidipine free base, having a purity of at least 95%, preferably at least 97%, more preferably at least 99%, and still more preferably at least 99.5%. The lercanidipine free base of the present invention is formed as an amorphous solid that is easily handled and particularly well suited to the formulation of pharmaceutical compositions.

Priority: US20050656741P Applic. Date: 2005-02-25

Inventor: BERLATI FABIO [IT]; LEONARDI AMEDEO [IT]; MOTTA GIANNI [IT]; CANDIANI ILARIA [IT]; CORCELLA FRANCESCO [IT]

Title: Salts of (-)-O-desmethylvenlafaxine

Applicant/Assignee:

Application No.: 11/418137   Filing Date: 05/May/2006

Abstract:Methods of preparing, and compositions comprising, derivatives of (-)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

Priority: US2004-806423 Applic. Date: 2004-03-23; US2002-222815 Applic. Date: 2002-08-19; US2001-014592 Applic. Date: 2001-12-14; US1999-450690 Applic. Date: 1999-11-30; US19980110488P Applic. Date: 1998-12-01

Inventor: JERUSSI THOMAS P [US]; SENANAYAKE CHRISANTHA H [US]; BHONGLE NANDKUMAR N [US]

Title: Chewing gum in the form of multi-layer tablets

Applicant/Assignee:

Application No.: 10/545348   Filing Date: 20/Jan/2004

Abstract:Disclosed are tablets having a sandwich-like structure comprising at least one inner layer of gum base containing one or more active pharmaceutical, dietetic or nutritional ingredients and two non-contigous outer layers comprising antiadhesion excipients and compression adjuvants preventing the adhesion to the punches of the tabletting machine and possibly active ingredients which are the same as or different from those present in the inner layer. Said tablets are obtainable by direct compression of mixtures or granulates of the various components of each layer.

Priority: EP20030003813 Applic. Date: 2003-02-20; WO2004EP00371 Applic. Date: 2004-01-20

Inventor: SALINI ALBERTO [CH]

Title: Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same

Applicant/Assignee: ALIOS BIOPHARMA, INC

Application No.: 11/351163   Filing Date: 08/Feb/2006

Abstract:The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites, as well as erythropoietin and darbepoetin alfa, each of which are linked to a penetrating peptide that facilitates translocation of a substance across a biological barrier as well as pharmaceutical compositions, including oral formulations, of the same.

The present invention further provides oral formulations of hyperglycosylated or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic.

The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof.

Priority: US2006-330917 Applic. Date: 2006-01-11; US2005-200531 Applic. Date: 2005-08-08; US20040600202P Applic. Date: 2004-08-09; US20040600134P Applic. Date: 2004-08-09; US20040604280P Applic. Date: 2004-08-24; US20040604415P Applic. Date: 2004-08-24

Inventor: BLATT LAWRENCE M [US]; SEIWERT SCOTT D [US]; HONG JIN [US]

Title: Fast dissolving orally consumable films containing an ion exchange resin as a taste masking agent

Applicant/Assignee: MCNEIL-PPC, INC

Application No.: 11/429547   Filing Date: 05/May/2006

Abstract:Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer, such as pullulan, and a taste masked pharmaceutically active agent, such as dextromethorphan. The taste masking agent is preferably a sulfonated polymer ion exchange resin comprising polystyrene cross-linked with divinylbenzene, such as AMBERLITE. Methods for producing the films are also disclosed.

Priority: US2000-535005 Applic. Date: 2000-03-23

Inventor: BESS WILLIAM S [US]; KULKARNI NEEMA [US]; AMBIKE SUHAS H [CA]; RAMSAY MICHAEL P [CA]

Title: Stable compositions of bupropion or its pharmaceutically acceptable salts

Applicant/Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED

Application No.: 11/373480   Filing Date: 10/Mar/2006

Abstract:A stable oral pharmaceutical composition comprising a therapeutically effective amount of bupropion or its pharmaceutically acceptable salt intimately blending with one or more compatible excipients selected from the group consisting of talc and potassium chloride, additional pharmaceutically acceptable excipients and total impurities are present in amounts from 0% to not more than 3.3% w/w of the bupropion hydrochloride, when the composition is stored at 40 DEG C. at 75% relative humidity for three months in closed containers with silica gel as dessicant.

Priority: IN2005MU00240 Applic. Date: 2005-03-12

Inventor: DHAVSE VAISHALI V [IN]; DHARMADHIKARI NITIN B [IN]

Title: Control release formulation containing a hydrophobic material as the sustained release agent

Applicant/Assignee: NOSTRUM PHARMACEUTICALS, INC

Application No.: 11/355346   Filing Date: 16/Feb/2006

Abstract:The present invention is directed to a sustained release pharmaceutical composition in oral dosage form consisting essentially of a pharmaceutically effective amount of a medicament and a hydrophobic material in the absence of a lactose or hydrophobic carbohydrate polymer, said medicament being present in an amount greater than about 25% of the pharmaceutical composition and having a water solubility greater than about 1 gram per 10 mL of water at 25 DEG C., said hydrophobic material having a melting point ranging from at least about 40 DEG C. to about 100 DEG C. at 1 atm pressure, and being present in an amount ranging from about 3% to about 20% by weight of the pharmaceutical composition and in an amount less than the of the medicament, and said hydrophobic material not being present in coating of said pharmaceutical composition

said pharmaceutical composition being prepared by direct compression in the absence of or melting the hydrophobic material or the use of high shear mixer. The present invention is also directed to a method of preparing said pharmaceutical composition.

Priority: US2002-167368 Applic. Date: 2002-06-10; US20010297140P Applic. Date: 2001-06-08

Inventor: MULYE NIRMAL [US]

Title: Dual controlled release dosage form

Applicant/Assignee:

Application No.: 11/355315   Filing Date: 15/Feb/2006

Abstract:A dosage form that provides a controlled release of at least two different active agents is provided. Particular embodiments include a dosage form that provides therapeutically effective levels of a first active agent and a second active agent in a mammal for an extended period of time following oral administration. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. The layers of the core are in stacked, substantially concentric or substantially eccentric arrangement.

Priority: US2005-321736 Applic. Date: 2005-12-29; US2001-992488 Applic. Date: 2001-11-06

Inventor: VERGEZ JUAN A [AR]; RICCI MARCELO A [AR]

Title: Multiple phase cross-linked compositions and uses thereof

Applicant/Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

Application No.: 11/434023   Filing Date: 15/May/2006

Abstract:The present invention is directed to pharmaceutical compositions, and method for preparing pharmaceutical compositions, comprising a cross-linked matrix physically entrapping at least one therapeutic agent. The matrix may comprise one or more phases in addition to an aqueous phase, such as a solid and/or oil phase. The matrix of the invention has at least one controlled release in-vivo kinetic profile, and may have additional profiles for the same agent. The matrix may also comprise more than one therapeutic agent, and each additional therapeutic agent may have one or more controlled release in-vivo kinetic profile.

Priority: US2001-883842 Applic. Date: 2001-06-18; US20000212511P Applic. Date: 2000-06-19

Inventor: STEIN STANLEY [US]; QIU BO [US]

Title: Use of film coating as taste-masking coating of oral dosage forms

Applicant/Assignee:

Application No.: 11/218533   Filing Date: 06/Sep/2005

Abstract:The present invention relates to the use of a film coating consisting of a) polyvinyl acetate b) hydrophilic additives c) other conventional coating ingredients d) and, where appropriate, a physiologically tolerated acid as taste-masking coating for oral dosage forms, and to a process for producing such dosage forms.

Priority: DE19991061897 Applic. Date: 1999-12-20; US2000-729460 Applic. Date: 2000-12-05

Inventor: KOLTER KARL [DE]; SCHEIFFELE SILKE [DE]; EINIG HEINZ [DE]; BODMEIER ROLAND [DE]

Title: Method and means for improving bowel health

Applicant/Assignee: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION LIMAGRAIN CEREALES INGREDIENTS SA

Application No.: 11/324063   Filing Date: 30/Dec/2005

Abstract:A method and composition for improving one or more indicators of bowel health or metabolic health in a mammalian animal. This comprises the delivering to the gastrointestinal tract of the animal an effective amount of an altered wheat starch in the form of or derived from the grain of a wheat plant. The proportion of amylose in the starch of the grain is at least 30% and/or the grain comprises a reduced level of SBEIIa enzyme activity and/or protein relative to wild-type grain.

Priority: AU20040907350 Applic. Date: 2004-12-30; US20050688944P Applic. Date: 2005-06-08

Inventor: BIRD ANTHONY R [AU]; MANN GULAY S [AU]; RAHMAN SADEQUR [AU]; REGINA AHMED [AU]; LI ZHONGYI [AU]; TOPPING DAVID L [AU]; MORELL MATTHEW K [AU]

Title: G-type peptides and other agents to ameliorate atherosclerosis and other pathologies

Applicant/Assignee: THE UNIVERSITY OF ALABAMA RESEARCH FOUNDATION

Application No.: 11/229042   Filing Date: 16/Sep/2005

Abstract:This invention provides novel peptides, and other agents, that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The peptides are highly stable and readily administered via an oral route.

Priority: US20040610711P Applic. Date: 2004-09-16

Inventor: FOGELMAN ALAN M [US]; NAVAB MOHAMAD [US]; ANANTHARAMAIAH GATTADAHALLI M [US]

Title: Topical and oral formulations of cardiac glycosides for treating skin diseases

Applicant/Assignee: AZAYA THERAPEUTICS, INC

Application No.: 11/255596   Filing Date: 21/Oct/2005

Abstract:The present invention provides method, preparation and use of a variety of pharmaceutical compositions containing at least one digitalis glycoside such as oleandrin, odoroside-A, neriifolin, proscillaridin-A, methyl-proscillaridin-A, digitoxin, digoxin alone or at least one digitalis glycoside complexed with cyclodextrins. In another aspect, the present invention provides an effective method to treat diseases in mammals. In yet another aspect, the present invention provides an effective method for treating skin diseases in a human or non-human animal.

Priority: US20040621102P Applic. Date: 2004-10-22

Inventor: STREEPER ROBERT [US]; SINGH CHANDRA U [US]

Title: Flupirtine preparation for the treatment of neurodegenerative diseases of the visual apparatus and diabetes mellitus

Applicant/Assignee:

Application No.: 11/316570   Filing Date: 21/Dec/2005

Abstract:The invention relates to the use of flupirtine in manufacture of a pharmaceutical preparation for therapy and/or prophylaxis of diabetes mellitus, diabetic retinopathy, diabetic maculopathy, genetically related maculopathies, apoptosis of the visual apparatus and/or human glaucomas and also a combination preparation comprising flupirtine and at least one further active ingredient for therapy and/or prophylaxis of said diseases.

Priority: DE20031028260 Applic. Date: 2003-06-23; WO2004EP06738 Applic. Date: 2004-06-22

Inventor: SCHMIDT KARL-GEORG [DE]

Title: 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect

Applicant/Assignee: FOREST LABORATORIES, INC

Application No.: 11/315581   Filing Date: 21/Dec/2005

Abstract:The present invention relates to the treatment of individuals diagnosed with multiple sclerosis, emotional lability or pseudobulbar affect comprising administering to said individual an effective amount of a 1-aminocyclohexane derivative, namely memantine or neramexane.

Priority: US20040638423P Applic. Date: 2004-12-22

Inventor: JONAS JEFFREY [US]; MANN ALLISON [US]

Title: Peptide useful in immunomodulation

Applicant/Assignee: MOR-RESEARCH APPLICATIONS LTD., CURETECH LTD MOR-RESEARCH APPLICATIONS LTD

Application No.: 11/411832   Filing Date: 27/Apr/2006

Abstract:The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.

Priority: IL20010145926 Applic. Date: 2001-10-15; US2004-821283 Applic. Date: 2004-04-09; WO2002IL00831 Applic. Date: 2002-10-15

Inventor: HARDY BRITTA [IL]; RAITER ANNAT [IL]; KLAPPER LEAH [IL]

Title: Co-precipitated amorphous losartan and dosage forms comprising the same

Applicant/Assignee:

Application No.: 10/542587   Filing Date: 21/Jan/2004

Abstract:The technical field of the invention relates to spray dried, co-precipitate amorphous losartan dosage forms that are stable over time and processes for their preparation. The processes stabilize the amorphous losartan. The process includes preparing an aqueous solution of losartan and one or more hydrophilic polymers

and spray drying the aqueous solution of losartan and one or more hydrophilic polymers to form a mixture. The amorphous losartan and one or more hydrophilic polymers are co-precipitated from the aqueous solution.

Priority: IN2003DE00054 Applic. Date: 2003-01-21; WO2004IB00144 Applic. Date: 2004-01-21

Inventor: KUMRA PANNANCHUKUNNATH M [IN]; MANIKANDAN RAMALINGAM [IN]; SINGH ROMI B [IN]; NAGAPRASAD VISHNUBHOTLA [IN]

Title: Surface modified particulate compositions of biologically active substances

Applicant/Assignee: SKYEPHARMA CANADA INC

Application No.: 11/272902   Filing Date: 14/Nov/2005

Abstract:This invention disclosure relates to compositions for the delivery of stable surface modified sub-micron and micron sized particles of water-insoluble biologically active substances from a non-aqueous medium that self-disperses on exposure to an aqueous environment.

Priority: US2000-667328 Applic. Date: 2000-09-21; US19990154964P Applic. Date: 1999-09-21

Inventor: PACE GARY W [US]; MISHRA AWADHESH K [CA]; SNOW ROBERT A [US]

Title: Sustained release delivery of isradipine

Applicant/Assignee:

Application No.: 11/377648   Filing Date: 17/Mar/2006

Abstract:Sustained release oral formulations of israpidine, methods of preparing same, and methods of using sustained release oral formulations to provide controlled delivery of israpidine. The sustained release oral formulations include israpidine and a sustained release polymer, and provide substantially zero order release of israpidine over an extended period.

Priority: US20050662370P Applic. Date: 2005-03-17

Inventor: STACH PAUL E [US]; KADRI BALAJI V [US]; BOBOTAS GEORGE [US]; FAWZY ABDEL A [US]

Title: Controlled release compositions of gamma-hydroxybutyrate

Applicant/Assignee:

Application No.: 11/239638   Filing Date: 30/Sep/2005

Abstract:The present invention is directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed/controlled release components of gamma-hydroxybutyric acid.

Priority: US20040614622P Applic. Date: 2004-09-30

Inventor: LIANG LIKAN [US]; SHAH NIRAJ [US]; BHATT PADMANABH P [US]; IBRAHIM SCOTT [US]

Title: Multi-particulate, modified-release composition

Applicant/Assignee:

Application No.: 11/085671   Filing Date: 21/Mar/2005

Abstract:A multi-particulate, modified-release pharmaceutical composition for the oral administration of an active ingredient to the colon, wherein said particles comprise: (a) a core comprising an active ingredient or a pharmaceutically acceptable salt or ester thereof, and optionally one or more excipients

(b) a first coating applied to the surface of the core, wherein said first coating is insoluble in gastric juice and in intestinal juice below pH 7, but soluble in colonic intestinal juice

and (c) a second coating applied to the surface of the first coating.

Priority:

Inventor: PATEL ASHISH A [US]; PALANISWAMY SURESH [US]; DAVILA PABLO [US]

Title: Use of ciclesonide for the treatment of inflammatory bowel diseases

Applicant/Assignee: ALTANA PHARMA AG

Application No.: 10/570986   Filing Date: 28/Mar/2006

Abstract:The invention relates to the novel use of ciclesonide in the treatment of inflammatory bowel disease.

Priority: EP20030020871 Applic. Date: 2003-09-15; WO2004EP52170 Applic. Date: 2004-09-15

Inventor: ABEL FLORIAN [DE]; BRUECK ANTJE [DE]; DIETZEL KLAUS [DE]; EISTETTER KLAUS [DE]; NAVE RUEDIGER [DE]; POSTIUS STEFAN [DE]; VON RICHTER OLIVER [DE]

Title: Amorphous lercanidipine hydrochloride and uses thereof

Applicant/Assignee: RECORDATI IRELAND LIMITED

Application No.: 11/364862   Filing Date: 27/Feb/2006

Abstract:The invention provides a substantially pure amorphous lercanidipine hydrochloride having a purity of at least 95% pure, preferably at least about 97% pure, more preferably at least about 99% pure, and still more preferably at least about 99.5% pure. The invention further relates to methods of preparing substantially pure amorphous lercanidipine, as well as methods of providing rapid relief from hypertension by administering the substantially pure amorphous lercanidipine hydrochloride of the present invention to a patient in need of such treatment.

Priority: US20050656836P Applic. Date: 2005-02-25

Inventor: LEONARDI AMEDEO [IT]; MOTTA GIANNI [IT]; BERLATI FABIO [IT]

Title: Method of modulation

Applicant/Assignee:

Application No.: 11/229415   Filing Date: 16/Sep/2005

Abstract:Disclosed are methods for modulating neuron activity, and in particular, for modulating motor neuron function and activity, particularly for use in the treatment, prevention, and/or amelioration of symptoms of one or more motor neuron conditions or diseases in a mammal. Also disclosed are compositions comprising one or more agonists or antagonists of a mammalian Müllerian Inhibitory Substance receptor polypeptide, as well as pharmaceutical formulations, isolated host cells, and therapeutic and/or diagnostic kits that comprises such agonists or antagonists.

Priority: NZ20050539036 Applic. Date: 2005-03-24

Inventor: MCLENNAN IAN S [NZ]; KOISHI KYOKO [NZ]; WANG PEI-YU [NZ]

Title: Pharmaceutical compositions comprising an oligonucleotide as an active agent

Applicant/Assignee:

Application No.: 11/266999   Filing Date: 04/Nov/2005

Abstract:A pharmaceutical composition is disclosed, which composition comprises an oligonucleotide as an active agent, the oligonucleotide being adapted to target nucleic acids encoding CD40 thereby to modulate the expression of CD40 in mammalian cells, and a liposome as an excipient. Said liposome is an amphoteric liposome. Also disclosed is a method for the treatment or prophylaxis of a disease or condition associated with the expression of CD40 in a human or non-human animal patient by administering to said patient a therapeutically or prophylactically effective amount of such a composition.

Priority: DE200410054731 Applic. Date: 2004-11-05; DE200410056659 Applic. Date: 2004-11-19; EP20050020218 Applic. Date: 2005-09-15; US20040625195P Applic. Date: 2004-11-05; US20040629600P Applic. Date: 2004-11-19; US20050717293P Applic. Date: 2005-09-15

Inventor: PANZNER STEFFEN [DE]; RAUCHHAUS UNA [DE]; ENDERT GEROLD [DE]; FANKHAENEL STEFAN [DE]

Title: Tablet punches and methods for tableting

Applicant/Assignee:

Application No.: 10/567055   Filing Date: 16/Aug/2004

Abstract:A tablet punch having a punch cup having a non-stick polymeric coating which may comprise a fluoropolymer such as polytetrafluoroethylene.

Priority: US20030497580P Applic. Date: 2003-08-25; WO2004IB02668 Applic. Date: 2004-08-16

Inventor: STROPPOLO FEDERICO [CH]; LEPORI SANDRO [CH]; CICCARELLO FRANCO [CH]; MILANI RITA [CH]

Title: AGGLOMERATED STARCH COMPOSITIONS

Applicant/Assignee: BPSI HOLDINGS, INC

Application No.: 11/376855   Filing Date: 16/Mar/2006

Abstract:Agglomerated starch compositions containing native starch and pre-compacted starch powder is disclosed. The agglomerated starch compositions have superior flow and less pH sensitivity than simple blends of the two components at equivalent ratios.

Priority: US20050664447P Applic. Date: 2005-03-23

Inventor: CUNNINGHAM CHARLES R [US]

Title: Pharmaceutical Compositions of Dispersions of Drugs and Neutral Polymers

Applicant/Assignee: PFIZER INC

Application No.: 11/383520   Filing Date: 16/May/2006

Abstract:In one aspect, pharmaceutical compositions comprising dispersions of an acid-sensitive drug and a neutral dispersion polymer are disclosed. The acid-sensitive drug has improved chemical stability relative to dispersions of the drug and acidic polymers. In another aspect, pharmaceutical compositions of low-solubility drugs and amphiphilic, hydroxy-functional vinyl copolymers are disclosed.

Priority: US2002-175132 Applic. Date: 2002-06-18; US20010300255P Applic. Date: 2001-06-22

Inventor: FRIESEN DWAYNE T [US]; GUMKOWSKI MICHAEL J [US]; KETNER RODNEY J [US]; LORENZ DOUGLAS A [US]; NIGHTINGALE JAMES A [US]; SHANKER RAVI M [US]; WEST JAMES B [US]

Title: Controlled release composition containing a strontium salt

Applicant/Assignee:

Application No.: 10/556150   Filing Date: 06/May/2004

Abstract:A controlled release pharmaceutical composition comprising a strontium salt. The invention also relates to the use of a strontium salt for treating a male suffering from diseases and conditions affecting metabolism and/or structural integrity of cartilage and/or bone. The invention also relates to the use of a strontium-containing compound for preventing a cartilage and/or bone condition in a subject, and for the treatment and/or prophylaxis of secondary osteoporosis.

Priority: DK20030000691 Applic. Date: 2003-05-07; DK20030001043 Applic. Date: 2003-07-08; DK20030001821 Applic. Date: 2003-12-09; US20030528409P Applic. Date: 2003-12-09; WO2004DK00326 Applic. Date: 2004-05-06

Inventor: HANSEN CHRISTIAN [DK]; NILSSON HENRIK [DK]; ANDERSEN JENS E [DK]; CHRISTGAU STEPHAN [DK]

Title: Novel cyclosporine analog formulations

Applicant/Assignee: ISOTECHNIKA INC., A CANADA CORPORATION ISOTECHNIKA INC

Application No.: 11/375532   Filing Date: 13/Mar/2006

Abstract:The present invention relates to formulations containing cyclosporin analogs that are structurally similar to cyclosporin A, in particular isomeric mixtures of cyclosporin analogs that are structurally similar to cyclosporin A. The formulations form stable microemulsion preconcentrates and may provide superior drug bioavailability and/or may reduce one or more adverse effects associated with the administration of cyclosporin. Also disclosed are methods for using and preparing the formulations.

Priority: US2002-274419 Applic. Date: 2002-10-17; US20020370597P Applic. Date: 2002-04-05; US20010346201P Applic. Date: 2001-10-19

Inventor: NAICKER SELVARAJ A [CA]; YATSCOFF RANDALL W [CA]; FOSTER ROBERT T [CA]

Title: Pharmaceutical composition and preparation method thereof

Applicant/Assignee: IPRBOX OY

Application No.: 11/097969   Filing Date: 01/Apr/2005

Abstract:The invention relates to an oral solid pharmaceutical composition comprising pharmacologically effective amounts of entacapone, levodopa and carbidopa, or a pharmaceutically acceptable salt or hydrate thereof, and one or more pharmaceutically acceptable excipients, wherein the excipients are long-chain polymers having an equilibrium moisture content of at least 2%, and to a preparation method thereof. The compositions can be used for the treatment of Parkinson's disease.

Priority:

Inventor: POLITI GIOVANNI [FI]

Title: Formulations of Fenofibrate

Applicant/Assignee:

Application No.: 11/323886   Filing Date: 29/Dec/2005

Abstract:The invention provides at least a composition for the treatment of elevated levels of triglycerides, comprising a therapeutically effective amount of fenofibrate or another fibrate drug intimately associated with menthol or a surfactant mixture, wherein the menthol can be menthol or menthol surfactant mixture, and wherein the surfactant mixture can be a mixture of a polyethylene glycol and a poloxamer such as PGE 1000 and poloxamer 407. The invention also provides a method for the treatment of elevated levels of triglycerides in a subject, comprising administering to the subject a composition comprising a therapeutically effective amount of fenofibrate or another fibrate drug and menthol or a surfactant mixture, wherein the fenofibrate or the other fibrate drug is in intimate association with the menthol or surfactant mixture, wherein the menthol can be menthol or menthol surfactant mixture, and wherein the surfactant mixture can be a mixture of a polyethylene glycol and a poloxamer such as PGE 1000 and poloxamer 407.

Priority: US20050666192P Applic. Date: 2005-03-30

Inventor: FLASHNER-BARAK MOSHE [IL]; LERNER E I [IL]

Title: Extended release pharmaceutical composition of phenytoin sodium

Applicant/Assignee:

Application No.: 10/539129   Filing Date: 16/Dec/2003

Abstract:The present invention relates to extended release pharmaceutical composition of phenytoin sodium that includes a blend of phenytoin sodium and one or more hydrophilic polymers. The blend forms a matrix after contacting an aqueous media and the matrix retains at least about 20% of the phenytoin after 1 hour. It also relates to a process for preparing the extended release pharmaceutical composition.

Priority: IN2002DE01264 Applic. Date: 2002-12-16; WO2003IB06007 Applic. Date: 2003-12-16

Inventor: MURPANI DEEPAK [IN]; MADAN ASHISH [IN]

Title: Particles containing an acitve agent in the form of a co-precipitate

Applicant/Assignee:

Application No.: 10/564786   Filing Date: 16/Jul/2004

Abstract:The invention relates to particles containing an active agent in the form of a co-precipitate, to a method for producing said particles and to pharmaceutical forms containing said particles.

Priority: FR20030008720 Applic. Date: 2003-07-17; WO2004FR01878 Applic. Date: 2004-07-16

Inventor: COUSIN GERARD [FR]; LAMOUREUX GAEL [FR]

Title: Modified release formulations and methods of treating inflammatory bowel disease

Applicant/Assignee: AGI THERAPEUTICS LTD

Application No.: 11/371958   Filing Date: 10/Mar/2006

Abstract:Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid, and pharmaceutically acceptable salts and pro-drugs thereof, to affected areas of the intestine, i.e., distal gut. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.

Priority: US2004-930743 Applic. Date: 2004-09-01; US20030499365P Applic. Date: 2003-09-03

Inventor: DEVANE JOHN [IE]; BUTLER JACKIE [IE]

Title: Targeting of glycoprotein therapeutics

Applicant/Assignee: GENZYME CORPORATION

Application No.: 11/398949   Filing Date: 05/Apr/2006

Abstract:Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.

Priority: US20050668920P Applic. Date: 2005-04-06

Inventor: STEFANO JAMES [US]

Title: Taste masked veterinary formulation

Applicant/Assignee: BAYER HEALTHCARE LLC

Application No.: 11/102426   Filing Date: 08/Apr/2005

Abstract:A method of producing a self-take anthelmintic that includes active components that are undesirable to at least one sense of a target animal. The active ingredients including praziquantel are mixed with artificial beef and yeast components and subjected to a first compression. The resulting rough tablet is then ground to increase the density of the material by approximately 100% of the original density. Thereafter, the material is subjected to a second compression to form a final self-take tablet.

Priority:

Inventor: ROSE JOHN [US]; RUETER JOCHEM [US]

Title: Flavored taste-masked pharmaceutical formulation made using a one-step coating process

Applicant/Assignee:

Application No.: 10/565609   Filing Date: 10/Aug/2004

Abstract:The present invention encompasses a flavored and taste-masked pharmaceutical composition comprising a plurality of pharmaceutically acceptable cores, such as microspheres, said pharmaceutically acceptable cores comprising etoricoxib, wherein the pharmaceutically acceptable cores are coated with a flavored taste-masking coating solution in a convenient one-step process.

Priority: US20030494370P Applic. Date: 2003-08-11; WO2004CA01483 Applic. Date: 2004-08-10

Inventor: DUMONT HUBERT [CA]; THIBERT ROCH [CA]

Title: Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration

Applicant/Assignee:

Application No.: 10/567699   Filing Date: 03/Aug/2004

Abstract:The present invention relates to microcapsules with a double-layer of natural polysaccharides-chitosan and alginate-gelified and stabilized by means of a divalent ion containing inside at least one biologically active substance. The microcapsules of the invention can be employed as carriers for the oral administration of biologically active substances, also associated with an adjuvant of the biological response of the same, administered for a preventive or therapeutic purpose. These substances can be chosen, for example, from antigens and adjuvants, suitable for immune response stimulation against infective and non-infective agents, or from chemotherapeutics and adjuvants with therapeutic type effects. According to the type of biologically active substance encapsulated in the microcapsules, there can be a variety of uses for oral vaccination or therapy in the human and veterinary field.

Priority: IT2003MI01617 Applic. Date: 2003-08-06; WO2004EP51693 Applic. Date: 2004-08-03

Inventor: SAVA GIANNI [IT]; ZORZIN LAURA [IT]

Title: Delivery of highly lipophilic agents via medical devices

Applicant/Assignee:

Application No.: 11/386469   Filing Date: 22/Mar/2006

Abstract:An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

Priority: US2004-769243 Applic. Date: 2004-01-30; US2004-796243 Applic. Date: 2004-03-09; US1998-159945 Applic. Date: 1998-09-24; US20030453555P Applic. Date: 2003-03-10; US20050664328P Applic. Date: 2005-03-23; US20050727080P Applic. Date: 2005-10-14; US20050726878P Applic. Date: 2005-10-14; US20050732577P Applic. Date: 2005-10-17; US20050727196P Applic. Date: 2005-10-14; US2004-977288 Applic. Date: 2004-10-29; US2002-235572 Applic. Date: 2002-09-06; US2001-950307 Applic. Date: 2001-09-10; US1999-433001 Applic. Date: 1999-11-02

Inventor: CROMACK KEITH R [US]; TONER JOHN L [US]; BURKE SANDRA E [US]; KRASULA RICHARD W [US]; SCHWARTZ LEWIS B [US]

Title: Delivery of highly lipophilic agents via medical devices

Applicant/Assignee:

Application No.: 11/386498   Filing Date: 22/Mar/2006

Abstract:An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

Priority: US20050727196P Applic. Date: 2005-10-14; US20050732577P Applic. Date: 2005-10-17; US20050726878P Applic. Date: 2005-10-14; US20050727080P Applic. Date: 2005-10-14; US20050664328P Applic. Date: 2005-03-23; US19970060015P Applic. Date: 1997-09-25; US20030453555P Applic. Date: 2003-03-10; US1998-159945 Applic. Date: 1998-09-24; US1999-433001 Applic. Date: 1999-11-02; US2001-950307 Applic. Date: 2001-09-10; US2002-235572 Applic. Date: 2002-09-06; US2004-977288 Applic. Date: 2004-10-29; US2004-769243 Applic. Date: 2004-01-30

Inventor: CROMACK KEITH R [US]; TONER JOHN L [US]; BURKE SANDRA E [US]; KRASULA RICHARD W [US]; SCHWARTZ LEWIS B [US]

Title: Reactor coated with a polymer

Applicant/Assignee:

Application No.: 10/554967   Filing Date: 27/Oct/2005

Abstract:The invention relates to the use of a coated manufacturing vessel in pharmaceutical production. A polymer coating (ECTFE, PVDF, PFA) avoids the adhesion or sticking of compounds within the vessel.

Priority: SE20030001260 Applic. Date: 2003-04-29; WO2004GB01775 Applic. Date: 2004-04-26

Inventor: BURNS STEPHEN J [GB]; FLETCHER IAN M [GB]; METCALF STEPHEN P [GB]

Title: Steroidal compositions containing hydroxycarboxylic acids and methods of using the same

Applicant/Assignee:

Application No.: 10/566079   Filing Date: 30/Jul/2003

Abstract:Pharmaceutical compositions suitable for topical administration comprising two active ingredients, a hydroxycarboxylic acid and prednicarbate, and a pyrrolidone carboxylate salt moisturizing agent. In a particular aspect, the two active ingredients in the present inventive compositions have a purity of at least 90% and a concentration of degradation product(s) less than about 10% of the starting concentration of the active ingredients. These compositions are used for topical medical applications, particularly to treat steroid responsive dermatoses.

Priority: WO2003US23723 Applic. Date: 2003-07-30

Inventor: SERIKAKU DANIELA [BR]

Title: Conjugates of an hGH moiety and a polymer

Applicant/Assignee:

Application No.: 11/388784   Filing Date: 23/Mar/2006

Abstract:Conjugates of an hGH moiety and one or more non-peptidic water-soluble polymers are provided. Typically, the non-peptidic water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising such conjugates, methods of making the conjugates, and methods of administering compositions comprising such conjugates to a mammalian subject.

Priority: US20050664401P Applic. Date: 2005-03-23

Inventor: BOSSARD MARY J [US]; ZHANG PING [US]

Title: Compositions and methods of therapy

Applicant/Assignee:

Application No.: 10/532291   Filing Date: 21/Oct/2003

Abstract:A method of inducing tolerance to an antigen in a patient, the method comprising administering to the patient an agent which raises the effective cAMP concentration in a monocyte cell and GMCSF or a derivative thereof. Preferably, the agent which raises the effective cAMP concentration in a monocyte cell is a prostaglandin or agonist thereof which stimulates cAMP production in a monocyte. Optionally, the antigen to which it is desired to induce tolerance, or a derivative thereof, may also be administered.

Priority: GB20020024415 Applic. Date: 2002-10-21; WO2003GB04537 Applic. Date: 2003-10-21

Inventor: KELLY RODNEY W [GB]

Title: Polymer-modified synthetic proteins

Applicant/Assignee: AMYLIN PHARMACEUTICALS, INC

Application No.: 11/446419   Filing Date: 05/Jun/2006

Abstract:The present invention relates to methods and compositions for modifying peptides, polypeptides and proteins with polymers, especially glyco-mimetic polymers, so as to improve their biological activity or pharmacokinetic properties. The invention further provides methods and uses for such polymer-modified peptides, polypeptides and proteins. The invention is particularly suitable for use in the synthesis of polymer-modified, synthetic bioactive proteins, and of pharmaceutical compositions that contain such proteins.

Priority: US2003-332385 Applic. Date: 2003-01-08; WO2001US21930 Applic. Date: 2001-07-12; US20000236377P Applic. Date: 2000-09-29; US20000231339P Applic. Date: 2000-09-08

Inventor: KOCHENDOERFER GERD G [US]; BOTTI PAOLO [IT]; BRADBURNE JAMES A [US]; CHEN SHIAH-YUN [US]; CRESSMAN SONYA [CA]; HUNTER CHRISTIE L [US]; KENT STEPHEN B [US]; LOW DONALD W [US]; WILKEN JILL G [US]

Title: Skin regeneration system

Applicant/Assignee:

Application No.: 10/565616   Filing Date: 28/Jul/2004

Abstract:A cell culture medium and system are provided which eliminate or at least reduce the requirement for exogenous components such as serum and feeder cells. The cell culture medium comprises an IGF and vitronectin or fibronectin and, optionally an IGFBP, and is particularly suitable for propagating keratinocytes for subsequent use in skin growth and regeneration. This invention also relates to compositions and methods for skin growth and regeneration in situ, which utilize aerosol delivery of cultured keratinocytes.

Priority: AU20030903896 Applic. Date: 2003-07-28; WO2004AU01006 Applic. Date: 2004-07-28

Inventor: UPTON ZEE [AU]; HARKIN DAMIEN [AU]; LEAVESLEY DAVID [AU]

Title: Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same

Applicant/Assignee:

Application No.: 10/543084   Filing Date: 21/Jan/2004

Abstract:The present invention concerns a dispersion of crystals or granules of active substance in a lipophilic vehicle, said crystals or granules being coated by a coating for taste masking purposes. The invention also it concerns unit dosage forms and preferentially chewable or fast dissolving soft gelatin capsules filled with said dispersion as well as process for manufacturing same.

Priority: FR20030000824 Applic. Date: 2003-01-24; WO2004US01463 Applic. Date: 2004-01-21

Inventor: MEISSONNIER JULIEN [FR]; ROSE FABRICE [FR]; BOHN MARIE M [FR]

Title: Taste masked sumatriptan tablets and processes for their preparation

Applicant/Assignee:

Application No.: 10/521402   Filing Date: 17/Jul/2003

Abstract:The technical field of the present invention relates to uncoated, taste masked sumatriptan tablets for oral administration and processes for their preparation. It also relates to wax polished sumatriptan tablets and processes for their preparation.

Priority: IN2002DE00759 Applic. Date: 2002-07-19; WO2003IB02838 Applic. Date: 2003-07-17

Inventor: MATHUR RAJEEV S [IN]; KUMAR T V [IN]; ROY SUNILENDU B [IN]; MALIK RAJIV [AT]

Title: Extended release formulation of beta-lactam antibiotics

Applicant/Assignee: LUPIN LIMITED

Application No.: 10/568325   Filing Date: 16/Feb/2006

Abstract:A pharmaceutical composition for controlled drug delivery comprising a beta-lactam antibiotic or its pharmaceutically acceptable hydrates, salts or esters, and one or more carbomers. The above beta-lactam antibiotics formulation avoids the limitations of known beta-lactam controlled release form which are found to be either complex and/or cost-extensive to obtain requiring multiphase and/or selective coatings or fail to achieve the desired controlled release for once daily dosage form. Importantly, in the beta-lactam antibiotic form of the above the rate-controlling polymer wherein the Cmax of the formulation is substantially the same as that of a single dose of the immediate release formulation. Also advantageously the formulation achieves a rate controlling polymer wherein the T>MIC for the formulation is more than 17 hours when the MIC is 0.25 mcg/ml and more than 10 hours when the MIC is 2 mcg/ml. The above beta-lactam antibiotic form is thus directed to serve as the much desired simple and cost-effective controlled release form suitable for once daily administration.

Priority: WO2003IN00326 Applic. Date: 2003-09-30

Inventor: BHAMARE SHAILESH [IN]; BHUSHAN INDU [IN]; SEN HIMADRI [IN]

Title: Use

Applicant/Assignee:

Application No.: 10/488166   Filing Date: 01/Mar/2004

Abstract:The present invention relates to the use of substances with oxytocin for the preparation of pharmaceutical composition against inflamation. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity against inflamation.

Priority: SE20010002910 Applic. Date: 2001-08-31; WO2002SE01560 Applic. Date: 2002-09-02

Inventor: UVNAES-MOBERG KERSTIN [SE]; LUNDEBERG THOMAS [SE]

Title: COMPOSITIONS FOR INHALATION

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/379721   Filing Date: 21/Apr/2006

Abstract:The present invention relates to new pharmaceutical compositions for inhalation containing one or more, preferably one anticholinergic 1 in combination with one or more betamimetics 2 and one or more steroids 3, processes for preparing them and their use in the treatment of respiratory complaints.

Priority: EP20050008956 Applic. Date: 2005-04-23

Inventor: BOUYSSOU THIERRY [DE]; KONETZKI INGO [DE]; PIEPER MICHAEL P [DE]; SCHNAPP ANDREAS [DE]

Title: COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND OTHER MATERIALS, AND METHODS OF MAKING AND USING THE SAME

Applicant/Assignee: PHARMAIN CORPORATION

Application No.: 11/428803   Filing Date: 05/Jul/2006

Abstract:In part, the present invention is directed to biocompatible compositions comprising a carrier with a first metal binding domain, a metal ion, an active agent with second metal binding domain and optionally a protective chain covalently attached to the polymeric carrier.

Priority: US2003-378100 Applic. Date: 2003-02-27; US20020360350P Applic. Date: 2002-02-27

Inventor: BOLOTIN ELIJAH M [US]

Title: Polymer-based compositions and conjugates of antimicrobial agents

Applicant/Assignee: NEKTAR THERAPEUTICS AL, CORPORATION

Application No.: 11/402641   Filing Date: 11/Apr/2006

Abstract:Provided herein are water-soluble polymer conjugates and polymer-based compositions of antimicrobial agents. Also provided are methods for synthesizing and administering such conjugates and compositions.

Priority: US20050671000P Applic. Date: 2005-04-12

Inventor: BOSSARD MARY J [US]; MITCHELL STACY [US]

Title: Pharmaceutical composition as solid dosage form and method for manufacturing thereof

Applicant/Assignee: FERRING B.V

Application No.: 11/396899   Filing Date: 04/Apr/2006

Abstract:The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein the pharmaceutical composition is composed of a compressed granulate and contains lubricant in an amount of from 0.05 to less than 0.50 percent by weight of said pharmaceutical composition.

Priority: US2003-626857 Applic. Date: 2003-07-25

Inventor: LOMRYD HAKAN [SE]; NICKLASSON HELENA [SE]; OLSSON LARS-ERIK [SE]

Title: Delivery of highly lipophilic agents via medical devices

Applicant/Assignee:

Application No.: 11/386587   Filing Date: 22/Mar/2006

Abstract:An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

Priority: US2004-769243 Applic. Date: 2004-01-30; US2004-796243 Applic. Date: 2004-03-09; US2004-977288 Applic. Date: 2004-10-29; US2002-235572 Applic. Date: 2002-09-06; US2001-950307 Applic. Date: 2001-09-10; US1999-433001 Applic. Date: 1999-11-02; US1998-159945 Applic. Date: 1998-09-24; US20030453555P Applic. Date: 2003-03-10; US20050664328P Applic. Date: 2005-03-23; US20050727080P Applic. Date: 2005-10-14; US20050726878P Applic. Date: 2005-10-14; US20050732577P Applic. Date: 2005-10-17; US20050727196P Applic. Date: 2005-10-14

Inventor: CROMACK KEITH R [US]; TONER JOHN L [US]; BURKE SANDRA E [US]; KRASULA RICHARD W [US]; SCHWARTZ LEWIS B [US]

Title: Pharmaceutical composition comprising a combination of metformin and a statin

Applicant/Assignee:

Application No.: 10/568523   Filing Date: 15/Feb/2006

Abstract:A pharmaceutical composition comprising: (i) metformin, optionally in the form of one of its pharmaceutically acceptable salts, (ii) a statin, optionally in the form one of its pharmaceutically acceptable salts, and optionally one or more pharmaceutically acceptable excipients, is suitable for use in the treatment of hyperglycemia non-insulin-dependent diabetes, dyslipidemia, hyperlipidemia, hypercholesterolemia, and obesity.

Priority: EP20030292077 Applic. Date: 2003-08-22; WO2004EP09337 Applic. Date: 2004-08-20

Inventor: JUNIEN JEAN-LOUIS [FR]; EDGAR ALAN [FR]

Title: Orally disintegrating pharmaceutical tablet formulations of olanzapine

Applicant/Assignee:

Application No.: 11/402416   Filing Date: 11/Apr/2006

Abstract:This invention provides orally disintegrating pharmaceutical tablet formulations comprising per tablet the following ingredients in the following percentages by weight: olanzapine as an active ingredient in an amount from about 2.5% to about 10%

mannitol in an amount from about 75% to about 95%

a disintegrating agent in an amount from about 1.0% to about 10%

and one or more excipient in a total amount of about 0.1% to about 10%. This invention also provides a method of treating a patient in need of treatment with olanzapine which comprises administering to the patient a therapeutically effective dose of the above pharmaceutical tablet formulations. Finally, this invention provides a method of producing the above pharmaceutical tablet formulation which comprises combining the ingredients in the appropriate relative percentages by weight.

Priority: US20050674077P Applic. Date: 2005-04-22

Inventor: CHUNGI SHUBHA [US]; BARNES CLAUDE R [US]; LONESKY STEVEN M [US]

Title: Controlled-release compositions

Applicant/Assignee:

Application No.: 11/111996   Filing Date: 22/Apr/2005

Abstract:A solid dosage formulation having a core with a pharmacological agent dispersed in a first controlled-release matrix from which release of the agent is relatively slow

and a coat formed over the core and having the agent dispersed in a second controlled-release matrix from which release of the agent is relatively fast. The first matrix can be a cross-linked high amylose starch and the second matrix can be a mixture of polyvinyl acetate and polyvinylpyrrolidone.

Priority: WO2003CA01637 Applic. Date: 2003-10-27; US20020509062P Applic. Date: 2002-10-25; US20030510000P Applic. Date: 2003-10-10

Inventor: LENAERTS VINCENT [CA]; OUADJI-NJIKI LAURE P [CA]; BACON JOHNATAN [FR]; OUZEROUROU RACHID [CA]; GERVAIS SONIA [CA]; RAHMOUNI MILOUD [CA]; SMITH DAMON [CA]

Title: Alpha-ketoglutarates of active ingredients and compositions containing same

Applicant/Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A

Application No.: 11/443458   Filing Date: 31/May/2006

Abstract:Novel stable and pharmacologically acceptable salts of L-carnitine and lower alkanoyl L-carnitines with alpha-ketoglutaric acid are disclosed as well as the compositions useful as dietary and dietetic supplements, nutraceuticals or drugs containing same.

Priority: IT2001RM00445 Applic. Date: 2001-07-25; US2004-484927 Applic. Date: 2004-04-07; WO2001IT00549 Applic. Date: 2001-10-29

Inventor: POLA PIETRO [IT]

Title: Multiepitope polypeptides for cancer immunotherapy

Applicant/Assignee: GAVISH-GALILEE-BIO APPLICATIONS LTD

Application No.: 11/388794   Filing Date: 24/Mar/2006

Abstract:Disclosed are recombinant multiple epitope polypeptides (MEPs) consisting of T cell epitopes derived from tumor-associated antigens capable of being presented by an antigen presenting cell (APC), the recombinant nucleic acid sequences and expression vectors encoding them, and host cells transfected with said expression vectors. Further described are LTB-MEP fusion proteins comprising the E. Coli heat labile enterotoxin subunit B (LTB) peptide fused to a MEP by a synthetic linker, the recombinant nucleic acid sequences and expression vectors encoding them and host cell transfected with said expression vectors. Further included are compositions for inducing an immune response against malignancies, pharmaceutical compositions and a transdermal drug delivery system for the treatment of malignant disorders. Also disclosed are methods for conferring immunity against malignancies and for the treatment of malignant disorders.

Priority: IL20030158140 Applic. Date: 2003-09-25; WO2004IL00894 Applic. Date: 2004-09-26

Inventor: PERETZ TAMAR [IL]; LOTEM MICHAL [IL]; FRANKENBURG SHOSHANA [IL]; PITCOVSKI JACOB [IL]; LEVI ADVA [IL]; MARGALIT HANAH [IL]; ALTUVIA YAEL [IL]

Title: Compositions and methods for combination antiviral therapy

Applicant/Assignee:

Application No.: 10/540794   Filing Date: 13/Jan/2004

Abstract:The present invention relates to therapeutic combinations of [2-(6-amino-purin-9 yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread(R)) and (2R,5S,cis)-4-amino-5-fluoro-1-(2 hydroxymethyl-1,3-oxathiolan-5-yl)-( 1 H)-pyrimidin-2-one (emtricitabine, Emtriva(TM), (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.

Priority: US20030440308P Applic. Date: 2003-01-14; US20030440246P Applic. Date: 2003-01-14; WO2004US00832 Applic. Date: 2004-01-13

Inventor: DAHL TERRENCE C [US]; MENNING MARK M [US]; OLIYAI REZA [US]

Title: Sustained release formulations of venlafaxine

Applicant/Assignee:

Application No.: 10/544624   Filing Date: 09/Feb/2004

Abstract:The present invention relates to sustained release tablet formulations of venlafaxine. Kollidon SR proved to be an excellent sustained release agent for venlafaxine, that is an extremely soluble drug.

Priority: IS20030006710 Applic. Date: 2003-02-07; IS20040007143 Applic. Date: 2004-02-05; WO2004IS00003 Applic. Date: 2004-02-09

Inventor: JOHANNSSON FJALAR [IS]

Title: Antiestrogenic glyceollins suppress human breast and ovarian carcinoma proliferation and tumorigenesis

Applicant/Assignee:

Application No.: 11/118431   Filing Date: 29/Apr/2005

Abstract:The flavonoid family of phytochemicals, particularly those derived from soy, has received attention regarding their hormonal activity and their effects on human health and disease. The types and amounts of these compounds in soy and other plants are controlled by both constitutive expression and stress-induced biosynthesis. The health benefits of soy may therefore be dependent upon the amounts of the various hormonally active phytochemicals present. We have identified increased biosynthesis of the isoflavonoid phytoalexin compounds, Glyceollins I, II and III, in soy plants grown under stressed conditions (elicited soy), which exhibit marked anti-estrogenic effects on ER function. Here we demonstrate that specific glyceollins, isolated from elicited soy, displayed anti-estrogenic activity, suppressing basal and estrogen stimulated colony formation of ER-positive estrogen dependent breast cancer cells and inhibiting ER-dependent gene expression of progesterone receptor (PgR) and stromal derived factor-1 (SDF1/CXCL12). Examining the effects of glyceollin on in vivo tumor formation/growth we demonstrate the ability of glyceollins to significantly suppress basal and estrogen-stimulated tumor growth of ER-positive MCF-7 breast and BG-1 ovarian carcinoma cells in ovariectomized female nude mice. We further demonstrate that the effects of glyceollins on suppression of tumor growth correlate with inhibition of estrogen stimulated PgR expression. In contrast to the uterotropic activity of tamoxifen the glyceollins displayed no uterine agonist activity. The Glyceollin (I-III) compounds may represent an important component of the health effects of soy as well as represent novel anti-estrogens useful in the prevention or treatment of breast and ovarian carcinoma.

Priority:

Inventor: CLEVELAND THOMAS E [US]; BOUE STEPHEN M [US]; BUROW MATTHEW E [US]; MCLACHLAN JOHN A [US]

Title: Use of debranched starch in extrusion-spheronization pharmaceutical pellets

Applicant/Assignee:

Application No.: 11/410375   Filing Date: 25/Apr/2006

Abstract:This patent pertains to the use of debranched starch in the preparation of pharmaceutical pellets by extrusion spheronization. Such excipients are useful in any dry dosage form, including tablets and capsules, for either immediate or sustained release.

Priority: US20050677182P Applic. Date: 2005-05-02

Inventor: DUKIC ALEKSANDRA [YU]; VERVAET CHRIS [BE]; REMON JEAN P [BE]; ALTIERI PAUL A [US]; FOREMAN PAUL B [US]

Title: Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy

Applicant/Assignee:

Application No.: 10/532320   Filing Date: 23/Oct/2003

Abstract:The present invention relates to a method of treating or preventing estrogen-suppressed tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula (I) in which formula R1, R2, R3, R4, independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms

precursors capable of liberating a substance according to the aforementioned formula when used in the present method

and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention is particularly useful in the treatment or prevention of colorectal and prostate cancer and, unlike commonly used estrogens, does not simultaneously enhance the risk of estrogen-stimulated cancers such as breast cancer.

Priority: EP20020079414 Applic. Date: 2002-10-23; WO2003NL00718 Applic. Date: 2003-10-23

Inventor: COELINGH BENNINK HERMAN J T [NL]; BUNSCHOTEN EVERT J [NL]

Title: Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides

Applicant/Assignee:

Application No.: 11/429100   Filing Date: 04/May/2006

Abstract:Provided are modified interferon-gamma (IFN-gamma) polypeptides and methods of generating modified interferon-gamma polypeptides. Also provided are methods of treatment using modified interferon-gamma polypeptides.

Priority: US20050678031P Applic. Date: 2005-05-04; US20050733835P Applic. Date: 2005-11-04

Inventor: BORRELLY GILLES [FR]; GUYON THIERRY [FR]; DRITTANTI LILA [FR]

Title: New pharmaceutical compositions based on anticholinergics and anti-tnf antibodies

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 10/544235   Filing Date: 16/May/2006

Abstract:The present invention relates to novel pharmaceutical compositions based on anticholinergies and anti-TNF antibodies, processes for preparing them and their use in the treatment of respiratory diseases.

Priority: EP20030002968 Applic. Date: 2003-02-11; WO2004EP01142 Applic. Date: 2004-02-07

Inventor: MEADE CHRISTOPHER J M [DE]; PIEPER MICHAEL P [DE]; PAIRET MICHEL [DE]

Title: Ferritin fusion proteins for use in vaccines and other applications

Applicant/Assignee: NEW CENTURY PHARMACEUTICALS, INC

Application No.: 11/374066   Filing Date: 14/Mar/2006

Abstract:An isolated ferritin fusion protein is provided in which ferritin is fused with a protein or peptide capable of being fused to ferritin without interfering with the polymeric self-assembly of the resulting fusion protein, and the protein may be of the endocapsid form when fused at the C terminus or an exocapsid form when fused at the N terminus. These fusion proteins may self-assemble into a variety of useful higher polymeric forms, e.g., capsid or other polymeric aggregate, and they are advantageous in that they are useful in a variety of applications, including human and veterinary vaccines and therapeutics, blood substitutes, image contrast agents, metal chelating agents, gelling agents, protein purification platforms, and therapeutic receptor-binding proteins.

Priority: US2003-435666 Applic. Date: 2003-05-12; US20020379145P Applic. Date: 2002-05-10

Inventor: CARTER DANIEL C [US]; LI CHESTER Q [US]

Title: Factor VII or VIIa - Like Molecules

Applicant/Assignee: MAXYGEN HOLDINGS, LTD

Application No.: 11/426394   Filing Date: 26/Jun/2006

Abstract:Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Priority: DK20000000218 Applic. Date: 2000-02-11; US2004-950747 Applic. Date: 2004-09-27; US2001-782587 Applic. Date: 2001-02-12; US20000184036P Applic. Date: 2000-02-22; US20000241916P Applic. Date: 2000-10-18; DK20000001558 Applic. Date: 2000-10-18

Inventor: PEDERSEN ANDERS H [DK]; ANDERSEN KIM V [DK]; BORNAES CLAUS [DK]

Title: Pharmaceutical composition as solid dosage form and method for manufacturing thereof

Applicant/Assignee: FERRING B. V

Application No.: 11/486214   Filing Date: 14/Jul/2006

Abstract:The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein at least one of said excipient, diluent and carrier is a substance selected from a monosaccharide, disaccharide, oligosaccharide and a polysaccharide, wherein the said substance has an average particle size in the range of from 60 to 1,000 mum. A method according to the present invention provides an improved production of solid dosage forms of desmopressin.

Priority: US2003-425993 Applic. Date: 2003-04-30

Inventor: LOMRYD HAKAN [SE]; NICKLASSON HELENA [SE]; OLSSON LARS-ERIK [SE]

Title: Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use

Applicant/Assignee:

Application No.: 11/123205   Filing Date: 06/May/2005

Abstract:The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate.

Priority:

Inventor: ALMEIDA JOSE L D [PT]; SOARES-DA-SILVA PATRICIO MANUE [PT]

Title: Dry powder inhaler system

Applicant/Assignee:

Application No.: 10/549124   Filing Date: 17/Mar/2004

Abstract:An improved dry powder inhalation system comprising: at least one micronized active ingredient in an hydroxypropylmethylcellulose capsule ( 10 ), and an dry powder inhaler device equipped with piercing systems ( 12 ) having an equivalent diameter of not less than 0.8 mm.

Priority: WO2003BE00048 Applic. Date: 2003-03-20; WO2004BE00039 Applic. Date: 2004-03-17

Inventor: DEBOECK ARTHUR [US]; BAUDUER PHILIPPE [BE]

Title: Medical product

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Application No.: 11/448773   Filing Date: 08/Jun/2006

Abstract:The invention discloses a medical product for use in a treatment of respiratory disorders, and comprises a metered dose of a tiotropium dry powder formulation, directly loaded and sealed into a container made to act as a dry high barrier seal to prevent the capture and ingress of moisture into the tiotropium powder. The dose of tiotropium is further adapted for inhalation and the container is so tight that the efficacy of the dose when delivered is unaffected by moisture. In a further aspect of the invention a type of inhaler is illustrated, which may accept at least one sealed, moisture-tight container of a dose of tiotropium, to deliver the dose with a consistent fine particle dose, over the expected shelf life of the product.

Priority: SE20030003269 Applic. Date: 2003-12-03; US2003-728986 Applic. Date: 2003-12-08

Inventor: ZIERENBERG BERND [DE]; MEMMESHEIMER HOLGER [DE]; LUNKENHEIMER CHRISTINE [DE]; CALANDER SVEN [SE]; NIEMI ALF [SE]; NILSSON THOMAS [SE]; MYRMAN MATTIAS [SE]

Title: Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions

Applicant/Assignee: BAUSCH & LOMB INCORPORATED

Application No.: 11/126625   Filing Date: 11/May/2005

Abstract:A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment to prevent or reduce the progression of proliferative diabetic retinopathy in said patient. Also disclosed is a non-surgical method of treating ocular conditions such as retinal ischemia, retinal inflammation, retinal edema tractional retinal detachment, tractional retinopathy, vitreous hemorrhage and tractional maculopathy by intravitreally administering to a patient suffering from one or more of these conditions with an effective amount of a serine proteinase enzyme to reduce or treat that particular ocular condition. Plasmin, microplasmin and miniplasmin are preferred serine proteinase enzymes and plasmin is the most preferred.

Priority:

Inventor: BARTELS STEPHEN P [US]; MCINTIRE GREGORY L [US]; COMSTOCK TIMOTHY L [US]; LEVY BRIAN [US]

Title: Pharmaceutical tablets of crystalline Type II aripiprazole

Applicant/Assignee:

Application No.: 11/377400   Filing Date: 17/Mar/2006

Abstract:Crystalline aripiprazole Type II can be formulated into pharmaceutical tablets having reduced dissolution profile variability upon storage.

Priority: US20050662552P Applic. Date: 2005-03-17; US20050692557P Applic. Date: 2005-06-22; US20050739640P Applic. Date: 2005-11-26

Inventor: ETTEMA GERRIT J [NL]; WESTHEIM RAYMOND J [NL]; KALMOUA FAYSAL [NL]; JANSEN KORINDE A [NL]; DORKOOSH FARID A [NL]

Title: Stable Sertraline Hydrochloride Formulation and Method

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/465427   Filing Date: 17/Aug/2006

Abstract:Pharmaceutically stable solid pharmaceutical dosage forms of sertraline hydrochloride Form II and Form V polymorphs formed by direct compression.

Priority:

Inventor: ECONOMOU JULIA [US]; MCPHILLIPS ANDREA M [US]; SMOLIGA JOHN A [US]; WILSON RANDALL S [US]

Title: Modified release, multiple unit drug delivery systems

Applicant/Assignee:

Application No.: 10/517101   Filing Date: 09/Jun/2003

Abstract:The invention relates to novel modified release multiple unit systems, and methods of preparing these systems, which can be easily compressed into tablets or filled into capsules or sachets without affecting the desired release characteristics of the pharmaceutical active ingredients incorporated within the systems. The multiple unit tablet includes multiple units. Each unit includes at least one core having an outer surface, a first coating layer surrounding at least a portion of the outer surface of the core and having an outer surface, one or more rate controlling polymers, and one or more one active pharmaceutical ingredients. The coating layer includes one or both of the one or more active pharmaceutical ingredients and the one or more rate controlling polymers. The tablet may further include an outer layer on the outer surface of the unit which includes a material that is one or both of elastic and compressible. The material may be a wax materials, such as polyethylene glycol's (PEGS).

Priority: IN2002DE00617 Applic. Date: 2002-06-07; IN2002DE01157 Applic. Date: 2002-11-15; IN2003DE00234 Applic. Date: 2003-03-06; WO2003IB02186 Applic. Date: 2003-06-09

Inventor: KUMAR PATRIK [IN]; JAIN GIRISH K [IN]; RAMPAL ASHOK [IN]; NITHYANANDAM RAVIKUMAR [IN]; RAGHUVANSHI RAJEEV S [IN]

Title: Controlled release bupropion dosage forms

Applicant/Assignee: ABRIKA PHARMACEUTICALS

Application No.: 11/125857   Filing Date: 10/May/2005

Abstract:A controlled release pharmaceutical dosage form comprising bupropion or pharmaceutically acceptable salt thereof.

Priority:

Inventor: YANG TIANRUN [US]; WENG TIMOTHY [US]

Title: Coated tablets

Applicant/Assignee:

Application No.: 11/492373   Filing Date: 24/Jul/2006

Abstract:Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.

Priority: US2003-428007 Applic. Date: 2003-05-02; US2001-838541 Applic. Date: 2001-04-20; US20020377237P Applic. Date: 2002-05-03; US20000234186P Applic. Date: 2000-09-20; US20000241761P Applic. Date: 2000-10-20

Inventor: VACHON MICHAEL [CA]; MISHRA AWADHESH K [US]; SNOW ROBERT A [US]; GUIVARC H POL-HENRI [CA]

Title: Use of inositol-tripyrophosphate in treating tumors and diseases

Applicant/Assignee:

Application No.: 11/396338   Filing Date: 31/Mar/2006

Abstract:Inositol-tripyrophosphate is an allosteric effector of hemoglobin due to its ability to cross the plasma membrane of red blood cells and deliver oxygen to solid tumors, by lowering the oxygen affinity of the hemoglobin of red blood cells. The present invention is directed to the use of inositol-tripyrophosphate to reduce hemoglobin's affinity for oxygen in circulating red blood cells. The present invention is further directed to the use of inositol-tripyrophosphate to inhibit angiogenesis and enhance radiation sensitivity of hypoxic tumors. The present invention is further directed to the use of inositol-tripyrophosphate for the treatment of various types of cancers, Alzheimer's disease, stroke and osteoporosis.

Priority: US2005-175979 Applic. Date: 2005-07-06; US2006-384012 Applic. Date: 2006-03-17; US20040585804P Applic. Date: 2004-07-06; US20050663491P Applic. Date: 2005-03-18

Inventor: NICOLAU CLAUDE [US]; GREFERATH RUTH [DE]; LEHN JEAN-MARIE [FR]; FYLAKTAKIDOU KONSTANTINA C [GR]

Title: Treating gastrointestinal diseases with modulators of retinoic acid

Applicant/Assignee:

Application No.: 11/413874   Filing Date: 28/Apr/2006

Abstract:T cells are programmed to target the gastrointestinal tract by activation with dendritic cells capable of producing and/or transporting retinoic acid. Methods for using the programmed dendritic cells and/or T and/or B cells to treat a variety of pathogens and infectious agents residing in the intestine are also disclosed. Similarly, inhibitors of retinoic acid synthesis by dendritic cells or other cells in the gut, and inhibitors of retinoic acid receptors in T and/or B cells or other cells in the intestinal mucosa, are disclosed for treating a variety of gastrointestinal autoimmune diseases such as inflammatory bowel disease and celiac disease.

Priority: US20050676249P Applic. Date: 2005-04-29

Inventor: ANDRIAN ULRICH H V [US]; MORA RODRIGO [US]

Title: Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same

Applicant/Assignee:

Application No.: 11/494131   Filing Date: 27/Jul/2006

Abstract:A free-flowing solid formulations of drugs or pharmaceutical agents which have poor aqueous solubility are obtained by admixing a liquid or gel composition that includes 1 to 30 per cent by weight of the drug, 5 to 60 per cent by weight of a surfactant, 10 to 40 per cent by weight of water

1 to 20 per cent by weight of unsaturated fatty acid ester, 0 to 50 per cent by weight water miscible pharmaceutically acceptable polyol and 1 to 10 per cent by weight of phospholipid with a pharmaceutically acceptable suitable solid carrier and thereafter drying the admixture. The free-flowing powder is suitable for being formed into tablets or capsules. The drug or pharmaceutical agent is solubilized in the formulation and has significantly improved bio-availability when compared to the drug tested in its pure form.

Priority: US2002-317657 Applic. Date: 2002-12-12

Inventor: LI WENJI [US]; ALOSIO EDWARD [US]; DEMA-ALA BRICINI F [US]; NGUYEN AMY [US]

Title: Compressible mixture, compressed pharmaceutical compositions, and method of preparation thereof

Applicant/Assignee:

Application No.: 11/133864   Filing Date: 20/May/2005

Abstract:A compressible mixture prepared from a waxy filler, cellulose filler, or a mixture thereof and a disintegrant is disclosed for the preparation of compressed pharmaceutical compositions containing coated pellets. The resulting compressed compositions exhibit substantially the same dissolution profiles as the pellets in the absence of the compressible mixture.

Priority:

Inventor: FENG HENGSHENG [US]

Title: Antifungal compositions with improved bioavailability

Applicant/Assignee:

Application No.: 11/445849   Filing Date: 01/Jun/2006

Abstract:The present invention is concerned with novel pharmaceutical compositions of itraconazole which can be administered to a mammal suffering from a fungal infection, whereby a single such dosage form can be administered once daily, and in addition at any time of the day independently of the food taken in by said mammal. These novel compositions comprise particles obtainable by melt-extruding a mixture comprising itraconazole and an appropriate water-soluble polymer and subsequently milling said melt-extruded mixture.

Priority: EP19960201430 Applic. Date: 1996-05-20; EP19970200698 Applic. Date: 1997-03-07; US2002-218851 Applic. Date: 2002-08-14; US1998-194480 Applic. Date: 1998-11-19; WO1997EP02507 Applic. Date: 1997-05-12

Inventor: BAERT LIEVEN E C [BE]; VERRECK GEERT [BE]; THONE DANY [BE]

Title: Methylene Blue Therapy of Viral Disease

Applicant/Assignee: BIOENVISION, INC

Application No.: 11/419426   Filing Date: 19/May/2006

Abstract:A method for using thiazine dyes, especially methylene blue or methylene blue derivatives, in an immediate or controlled release formulation, alone or in combination with low levels of light or other drugs, to selectively inactivate or inhibit hepatitis infection, has been developed. Clinical trial results demonstrate efficacy in a human clinical trial for treatment of hepatitis C by oral administration of methylene blue immediate release formulation, in a dosage of 65 mg twice daily, over a period of at least 100 days. A method for using thiazine dyes, especially methylene blue or methylene blue derivatives, in an immediate or controlled release formulation, along or in combination with low levels of light or other drugs, to prevent or decrease reactivation of viruses, is also described. The preferred class of patient is infected with, or has been exposed to, viruses such as Herpes simplex virus type 1 & 2, Varicella zoster virus, Epstein-Barr virus, Cytomegalovirus, and Herpes virus type 6 & 7, Adenovirus, and Human polyoma viruses, e.g. JC virus and BK virus. In one embodiment the thiazine dye is administered to a patient experiencing symptoms or disease caused by reactivation of a virus. In a preferred embodiment the thiazine dye is administered to a patient at risk for or experiencing symptoms or disease caused by reactivation of a virus, prior to or during immunosuppression or chemotherapy.

Priority: US20050682891P Applic. Date: 2005-05-20; US20050718804P Applic. Date: 2005-09-20; US20050697094P Applic. Date: 2005-07-07; US20050720066P Applic. Date: 2005-09-23; US20050720147P Applic. Date: 2005-09-23; US20050720058P Applic. Date: 2005-09-23

Inventor: WOOD CHRISTOPHER [GB]; HABIB NAGY [EG]

Title: Oral modified release formulations containing 8-prenylnaringenin for continuous estrogen support

Applicant/Assignee:

Application No.: 11/366947   Filing Date: 02/Mar/2006

Abstract:This invention is directed to an oral modified release formulation of the phytoestrogen 8-prenylnaringenin and methods for the treatment of symptoms of estrogen deficiency.

Priority: EP20050090049 Applic. Date: 2005-03-02; EP20050076899 Applic. Date: 2005-08-12

Inventor: HUEMPEL MICHAEL [DE]; KRANZ HEIKO [DE]

Title: Multilayer pharmaceutical dosage form containing a substance that acts in a modulatory manner with regard to the release of active substances

Applicant/Assignee: ROEHM GMBH & CO. KG

Application No.: 10/572963   Filing Date: 21/Mar/2006

Abstract:The invention relates to a multilayer pharmaceutical dosage form for the controlled release of active substances, containing: a) a core layer containing a substance that acts in a modulatory manner with regard to the release of active substances, optionally a neutral core and/or an active substance

b) an inner control layer that influences the release of the substance that acts in a modulatory manner and of the optionally contained active substance from the core layer, containing pharmaceutically useable polymers, waxes, resins and/or proteins

c) an active substance layer containing a pharmaceutical active substance and, optionally, a substance that acts in a modulatory manner

d) an outer control layer containing a (meth)acrylate copolymer or a mixture consisting of a number of (meth)acrylate copolymers comprised of 98 to 85 C1-C4 alkyl esters of (meth)acrylic acid and 2 to 15% by weight of methacrylate monomers with a quaternary ammonium group in the alkyl radical and optionally containing pharmaceutically useable polymers that are insoluble in water, whereby the layers can contain, in addition and in a known manner, pharmaceutically conventional adjuvants.

Priority: DE20031053186 Applic. Date: 2003-11-13; WO2004EP10297 Applic. Date: 2004-09-15

Inventor: LIZIO ROSARIO [DE]; PETEREIT HANS-ULRICH [DE]; ASSMUS MANFRED [DE]; RAVISHANKAR HEMA [IN]

Title: Timed, sustained release systems for propranolol

Applicant/Assignee: EURAND, INC

Application No.: 11/500892   Filing Date: 09/Aug/2006

Abstract:A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity/manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.

Priority: US2003-453848 Applic. Date: 2003-06-02; US2002-334052 Applic. Date: 2002-12-30; US2001-971167 Applic. Date: 2001-10-04

Inventor: PERCEL PHILLIP J [US]; VISHNUPAD KRISHNA S [US]; VENKATESH GOPI M [US]

Title: Pharmaceutical formulation

Applicant/Assignee:

Application No.: 10/543289   Filing Date: 02/Feb/2004

Abstract:The present invention provides processes for making and forms of solid dispersions of pharmaceutical active ingredients.

Priority: US20030444602P Applic. Date: 2003-02-03; WO2004EP00925 Applic. Date: 2004-02-02

Inventor: ABU SHMEIS-ZIADEH RAMA A [US]; KOWALSKI JAMES [US]; KRILL STEVEN L [US]; PARTHIBAN LAKSHMAN J [US]; WANG ZEREN [US]

Title: Formulations and methods of administration of cephalotaxines, including homoharringtonine

Applicant/Assignee: CHEMGENEX PHARMACEUTICALS, INC

Application No.: 11/497739   Filing Date: 01/Aug/2006

Abstract:The present invention is directed to compositions and methods for the treatment of patients with cephalotaxines, for example, homoharringtonine. The invention is also directed to improvements in the purity, manufacturing process, formulation and administration of homoharringtonine for the treatment of cancer and other aberrant cellular diseases. The invention also provides methods and compositions for antiparasitic, antifungal, antiviral and antibacterial treatments.

Priority: US2003-617927 Applic. Date: 2003-07-10; US20020396926P Applic. Date: 2002-07-17

Inventor: BROWN DENNIS M [US]

Title: Processes for extracting phytochemicals from pomegranate solids and compositions and methods of use thereof

Applicant/Assignee: POMWONDERFUL LLC POM WONDERFUL, LLC

Application No.: 11/137248   Filing Date: 24/May/2005

Abstract:Processes for producing an extract containing phytochemicals from pomegranates are disclosed. The processes generally comprise providing pomegranate solids, such as the pericarp, inner membrane and seeds

creating a mixture comprising the pomegranate solids in an aqueous solution

adding enzymes to the mixture in an amount sufficient to at least partially degrade the pomegranate solids

heating the mixture to a temperature that permits the maximum rate of catalysis of the enzyme

maintaining the temperature of the heated mixture for a time sufficient to allow at least partial degradation of the pomegranate solids

and removing residual insoluble solid materials from the mixture. Compositions containing the extract may be used as a food product, beverage, pharmaceutical preparations, nutritional supplements, vitamin supplements, food additives, and food supplements.

The composition may also be used for preventing or ameliorating disease conditions by administering an effective amount of the composition to a subject in need thereof.

Priority:

Inventor: BATES BYRON [US]; FRITZ ERICH A [US]; HENIG YAIR S [US]; LIKER HARLEY R [US]

Title: Therapeutic combination

Applicant/Assignee:

Application No.: 11/499753   Filing Date: 07/Aug/2006

Abstract:This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.

Priority: WO1998IB01225 Applic. Date: 1998-08-11; US2002-214058 Applic. Date: 2002-08-07; US2000-512914 Applic. Date: 2000-02-25; US19970057275P Applic. Date: 1997-08-29

Inventor: BUCH JAN [US]

Title: Oral dosage forms comprising progesterone and methods of making and using the same

Applicant/Assignee:

Application No.: 11/441447   Filing Date: 26/May/2006

Abstract:The present invention relates to an oral pharmaceutical dosage form comprising micronized progesterone, an edible oil, a disintegrant, and a hydrophilic excipient. Particularly, the invention relates to a pharmaceutical dosage form wherein the dosage form is in a powder form and is contained in a pharmaceutically acceptable capsule. The present invention is also directed toward methods of making the dosage form, methods of using the dosage form, and kits comprising the dosage form.

Priority: US20050684557P Applic. Date: 2005-05-26

Inventor: AHMED SALAH U [US]; DILIBERTI CHARLES E [US]; VATTIKONDA CHANDRA [US]; GORUKANTI SUDHIR R [US]; GUPTA SANJEEV K [US]

Title: Rapidly-dissolving pharmaceutical composition for inhibiting ovulation

Applicant/Assignee:

Application No.: 11/146314   Filing Date: 03/Jun/2005

Abstract:A rapidly-dissolving oral dosage pharmaceutical composition for inhibiting ovulation in a mammal, said composition comprising drospirenone or a pharmaceutically acceptable salt or ester thereof, optionally ethinyl estradiol or a pharmaceutically acceptable salt, ester or ether thereof, a surfactant and at least one pharmaceutically acceptable excipient, wherein the drospirenone has a surface area of less than 10,000 cm<2>/g.

Priority:

Inventor: DAVILA PABLO [US]; PANIAGUA MARCOS PAOLA H [ES]; PAJUELO BENITO L [ES]